

Global Research and Innovation for Health Emergencies

**Building the world's resilience against
future outbreaks and pandemics**

October 2023



**World Health
Organization**



R&D Blueprint

Powering research
to prevent epidemics

Contents

3	Introduction
4	Acronyms and abbreviations
7	Global research collaboration and action – at the heart of pandemic preparedness and response
21	The research continuum – critical work delivered before, during and after outbreaks
24	Research in the interepidemic period
28	Vital vaccines and therapeutics research in the interepidemic period
30	Human-animal-environment interface
34	Epidemiology
40	Health emergency intelligence and surveillance
44	Research integrated in the outbreak response
48	Vital vaccines and therapeutics research in the outbreak response
54	Clinical management
58	Infection prevention and control (IPC)
62	Public health and social measures (PHSM)
66	Enabling research
70	Regulatory science
74	Biological standardization
78	Ethics
82	Community-centred readiness and response
86	Tackling infodemics
90	WHO Initiative on Trust and Pandemic Preparedness
94	Good participatory practice for clinical trials of new or re-emerging pathogens (GPP-EP)
99	Building on the global research response to the pandemic to combat the next one
106	Publications and further resources

Disclaimer: All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind either expressed or implied. The responsibility for interpretation and use of the material lies with the reader. In no event shall the WHO be liable for damages arising from its use. The report does not constitute a formal publication of WHO.

**We cannot
make the world
safer without
investments
in science,
research and
innovation.**



Tedros Adhanom
Director-General
World Health Organization

Introduction

Welcome to the 3rd edition in this WHO R&D Blueprint for Epidemics series of reports dedicated to global research and innovation (RI) for health emergencies.

Within these pages, we continue to showcase the life-saving impact of science in our ongoing battle against deadly diseases with the potential to cause epidemics and pandemics worldwide, especially those for which effective medical countermeasures remain limited or absent.

The COVID-19 pandemic has been at the centre of WHO's research endeavours over the past 12 months and our progress is reported in alignment with the priorities outlined in the 2022 Research and Innovation [Achievements Report](#).

In May 2023, the WHO marked a significant milestone by officially declaring the end of the global emergency status of COVID-19. However, the shadow of COVID-19 still looms large and our work to monitor and manage this devastating disease remains vital.

In this report, we also present critical advances in research related to other significant pathogens that pose substantial threats, yet for which there are limited or no medical countermeasures available. This combined research approach (COVID-19 and beyond) is essential to defending our world.

Today, we stand at a crossroads in shaping global resilience, preparedness and response strategies for the next major epidemic or pandemic.

It is critical that we assimilate the lessons learned from the pandemic and harness the wealth of research knowledge, platforms and collaborative frameworks forged during the COVID-19 crisis to help protect the world from future threats.

Finally, we take a moment to honour the memory of the millions of people we have lost in the past year to devastating diseases, and we renew our commitment to combatting new or re-emerging pathogens that threaten people right across the globe.

We extend our deepest appreciation to the patients, volunteers, and their families whose participation in WHO's research has been pivotal in every study and initiative conducted in the last 12 months. Their contributions remain the cornerstone of this extraordinary global effort.

We would also like to convey our gratitude to the worldwide community of funders and partners, without whose unwavering support none of our work would be attainable.

Acronyms and abbreviations

AC advisory committee	EWG expert working group
ACT-A Access to COVID-19 Tools-Accelerator	FAO Food and Agricultural Organization
AFIRM Agenda for Filovirus Research and Monitoring	GACVS Global Advisory Committee on Vaccine Safety
AI artificial intelligence	GCP good clinical practice
ARIA Airborne Risk Indoor Assessment	GPP-EP good participatory practice for new or re-emerging pathogens
ASCSoMP Advisory Committee on Safety of Medicinal Products	G7 Group of 7
CCHF Crimean Haemorrhagic Fever	G20 Group of 20
CEPI Coalition for Epidemic Preparedness and Innovation	HAI health care-associated infection
CERN European Organization for Nuclear Research	HEPR health emergency preparedness, response and resilience
CIP Coalition of Interested Parties	HIC high-income country
COVID-19 coronavirus disease	HTP high-threat pathogen
CRP collaborative registration procedure	IANPHI International Association of National Public Health Institutes
DSMC Data Safety Monitoring Committee	IDS integrated disease surveillance
EB Executive Board (WHO)	IHR International Health Regulations
EDCARN Clinical Network/Emerging Diseases Clinical Assessment and Response Network	IMST COVID-19 Incident Management Support Team
EID emerging infectious disease	ICMRA International Coalition of Medicines Regulatory Authorities
EIOS epidemic intelligence from open sources	IOA Integrated Outbreak Analytics
EPI-WIN WHO Information Network for Epidemics	IPC infection prevention and control
EU European Union	ISIDORe Integrated Services for Infectious Disease Outbreak Research (EU)
EUL emergency use listing	IU International Unit
EVD Ebola virus disease	JFHTF Joint Finance-Health Taskforce
	KPI key performance indicator

LMIC low and middle-income country	RCT randomized controlled trial
MARVAC Marburg Virus Vaccine (Consortium)	R&D research and development
MERS Middle East respiratory syndrome	REMAP-CAP Randomized, Embedded, Multi-factorial, Adaptive Platform trial for Community-Acquired Pneumonia
MEURI monitored emergency use of unregistered and experimental interventions	RI research and innovation
MIC middle-income country	RPQ WHO Department of Regulation and Prequalification
mpox monkeypox (formerly)	SAGO WHO Scientific Advisory Group on the Origins of Novel Pathogens
MVD Marburg virus disease	SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
NLP natural language processing	SOP standard operating procedure
NPHA national public health agency	STT Solidarity Trial Therapeutics
NAPHS national action plan for health security	STV Solidarity Trial Vaccines
NRA national regulatory authority	SVD Sudan virus disease
OIE World Organisation for Animal Health (now WOAHP see below)	TAG technical advisory group
OHIS One Health Intelligence System	TPP Target Product Profile
OHISS One Health Intelligence Scoping Study	UHC universal health care
PHC primary health care	UN United Nations
PHEIC public health emergency of international concern	UNICEF United Nations Children's Fund
PHI public health intelligence	UNEP United Nations Environment Programme
PHSM public health and social measures	WASH water, sanitation and hygiene
PPE personal protective equipment	WHA World Health Assembly
PPR prevention, preparedness and response	WHE World Health Emergencies
PRET Preparedness and Resilience for Emerging Threats Initiative	WHO World Health Organization
RCCE risk communication and community engagement	WOAH World Health Organisation for Animal Health (founded as OIE)

IN TIO N S



**Global research
collaboration and
action – at the
heart of pandemic
preparedness and
response**

Overview

This chapter gives an overview of the significant milestones achieved in global research in the past 12 months to prevent and combat outbreaks and pandemics. This has been achieved, through the leadership of the World Health Organization (WHO) Research and Development (R&D) Blueprint for Epidemics in collaboration with an extensive network of some 50,000 researchers and scientists from around the world.

While COVID-19 research has dominated WHO's work in the past year and since 2020, equally important have been efforts to advance research on other priority diseases with epidemic and pandemic potential.

The achievements cited in this section have been pivotal in protecting the global community from the persistent threat of COVID-19. At the same time they have bolstered our ability to predict and manage outbreaks of other pathogens, including recent outbreaks of Ebola and Marburg. And

they have initiated significant steps towards building the necessary tools and platforms in readiness for the next pandemic.

Through these efforts, we have collectively expanded the field of medical and non-medical countermeasures to include interventions and solutions not previously prioritized to this extent in outbreak preparation and response – including an enhanced role for social sciences, engagement and trust initiatives, which now underpin how we can effectively engage with different communities with speed during major disease outbreaks.

The COVID-19 pandemic truly saw an augmented and integrated research response which helped accelerate the testing of vaccines, treatments and diagnostics, but also underpinned public policy, regulatory and communications initiatives to tackle the spread of disease and reduce its health and social harms.

New strategic components steering future global research agenda

a) The possibility of a new pandemic convention, agreement or other international instrument

The COVID-19 pandemic laid bare vulnerabilities in the global response system, emphasizing the interconnectedness of health crises and how no one in the world is safe until everyone is safe.

In December 2021, the World Health Assembly (WHA) voted at a special session to establish an Intergovernmental Negotiating Body (INB) to draft and negotiate an international accord on pandemic prevention, preparedness and response to align and strengthen the International Health Regulations (IHR), which continue to constitute the primary global framework for managing health emergencies.

Member States of the World Health Organization (WHO) have agreed to a global

process to draft and negotiate a convention, agreement or other international instrument under the WHO Constitution to strengthen pandemic prevention, preparedness and response.

A draft document will be submitted for consideration by the 77th WHA in May 2024. If ratified, this new pandemic convention, agreement or other international instrument will at a broader level help deliver a stronger global research ecosystem with a more coordinated response to future epidemics and pandemics. At the research and innovation (RI) level meanwhile, it will contribute to expediting global research, development, and equitable deployment of diagnostics, vaccines and medicines.

b) A new approach to prioritizing the most dangerous pathogens

Since 2015, WHO has implemented a comprehensive global research strategy and preparedness plan known as the WHO R&D Blueprint for Epidemics. The R&D Blueprint for Epidemics' primary goal is to accelerate the development and availability of medical countermeasures, such as vaccines and medicines, for diseases with epidemic and pandemic potential, thereby preventing large-scale health crises and saving lives during outbreaks.

A centrepiece of this work is the WHO pathogen priority list which ensures research efforts are concentrated on diseases with epidemic or pandemic potential where medical countermeasures and limited or non-existent.


Since November 2022, a new approach is being implemented, focusing on entire classes of viruses or bacteria rather than individual pathogens. So, this year, around 300 scientists from 53 countries have independently evaluated evidence related to 27 viral families, one core group of bacteria, and "Disease X" – an unknown pathogen

with the potential to trigger a severe global epidemic.

There has been growing support for this approach as it offers a framework to fast-track research and encourages research efforts on entire classes of viruses (e.g., flaviviruses), instead of just the individual strain (e.g. Zika virus). This improves the capability to respond to unforeseen strains, zoonotic viruses (an animal virus that could jump to humans), and the potential threat of a Disease X.

This new approach will help identify representative viruses (or prototypes) within a viral family as a pathfinder in generating evidence and filling knowledge gaps that may then be applicable to other viruses of threat in the same family.

Ultimately it is intended to better identify priority pathogens and accelerate global research, leading to better outcomes, faster research and a more cost-efficient use of resources.



The pivotal work of the WHO R&D Blueprint for Epidemics

The following core activities form the foundation of the work of the WHO R&D Blueprint for Epidemics to ensure the world has a robust and coordinated global response to emerging disease threats:

- Disease prioritization:** WHO's efforts in research and innovation for diseases with epidemic or pandemic potential are grounded in a rigorous and comprehensive process. This process scientifically identifies viral and bacterial families that require collective research attention due to their epidemic threat and the absence of safe and effective medical countermeasures. The periodically updated list of prioritized viral and bacterial families is guided by evolving evidence spanning diverse domains such as science, epidemiology, socioeconomic impact, access, and equity. An updated version of this list is scheduled for release in 2024.
- R&D Roadmaps and Target Product Profiles (TPPs):** For each prioritized viral and bacterial family, the R&D Blueprint formulates an R&D Roadmap and a TPP for the three medical countermeasures: vaccines, treatments, and diagnostics. These roadmaps function as strategic blueprints, directing crucial research initiatives focused on each priority viral or bacterial family. They draw expertise from scientists and experts across the world committed to developing safe and effective diagnostics, medicines and vaccines. The TPPs provide the vital specifications and attributes necessary in formulating vaccines, treatments or diagnostic tests.
- Pipeline monitoring and prioritization for evaluation:** A critical activity in delivering effective medical countermeasures is the dissemination of the best available knowledge and evidence on the clinical development pipeline of candidate vaccines and treatments. This is achieved by meticulously tracking the progress of promising candidate products throughout the clinical research pipeline. An independent expert group provides advice on which ones should be given priority for evaluation in the context of an outbreak. This proactive approach facilitates the agreement on clinical trial designs and the selection of investigational products and candidates to prioritize in clinical trials during an outbreak.
- Clinical research in the context of outbreaks and pandemics:** The WHO R&D Blueprint for Epidemics collaboratively co-sponsors clinical trials for vaccines and treatments with Ministries of Health. This collaboration involves the development of streamlined CORE research protocols, standard operating procedures (SOPs), clinical trial tools, and data platforms. Additionally, the R&D Blueprint for Epidemics invests in building capacities to conduct clinical trials in accordance with good clinical practice (GCP) standards.



© WHO/Natalie Naccache

Figure 1 shows progress on the delivery of key activities within the R&D Blueprint up to May 2023

Pathogen	R&D Roadmap	Vaccines					Therapeutics					Diagnostics					Research priorities for other areas of research and innovation.
		Landscape Candidate Vaccines	TPP Vaccines	Trial design Vaccines	Simple protocol available	Regulatory pathway consultations	Landscape Candidate Therapeutics	TPP Therapeutics	Trial design Therapeutics	Simple protocol available	Regulatory pathway consultations	Landscape Candidate Diagnostics	TPP Diagnostics	Trial design Diagnostics	Simple protocol available	Regulatory consultations	
COVID-19	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
MERS-CoV	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Zika	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Nipah	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Lassa fever	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Ebola ZBOV	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Ebola SUDV	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Marburg	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Crimean-Congo hemorrhagic fever	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Rift Valley fever	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Chikungunya	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Plague	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Mpox	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Pathogen X	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓

Expanded collaborative platform for research

During the COVID-19 pandemic, WHO collaborated with over 50,000 scientists and experts worldwide, spanning the various thematic research areas covered in this report, from vaccine research to epidemiology, as well as enabling initiatives promoting the values of speed, quality, equity and trust.

The efforts of this partnership were coordinated by WHO, and thematic research areas were overseen by independent global advisory committees (ACs) and expert working groups (EWGs), which further collaborated with international, national, and

local researchers. This global collaborative approach is depicted in the ensuing pages of the report.




Together, scientists and experts undertook global research and innovation to combat global pathogen threats on an extraordinary scale and at pace.

Moving forward, this global collaborative platform, catalysed by COVID-19, for research on pathogens of epidemic and pandemic threat, will continue to be the bedrock of WHO's research effort.



© ISDC/Tiago_Fernandes

Global collaborative research approach to prevent and tackle outbreaks, epidemics and pandemics



Enabling research

Figure 2 shows over 750 global conferences, meetings and training sessions took place across all global research and innovation areas between May 2022 and May 2023. And over 50,000 global scientists, researchers and policy, engagement and regulatory experts were in attendance. These discussions and collaborations, as well as subsequent communications between other networks, have been critical to this area of work.





Figure 3 depicts all of the countries across the globe that have participated in WHO coordinated research activities between May 2022 and May 2023. Activities have been diverse and include a range of countries that took part in large global clinical trials to test vaccines and treatments for COVID-19.



Research and innovation key achievements 2022-2023

Follows is a summary of the latest research achievements, coordinated by WHO and partners, targeting COVID-19 and other key pathogens in the last 12 months across the broad spectrum of critical research areas delivered before, during and after an outbreak.

Follows are some highlights of this coordination and research work, all undertaken in the last 12 months. This brief summary helps spotlight the real breadth and impact of the global research effort in this area.


1

Global trials test the effectiveness of promising treatments against major health threats

Since the early stages of the COVID-19 pandemic, numerous randomized controlled trials (RCTs) have been initiated to address unmet clinical needs. Notably, global platform trials have emerged as an evaluation approach in clinical research in response to outbreaks and pandemics. Examples of trials include the WHO Solidarity trials, RECOVERY, the Randomized, Embedded, Multi-factorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP), among others.

The outcomes of several of these trials have influenced the development of guidelines globally for the treatment of COVID-19 patients.

The Solidarity PLUS global platform trial has evaluated seven potential treatments in the clinical management of COVID-19. These drugs were chosen after careful consideration by independent experts for their potential to reduce mortality. Across the whole trial, thousands of patients have been randomized in over 50 countries with 600 hospitals taking part.



2

Global trials test the effectiveness of promising vaccines against major health threats

WHO facilitated worldwide research efforts to develop and deploy COVID-19 vaccines, and sponsored numerous consultations to support research to determine the most effective way to evaluate and use COVID-19 vaccines. Similarly, it supported consultations on vaccine evaluation for Plague and Marburg, Sudan. WHO also sponsored the Solidarity Trial Vaccines (STV) of COVID-19 vaccines. This continues to collect vaccine efficacy data from thousands of volunteers. In 2024, WHO will publish safety and efficacy data on a COVID-19 vaccine from the STV.

Clinical trials of potential vaccines against Ebola (in Uganda) and Marburg disease (in Tanzania/Philippines) were also coordinated and planned in 2022 at rapid pace – but strong infection control and public health measures, as part of the emergency response, were effective in reducing prevalence rates of both diseases to undetectable levels. The trials may still take place in the future if further outbreaks occur.

These global platform clinical trials testing both vaccines and treatments are now seen as an approach to provide robust high-quality global answers to important public health questions.

The experience has indicated that clinical trials in the context of outbreaks need to be of high quality. Affected countries (and local researchers) must be in the driving seat and part of a global collaborative effort to design CORE protocols. These must be discussed and pre-approved ahead of time.

Since outbreaks often occur in areas with very limited infrastructure and can be of short duration, the trial design needs to allow for possible innovation. Importantly research must be fully integrated in the outbreak response team's remit. In brief, trial design in the context of outbreaks necessitates and benefits from innovation and simplification of procedures. This should not affect quality however. Simple does not and must not mean low quality.

3

Global and national collaboration to help drive improvements in rapid detection, monitoring and tackling of emerging pathogens crossing the human-animal-environment interface

The newly established WHO Scientific Advisory Group on the Origins of Novel Pathogens (SAGO) has continued to work with a range of national and local partners to improve the rapid detection, monitoring and evolution of emerging zoonotic pathogens and ensure coordination of rapid control measures. As part of this work, the Food and Agriculture Organization (FAO), the World

Organisation for Animal Health (WOAH) and the World Health Organization (WHO) have rolled out national bridging workshops in 46 countries so the food, animal health, human health, and agriculture sectors strengthen their collaboration at the human-animal-environment interface, while improving their compliance to international standards.

4

New epidemiological initiatives help drive better data, decisions and outcomes

The WHO Unity Studies global initiative has provided a pandemic preparedness and readiness framework for conducting epidemiological studies to rapidly assess pathogen transmissibility, population susceptibility/immunity and infection severity – as well as aid identification of population groups in need. The data will help target interventions and assess their effectiveness.

Meanwhile researchers working collaboratively to assess indoor airborne risk have been producing evidence and tools to inform actions to mitigate airborne transmission of SARS-CoV-2. The group has, in consultation with a wide range of national and international experts, developed an innovative online tool to assess the risk of SARS-CoV-2 airborne transmission in indoor residential, public and health care settings (<https://partnersplatform.who.int/aria>) as well as training tools for using it.

5

Supporting the delivery of better surveillance of dangerous pathogens across the world

Health emergency intelligence and surveillance has helped support better global and national surveillance by providing technical input into a deep dive study implemented by the International Association of National Public Health Institutes (IANPHI)

This has explored the status of national surveillance systems and the extent to which

integrated data surveillance (IDS) systems have been developed and operationalized. Key recommendations included establishing and formalizing professional networks to strengthen workforce, building an environment of interoperable data and systems across all sectors, and strengthening national public health agencies (NPHAs) to catalyse key surveillance systems.

6

A key global clinical database/platform has been expanded to log and identify the clinical impact of dangerous pathogens on patients

The pivotal WHO Global Clinical Platform was originally set up for COVID-19 – but now includes clinical data for cholera, filoviruses (generic), mpox and acute hepatitis of unknown origin. The database, which stores over one million anonymized, standardized

patient files from around the globe is a critical resource for the global research community to increase understanding of the clinical impact on patients of new or re-emerging infectious pathogens.

7 Infection prevention and control (IPC) continue to be rigorously evaluated against different pathogen threats

Major literature reviews have been undertaken, and peer-reviewed articles published, to underpin evidence-based IPC recommendations for COVID-19, mpox, Ebola and Marburg disease. This work has included comparing the effectiveness of medical masks versus filtering facepiece respirators for health workers providing care to COVID-19 patients, as well as developing standards

for disinfection of surfaces, laundering of linens, and hand hygiene in health care and community settings on caring for patients with mpox.

Another major area of work was evaluating infections and exposure risks, for health workers.

8 Providing vital support for low and middle-income countries (LMICs) in accelerating regulatory clearance for lifesaving COVID-19 medical interventions

WHO regulatory teams assisted national regulatory authorities (NRAs) in nearly 150 LMICs to issue approximately 5,500

expedited regulatory clearances for agreed emergency use listing (EUL) COVID-19 vaccines.

9 Driving and promoting key international standards for the manufacturing, licensing and approval of medical interventions to combat deadly pathogens

The biological standardization research area delivered key international measurement standards to facilitate the development

and regulatory convergence of vaccines, diagnostics and therapeutics relevant to priority pathogens.

10 Updating ethics guidance to underpin research and clinical actions during a pandemic

All actions to combat pandemics should be ethical, inclusive and sustainable. One key example of recent work in this area has been updating the pivotal monitored emergency use of unregistered and experimental interventions (MEURI) ethical framework.

This provides the world with definitive ethical guidance for the expanded use of unproven clinical interventions outside clinical trials during public health emergencies – a practice which surged during the COVID-19 pandemic.

11 Supporting local action to engage communities in policy and research during pandemics

Community engagement work is important before, during and after an outbreak.

Engaging communities early in the research process can help researchers understand the questions that are most relevant to key populations and help them design clinical trials and other studies that affected groups are willing to participate in.

WHO has delivered tools, materials and capacity-building resources for local and national teams to work with communities and key stakeholders to develop and deliver research on key pathogen threats (such as COVID-19, mpox and Ebola), including clinical trials testing new medical interventions to address these threats.

12 Expanded capacities for evidence and analytics to strengthen risk communication, community engagement and infodemic management for emergency response

The actions that members of the public take make a big difference in outbreaks.

Strong risk communication and community engagement (RCCE), and infodemic management, are key to promote uptake of public health and safety measures (PHSM) and to build and maintain trust.

Increasingly evidence and analytics are used to underpin these technical areas of emergency response. Over the past 12 months alone, 150+ studies were conducted at country and regional level, with multiple

waves of data collection and analysis, to inform policy and practice. The new WHO-led Trust Initiative also aims to deepen and develop the global health community's understanding of trust and translate this understanding into concrete actions that build trust prior to epidemics and sustain it during emergencies.

In the area of infodemics, over 1,300 infodemic managers from 142 countries have now been trained in infodemiology and evidence-based approaches to managing infodemics.

Global research – building on the lessons learned during the pandemic

While COVID-19 still affects virtually every part of the world, its health, social and economic effects have been significantly reduced, thanks to the medical countermeasures and other tools we now have. Global research has played a major role in developing these protective measures and in moving COVID-19 from a state of 'global health emergency' into a new era of monitoring and management.

In the final chapter of this report, we discuss how the global research community is already learning the hard-won lessons from the pandemic, and building on the connections and platforms that were made. This is to ensure the world is ready for the next event.

NON-CRITICAL

2



The research continuum – critical work delivered before, during and after outbreaks

The history and value of the research continuum - delivering critical work before, during and after outbreaks

The Constitution of the World Health Organization (WHO) states that one of WHO's key roles is to promote, conduct and coordinate research in the field of health.

In May 2015, the 68th World Health Assembly (WHA) welcomed the development of an R&D Blueprint for Epidemics, in consultation with Member States and relevant stakeholders, for accelerating research and development (R&D) in epidemics or health emergency situations where there are no, or insufficient, preventive and therapeutic medical countermeasures.

The vision of the WHO R&D Blueprint for Epidemics is a world where diagnostics, medicines and vaccines are available to prevent and respond to epidemics across the world.

The Mission of the WHO R&D Blueprint for Epidemics is to achieve its vision by coordinating and accelerating global research work to:

- target diseases that threaten humanity
- develop diagnostics, medicines and vaccines fast
- respond to outbreaks, preventing epidemics

The WHO R&D Blueprint for Epidemics's mission calls for a comprehensive end-to end approach to research. It is essential before, during and after epidemics.

The COVID-19 pandemic truly saw an augmented and integrated research response which helped accelerate the testing of vaccines, treatments and diagnostics, but also underpinned public policy, regulatory and communications initiatives to tackle the spread of disease and reduce its health and social harms.

The mission also calls for a comprehensive end-to-end approach to research. It is essential before, during and after outbreaks and pandemics. We will look at the achievements and priorities of different research areas in detail in this section.

Finally, it is important to stress that coordinating and accelerating global research must promote universal values.

With regards to a collaborative effort to ensure access to medical countermeasures, some have emphasized the importance of speed and sometimes cost in responding to future pandemics. It is equally important to take a broader view that recognizes the primary importance of quality, equity in availability, and trust in the product's safety and efficacy.

The COVID-19 pandemic saw a truly augmented and integrated research response which helped accelerate the testing of vaccines, treatments and diagnostics, but also underpinned public policy, regulatory and communications initiatives to tackle the spread of disease and reduce its health and social harms.



Research undertaken before an epidemic is critical – with one key focus being the global prioritization, detection and monitoring of new or existing pathogen threats.

Research in the interepidemic period

Vital vaccines and therapeutics research in the interepidemic period	28
Human-animal-environment interface	30
Epidemiology	34
Health emergency intelligence and surveillance	40


Research in the interepidemic period: Global network of expert groups/committees coordinated by the WHO R&D Blueprint for Epidemics

Therapeutics research

- Executive Group of the International Steering Committee of the Solidarity Trial Therapeutics (STT)
- International Steering Committee of the Solidarity Therapeutics Trial (STT)
- WHO Advisory Group on Therapeutics Prioritization for COVID-19
- Advisory Group Technical Expert Panel on Thrombostasis
- Advisory Group Technical Expert Panel on Inflammation
- COVID-19 Working Group on Outpatient Therapeutics Protocols

Vaccines research

- Technical Advisory Group Candidate Vaccine Prioritization
- Assays - COVID-19 and Priority Pathogens
- Animal Models - COVID-19 and Priority Pathogens
- Marburg Virus Vaccine (MARVAC) Consortium
- Target Product Profiles (TPPs) for COVID-19 Vaccines Working Group
- Core Protocol for Vaccines against COVID-19 Working Group
- Vaccines R&D for COVID-19 Vaccines Working Group
- Solidarity Trial Vaccines (STV) Executive Group
- Solidarity Trial Vaccines (STV) Data Safety Monitoring Committee (DSMC)



- Epidemiology Technical Advisory Group
- Expert Group on Mathematical Modelling
- Contact Tracing Guideline Development Group
- WHO Europe and Africa region sero-epidemiology scientific seminars
- Airborne Risk Indoor Assessment (ARIA) Working Group
- WHO Unity Studies

- EPI-BRAIN
- Health Emergency Intelligence and Surveillance

- Access to COVID-19 Tools - Accelerator (ACT-A) Diagnostics Expert Group
- Technical Working Group on Rapid Diagnostic Tests
- Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE)

- Scientific Advisory Group for the Origins of Novel Pathogens (SAGO)
- PREZODE Initiative Working Group - Preventing future pandemics: monitoring risk reduction of emerging zoonotic diseases

Vital research preparations to combat the next global threat

In the interepidemic period, all research areas, ranging from epidemiology to health intelligence and surveillance, learn lessons from previous outbreaks and make intensive preparations for the next event. Each area broadly analyses and publishes evidence to help formulate forward plans, guidance, actions and resources to be rapidly enacted and deployed when the next outbreak occurs.

Focusing on the centrepiece role of vaccines and therapeutics research, work during the interepidemic period and beyond:

- provides reliable data to evaluate the quality of vaccines and therapeutics
- promotes the equity of their distribution
- facilitates trust in their safety and efficacy
- ultimately saves lives and improves outcomes in future outbreaks and pandemics

For viral and bacterial families identified as being major outbreak/pandemic risks, WHO has convened and will continue to convene consultations to develop R&D Roadmaps for vaccines, therapeutics, and diagnostics.

This pivotal work during the interepidemic period leads to:

Global and regional level

- Development of a **landscape of candidate products** in the pipeline and their status regarding development and evaluation
- Creation of **Target Product Profiles (TPPs)** outlining the public health perspective
- **Pre-outbreak trial design** considerations
- **An independent process for prioritization** of vaccine and therapeutics candidates for inclusion during trials conducted in the context of outbreaks
- **A virtual process** to ensure that candidate vaccines and therapeutics are funded and available for rapid international delivery in vials thus deployment for use in studies that will collect data that are needed
- An open convening of **collaborative scientific networks** to rapidly conduct/support research during outbreaks
- Identification of **research priorities** for other areas
- Creation/maintenance of **legal and insurance frameworks** needed to conduct studies of investigational vaccines and therapeutics

Country and subregional level

- Development of a **collaborative research framework** (including all key international stakeholders) with the countries at risk in the driving seat including in protocol design and implementation
- **Ministries of Health designated researchers** and research institutions (to lead research during outbreaks) being identified and collaborating across various countries at risk
- Clarity regarding **national regulatory pathways**
- **Pre-approved CORE protocols** for both randomized controlled trials (RCTs) and expanded access use and/or MEURI. Approval by national regulatory authorities (NRAs) and ethics committees in countries at risk for use during an outbreak integrated as part of the outbreak response
- **Support of national research capacity** of designated national research institutions for the implementation of pre-approved research protocols

Vital vaccines and therapeutics research in the interepidemic period

Building protection and readiness in preparation for outbreaks

Human-animal-environment interface

The interaction of humans, animals and the environment in a changing world

Introduction

An estimated 75% of emerging infectious diseases are of zoonotic origin. Recent examples include mpox, COVID-19, Ebola and Middle Eastern respiratory syndrome (MERS).

The key aim of this research thematic area is to better understand the interface between humans, animals and the environment regarding zoonotic pathogens of epidemic and pandemic potential to reduce the risk of transmission.

Objectives

- Assessing the origins of novel pathogens of epidemic and pandemic potential**
The WHO Scientific Advisory Group on the Origins of Novel Pathogens (SAGO) was established in November 2021 following the World Health Assembly (WHA)'s recommendations. These gave the WHO Director-General the mandate to bring together international experts from diverse backgrounds to guide scientific and collaborative studies into the origins of all emerging and re-emerging high-threat pathogens (HTPs), including SARS-CoV-2, to prevent future epidemics and pandemics.
- Developing risk mitigation strategies at the human-animal-environment interface**
Newly emerging zoonotic diseases often come with limited knowledge on the animal reservoirs and/or major routes of transmission between animals and humans. Increasing our collective understanding of the susceptibility of animals, risks of reservoir formation, the evolution of pathogens in animal hosts, modes and drivers of transmission between animals and humans, and new interfaces between human and animals in a changing environment, is critical to establishing effective risk mitigation strategies during public health crises.
- Fostering multisectoral collaboration to jointly manage zoonotic threats**
Effective response to zoonotic disease outbreaks requires coordination between the human, animal, and environment health sector (among others). The Quadripartite Organizations - the Food and Agriculture Organization of the United Nations (FAO), the United Nations Environment Programme (UNEP), the World Organisation for Animal Health (WOAH, founded as OIE), and WHO - are supporting Member States with resources to enhance operational collaboration between all sectors relevant to manage zoonotic diseases. They have launched the One Health Joint Plan of Action which outlines the commitment of the four organizations to collectively advocate and support the implementation of One Health.

Increasing our collective understanding of the susceptibility of animals, risks of reservoir formation, the evolution of pathogens in animal hosts, modes and drivers of transmission between animals and humans, and new interfaces between human and animals in a changing environment, is critical.

Achievements

Follows are the main achievements in human-animal-environment interface research for COVID-19/other key diseases and pathogens in the past 12 months:

1

Assessing the origins of novel pathogens of epidemic and pandemic potential

WHO published SAGO's first preliminary report on 9 June 2022. In this report, SAGO provided WHO with key recommendations on critical studies that are needed to better understand the emergence or re-emergence of pathogens with epidemic and pandemic potential.

The report also included a plan for its upcoming global framework for studying the emergence of pathogens by outlining critical studies needed in human and animal studies at the human-animal interface and in the environment where and when such pathogens are detected.

For SARS-CoV-2, SAGO offered its recommendations on critical studies that

continue to be urgently needed in China and around the world that would provide additional information and contribute to a better understanding of how SARS-CoV-2 entered the human population and spread.

In December 2022, SAGO published a second report summarizing its recommendations for studies to be conducted to better understand the origins and factors for the emergence and re-emergence of mpox using the global framework. To date, SAGO has held 17 plenary meetings, including two face-to-face meetings, and numerous working group meetings.

2

Understanding susceptibility of animals, risks of reservoir formation, the evolution of pathogens in animal hosts, and modes of transmission between animals and humans

WHO is working together with international organizations, national institutions, academia, and other partners in charge of animal health, to improve the rapid detection, monitoring and evolution of emerging zoonotic pathogens and to ensure coordination of rapid control measures.

As an example, for the risk of spillback of emerging zoonosis from humans to animals, during the COVID-19 pandemic, SARS-CoV-2 was shown to have a large animal host range, established continuous circulation in a wildlife reservoir (white-tailed deer), and infected pets and farmed fur animals.

Circulation in animals may hamper elimination strategies for pathogens, but SARS-CoV-2 also quickly adapted to novel

hosts, resulting in viral evolution. On the other hand, continuous spillover from animal reservoirs into the human population leads to local human suffering. But it also harbours the constant risk of a wider spread in the human population, as seen in the 2022-2023 multicountry outbreak of mpox.

Working with our partners at FAO and WOAHA, several documents were published including joint risk assessment and guidance on increasing surveillance in animals, as well as on reducing the risk of spillover and spillback.

3

Fostering multisectoral collaboration to jointly manage zoonotic threats

Taking a multisectoral, One Health approach is necessary to address complex health threats at the human-animal-environment interface, such as emerging zoonotic diseases. The Tripartite Organizations – FAO, WOAHA and WHO – have rolled out National Bridging Workshops in 46 countries. These allow the different sectors to strengthen their collaboration at the human-animal-environment interface, while improving their compliance to international standards and regulations.

In addition, over 20 countries have installed a One Health catalyst to implement the resulting joint One Health roadmaps to improve collaboration, and more than 50 countries have used the Tripartite Zoonosis Guide (TZG) operational tools to improve their collaboration in critical technical areas for managing zoonotic threats, such as joint risk assessment or joint surveillance and information-sharing.

Future priorities

Follows are the main priorities for 2023-2024 in human-animal-environment interface research in this area:

- The next SAGO output is the “WHO global framework to define and guide studies into the origins of emerging and re-emerging pathogens of epidemic and pandemic potential”, which SAGO hopes to finalize by the end of Q4 in 2023. The SAGO will continue to meet in plenary and working groups to apply the global framework to advancing our understanding of where the SARS-CoV-2 virus originated. The SAGO will also apply the global framework to other emerging or re-emerging pathogens, as it has done for mpox.
- There is an urgent need to increase and fund the development, coordination and implementation of multisectoral research agendas in the context of emergencies, to rapidly fill critical knowledge gaps at the human-animal-environment interface impacting the response capacities to zoonotic threats.
- Enhancing coordination between the various institutional actors involved in zoonotic disease management remains a priority. The development of joint technical capacities needs to be further promoted to improve countries' preparedness for zoonotic disease outbreaks, using operational tools developed by the Quadripartite and its partners. An institutionalized, multisectoral environment will also promote optimal use of practical research conducted at the human-animal-environment interface.

Epidemiology

Producing key evidence and standardizing protocols to underpin the world's readiness and response to dangerous pathogens

Introduction

The epidemiology research area has focused on two key initiatives in this period: airborne risk indoor assessment (ARIA) and the WHO Unity Studies.

Follows are the objectives, achievements and future priorities for these pivotal initiatives.

© iStock/Bertlmann

Collaborating to assess indoor airborne risks (ARIA)

Providing evidence and tools to inform actions to mitigate airborne transmission of SARS-CoV-2

The European Organization for Nuclear Research (CERN) and WHO have had a mutual collaboration agreement since 2013. During COVID-19, the two organizations have identified a new area of mutual interest: airborne transmission of SARS-CoV-2.

The departments of Epidemic and Pandemic Preparedness (EPP), Strategic Health Operations (SHO) and Environment, Climate Change and Health (ECH) have had an ongoing collaboration with CERN for the past two years to develop this project.

Objectives

- Convene a multidisciplinary working group to define a standardized algorithm to quantify airborne risk transmission in indoor settings.
- Develop an online, user-friendly tool to enable users and building managers to assess airborne risk transmission in residential, public and health care settings and therefore implement risk reduction measures; the tool is composed of a complex model that was developed to quantify the risk of SARS-CoV-2 airborne transmission in a standardized manner (using a standardized model) in residential, public and health care settings). It is essential to informing non-pharmaceutical risk reduction measures, such as increasing ventilation, air cleaning and disinfection, source control interventions, and controlling the occupancy, as well as to communicating the risk and enabling informed decisions by the occupants.
- Provide a standardized methodology manual and recommended threshold values for this model to inform policy and regulatory interventions related to indoor air quality and infectious diseases.
- Adapt and apply the model to other respiratory infections.

Achievements

Follows are the main achievements of the the collaborative research to assess indoor airborne risks (ARIA) for COVID-19/other key diseases and pathogens in the past 12 months:

1 Key evidence review and risk assessment tools to underpin this work

The ARIA Working Group has so far convened numerous times throughout 2022 to conduct a rapid review of building ventilation and transmission of airborne diseases, reviewed all relevant airborne risk assessment tools published, reviewed and presented during the International Society of indoor Air Quality and Climate (ISIAQ) webinar "modelling infection risk from indoor aerosol exposure to SARS-CoV-2", as well as the COVID Airborne Risk Assessment (CARA) tool presented during a WHO expert panel meeting.

2 Delivery of innovative online tool to assess SARS-CoV-2 airborne transmission risk in different settings

The working group has, in consultation with national and international expert members of the WHO's Global Infection Prevention and Control Network (GIPCN), the WHO's Environment and Engineering Control Expert Advisory Panel (ECAP) for COVID-19, the WHO's Expanded Programme on Immunization (EPI) Group, and the WHO Secretariat, developed an online user-friendly tool to assess SARS-CoV-2 airborne transmission risk in indoor residential, public and health care settings (<https://partnersplatform.who.int/aria>). A manual on the method and application of the creation of this tool was developed and will be soon made available online, alongside a training course on OpenWHO.

Future priorities

What follows are the research priorities for 2023-2024 related to airborne transmission of SARS-CoV-2, with implications for other airborne pathogens and future outbreaks/pandemics thereof.

The first three objectives are intrinsically linked in providing public health guidance on the inhalation (airborne) transmission mechanism of SARS-CoV-2. The fourth objective aims to study the possibility of developing a novel mechanism to automatize and systematize knowledge extraction from literature reviews, and applying this model to additional pathogens.

WHO would like to expand this project to:

- further improve the [ARIA web app](#) to increase accessibility and accuracy
- further improve the model and, most importantly, expand to other respiratory pathogens (e.g. TB, influenza, etc.)
- enable automatic data extraction to update model parameters (this was previously done by hand through multiple systematic reviews for each variable)
- automatize and improve the systematic literature review process through the development of a "natural language processing (NLP) engine" for systematic reviews

Unity Studies

Creating equitable opportunities for enhanced surveillance, operational capacity-building and global knowledge-sharing

Objectives

The WHO Unity Studies global initiative provides a pandemic preparedness and readiness framework for conducting targeted investigations and epidemiological studies that are critical to the risk assessment of any emerging or re-emerging respiratory pathogens of pandemic or epidemic potential.

The WHO Unity Studies initiative is intended to be used to rapidly assess transmissibility, estimate population susceptibility/immunity and infection severity, aid identification of population groups in need to target interventions, and assess effectiveness of interventions (e.g. vaccine effectiveness).

Achievements

The Unity Studies provided a standardized and timely international investigation framework during the COVID-19 pandemic. The suite of existing pandemic preparedness early investigation protocols was rapidly adapted for SARS-CoV-2 and promoted globally for the implementation of standardized and quality investigations and epidemiological studies.¹ Of note in the last 12 months:

1 Global data analysis and tools to inform key public health actions

Aggregation and analysis of global results shared with WHO has facilitated several pooled analyses generating much needed robust and comparable results to inform national, regional and global public health actions.^{2,3,4}

2 Tools and guidance help connect researchers and investigators to implement key investigations and epidemiological studies

In parallel, this work has led to the development of guidance and tools to help the optimal design and critical appraisal of investigations and epidemiological studies by supporting partners.^{5,6,7} An external evaluation⁸ showed that the initiative created equitable operational research and enhanced surveillance opportunities, connected researchers and investigators and expertise across countries, and facilitated study implementation.

3 Delivery of key seminars and online workshops

Continuation of monthly seroepidemiology scientific seminars in WHO Africa and Europe regions. Provision of online workshops and tailored support on statistical analysis and data management in collaboration with key partners, Serotracker, University of Melbourne, and EpiConcept.

4 Showcasing investigations and epidemiological studies from low and middle-income countries (LMICs)

To reduce the publication bias towards high-income countries (HICs), development of a Special Issue on Unity Studies in Influenza and Other Respiratory Diseases (the "Journal"). The special issue shall consist of approximately 23 manuscripts from only LMICs who have participated in the Unity Studies initiative.

Future priorities

Building on the lessons learned during the COVID-19 pandemic and for the Unity Studies to be operational during a future pandemic, WHO is planning to:

- update and develop standardized protocols for disease-specific aspects and others that are fit for purpose for any novel respiratory virus of pandemic potential
- build a global network of sites, which can be primed to conduct one or more country-specific standardized, pre-planned and pre-approved investigations and epidemiological studies in the event of a pandemic
- support quality implementation and dissemination of results through the development and use of toolkits for (i) WHO and (ii) implementing partners. Real-time data-sharing and other processes involving multisite data coordinated by WHO to enable timely sharing of results
- publish online and open-access the Special Issue on Unity Studies in Influenza and Other Respiratory Diseases (the "Journal")

The WHO Unity Studies initiative is intended to be used to rapidly assess transmissibility, estimate population susceptibility/immunity and infection severity, and aid identification of population groups in need.



Health emergency intelligence and surveillance

Health emergency intelligence and surveillance work has the aim of catalysing transformation in collaborative surveillance across all levels and serving countries by connecting, innovating, and strengthening capabilities to produce better data, analytics and decisions.

Through its “innovate” role, it aims to transform academic research into pioneering new tools and approaches that fit country and regional contexts.

Objectives

One of three strategic objectives of health emergency intelligence and surveillance work is introducing and adapting effective solutions to meet country needs to improve the analysis and sharing of high-quality surveillance data. This entails enhancing decision-making through the integration of data from a broad range of sources by pioneering innovative approaches.

Achievements

Follows are the main achievements of health emergency intelligence and surveillance work for COVID-19/other key diseases and pathogens in the past 12 months:

1 International Association of National Public Health Institutes (IANPHI) integrated disease surveillance (IDS) – global study

This area of work provided technical input into a deep dive study implemented by the IANPHI to explore the status of national surveillance systems and the extent to which IDS systems have been developed and operationalized.

This study was divided into three projects which includes: i) a systematic literature scoping review ii) a survey of IANPHI members, and iii) seven deep dives in three high-income countries (HICs), and four low and middle-income countries (LMICs), undertaken April-October 2022.

The study led to six key recommendations:

- Guiding definition for IDS
- Establishing and formalizing professional networks to strengthen workforce
- Facilitating opportunities for surveillance research, evaluation and learning
- Aligning resource needs with sustainable investment and funding
- Building an environment of interoperable data and systems across all sectors
- Strengthening national public health agencies (NPHAs) as catalysts for IDS

2 Anomaly detection for public health intelligence (PHI)

PHI digital solutions such as the epidemic intelligence from open sources (EIOS) system, and the communities that use them, do not currently utilize automated threat detection, identification, and alerting – a need that was made increasingly evident through the COVID-19 pandemic. The challenge faced is the ability to rapidly identify meaningful patterns, evolving changes and parallel threats, with a data influx that continues to exponentially grow.

This complex and innovative initiative incorporates automated mechanisms to identify unusual or unexpected events for PHI. Areas covered include the emergence of new COVID-19 strains, unusual increases in counts or affected populations, events linked to vaccination, and new rumours or misinformation campaigns.

3 Integrated Outbreak Analytics (IOA)

Integrated Outbreak Analytics (IOA) applies a multidisciplinary approach to understanding outbreak dynamics and to inform outbreak response. It is primarily a field-based initiative that leverages support from national, regional, and international experts to reinforce pre-existing local capacity to better respond to outbreaks and their impacts on communities in a holistic and evidence-based manner. Its members consist of experts from organizations and institutions with an international public

health emergency mandate and/or a global health operational research agenda.

In 2022, a standing IOA cell was established in the Democratic Republic of Congo (DRC), and several short-term IOA cells were set up during emergencies. In addition, operational research into the case for collecting, analysing and utilizing sex-disaggregated data and gendered data to inform outbreak responses was conducted.

4 Global One Health Intelligence Scoping Study (OHISS)

Vast amounts of data are captured across the One Health spectrum yet are insufficiently coordinated and leveraged to support better integration of health services across the human, animal and environmental sectors.

This study set out to develop best practices and a framework for an improved platform for effective sharing of One Health

information. This entailed mapping of existing information systems and platforms within Tripartite Organizations, international organizations, other international systems/networks, and the programmes within WHO Member States.

5 Mpox Analytics and Parameter Repository

In efforts to better understand the 2022 multicountry mpox outbreak, a specialized community of practice of infectious disease modellers was established to access, analyse and understand data on mpox transmission dynamics, as well as inform interventions to reduce risk for further spread.

The challenges they had to overcome included:

- limited access to data as well as limited insights from the data available
- limited sharing and comparison of models and related components
- lack of sharing of analytical tools (e.g. packages used)

- lack of central content repository
- limited adoption of collaboration and communication tools beyond email

In leveraging the Repository, an initiative led by the WHO Hub for Pandemic and Epidemic Intelligence, a virtual space was made available to stakeholders from Ministries of Health and national action plans for health security (NAPHSS) to test and jointly develop models. This allowed for joint comparison of models, relevant assumptions, estimates and projections, prior to wider release.

Future priorities

Follows are the main priorities for 2023-2024 of health emergency intelligence and surveillance work:

- In collaboration with IANPHI, socialize and support the implementation of the six resulting recommendations in the context of health emergency preparedness response and resilience (HEPR).
- Following the current prototyping and testing stages, incorporate the new mechanisms and solution into existing PHI digital solutions, with further iteration and scaling with the community of users.
- Continue to document of the added value of using IOA to inform decision-making processes during public health emergencies. IOA assessment of the current integration of sex and gender data across the outbreak response, and participatory assessment of the capacity of response actors to systematically integrate the collection, analysis and use of sex-disaggregated data and gender data into the response, are critical priorities.
- Prototype, develop and scale a global One Health intelligence System (OHIS).
- Outline potential future transmission scenarios for mpox beyond the ongoing 2022-2023 outbreak, and be able to foresee the potential spreading dynamics, within and outside the men who have sex with men (MSM) community through expert consultation.

During a disease outbreak, different plans and strategies across all the research areas are rapidly enacted.

A core focus of this phase is delivering major clinical trials of promising vaccines and treatments quickly and robustly.

Research integrated in the outbreak response

Vital vaccines and therapeutics research in the outbreak response	48
Clinical management	54
Infection prevention and control (IPC)	58
Public health and social measures (PHSM)	62


Research integrated in the outbreak response: Global network of expert groups/committees coordinated by the WHO R&D Blueprint for Epidemics

Therapeutics research

- Executive Group of the International Steering Committee of the Solidarity Trial Therapeutics (STT)
- International Steering Committee of the Solidarity Therapeutics Trial (STT)
- WHO Advisory Group on Therapeutics Prioritization for COVID-19
- Advisory Group Technical Expert Panel on Thrombostasis
- Advisory Group Technical Expert Panel on Inflammation
- COVID-19 Working Group on Outpatient Therapeutics Protocols

Vaccines research

- Technical Advisory Group Candidate Vaccine Prioritization
- Assays - COVID-19 and Priority Pathogens
- Animal Models - COVID-19 and Priority Pathogens
- Marburg Virus Vaccine (MARVAC) Consortium
- Target Product Profiles (TPPs) for COVID-19 Vaccines Working Group
- Core Protocol for Vaccines against COVID-19 Working Group
- Vaccines R&D for COVID-19 Vaccines Working Group
- Solidarity Trial Vaccines (STV) Executive Group
- Solidarity Trial Vaccines (STV) Data Safety Monitoring Committee (DSMC)



- WHO O2CoV2 - Oxygen Requirements and Approaches to Respiratory Support in COVID-19 Patients in LMICs study
- O2CoV2 International Steering Committee
- Clinical Severity Working Group
- Therapeutics and COVID-19 Guideline Development Group
- Clinical Management of COVID-19 Guideline Development Group
- Drugs to Prevent COVID-19 Guideline Development Group
- Filovirus Viral Haemorrhagic Fever (VHF) Working Group
- Mpox Guideline Development Group
- PMA Expert Working Group - Heparin, SGLT2
- Post-COVID-19 Expert Working Group
- Atlas for Mpox Lesions Working Group
- Clinical Characterization and Management Working Group
- Risk Factors for Severe or Fatal COVID-19 in the Paediatric Population
- Clinical Network/Emerging Diseases Clinical Assessment and Response Network (EDCARN)
- Neurology and COVID-19 Global Forum

- Public Health and Social Measures (PHSM) Working Group
- Public Health and Social Measures (PHSM) Methods Working Group (informal)

- Infection Prevention and Control (IPC) R&D Expert Group
- Global Infection Prevention and Control (IPC) Network
- WHO Infection Prevention and Control (IPC) Hub
- Infection Prevention and Control (IPC) in the Context of COVID-19: Guideline Development Group
- Infection Prevention and Control (IPC) for Ebola/Marburg Disease Guideline Development Group
- Clinical Management and Infection Control for Mpox Guideline
- Working Group Reviewing Mpox Disinfectant Protocol
- Public Health Emergencies of International Concern (PHEIC) Working Group (and subgroups)

Vital vaccines and therapeutics research in the outbreak response

At the heart of the global response against deadly outbreaks

Despite research being essential in underpinning preparations for outbreaks and pandemics, the unpredictable nature of these events means core uncertainties will only ever be addressed by conducting research during the health emergencies themselves.

All research areas will rapidly adapt and refine their pre-epidemic plans and put them into action to help in the coordinated collaborative research effort.

With their capability to prevent and treat serious illness over an extended period of time, vaccines and therapeutics are an essential component of any integrated response to outbreaks and pandemics. A core focus of this outbreak phase is delivering major clinical trials of promising vaccines and treatments quickly and robustly.

While speed (and sometimes cost) in responding to future pandemics is often emphasized, it is imperative to take a broader view that recognizes the primary importance of vaccine quality, equity in availability, and trust in a product's safety and efficacy.

Drawing on these key principles, R&D Roadmaps will be refined and developed during a disease outbreak or pandemic. This leads to:

Global and regional level

- Development of an **updated list of prioritized vaccine and therapeutics** candidates for inclusion during trials conducted in the specific outbreak
- **Activation of the facilitated process** to ensure that prioritized candidate vaccines and therapeutics are promptly deployed for use in studies integrated into the outbreak response. Such studies are initiated within two weeks of the declaration of an outbreak
- Prompt convening of the relevant **collaborative scientific networks** to update on the situation and mobilize support research during the specific outbreak
- **Support for RI priorities** previously identified and mobilized
- Activation of **legal and insurance frameworks** needed to conduct studies of investigational vaccines and therapeutics

Country and subregional level

- **Ministries of Health designated researchers** and research institutions (to lead research during outbreaks) activated and engaged with relevant international scientific networks
- **Final approval of CORE protocols** for both randomized controlled trials (RCTs), and expanded access use and/or MEURI obtained
- **Support of national research capacity** of designated national research institutions for the implementation of pre-approved research protocols mobilized to fill any remaining gaps

The key steps involved in the development and evaluation of medical countermeasures (MCMs) are also summarised in Figure 4 on page 52.

Achievements

Follows are the main achievements in vaccines and therapeutics research for COVID-19/other pathogens in the past 12 months:

1 Completing core elements of R&D Roadmaps for the majority of priority pathogens

As noted above, WHO has completed elements of R&D Roadmaps for most of the pathogens on its 2018 priority list of diseases with epidemic or pandemic potential.

2 Convening experts to update R&D Roadmaps for specific virus families

Recently, WHO refined this strategy and convened multiple consultations to support updated R&D Roadmaps for beta-sarbecoviruses, filoviruses, and mpox.

3 Ensuring rigorous, transparent approaches to reliable data collection to build public confidence

During an emergency such as a pandemic, there can be pressure to make decisions quickly based on limited clinical data. But public confidence in vaccines and therapeutics depends on the rigour and transparency with which data are collected. WHO has convened consultations to discuss approaches to collecting reliable data during the COVID-19 pandemic, and plans more of such meetings for priority viral and bacterial families.

4 Global consultations on the most effective use of COVID-19 medical countermeasures

WHO facilitated worldwide research efforts to develop and deploy COVID-19 vaccines and sponsored numerous consultations to support research to determine the most effective way to evaluate and use COVID-19 vaccines. Similarly, it supported consultations on vaccine evaluation for Plague, and Marburg, Sudan.

5 Sponsoring the global Solidarity platform trials for COVID-19 vaccines and therapeutics

WHO sponsored the global Solidarity Trial Vaccines (STV) of COVID-19 vaccines and the Solidarity Trial Therapeutics (STT) and Solidarity Plus. These continue to collect critical efficacy data. In early 2024, WHO will publish safety and efficacy data for both trials.

Future priorities

Follows are the main priorities for 2023-2024 in vaccines and therapeutics research in this area:

- The WHO R&D Blueprint will continue to refine existing R&D Roadmaps and complete additional viral and bacterial R&D Roadmaps, including for key viral families and bacteria identified in the current pathogen prioritization process. WHO will also convene a consultation to discuss current needs and gaps for plague vaccines.
- WHO will continue to convene experts to discuss and provide advice on seamless clinical trial designs, an approach used by developers in the COVID-19 pandemic to rapidly collect data, and which holds promise for other priority viral and bacterial families.
- Starting in 2023, WHO has convened international meetings to discuss standards for performing and reporting observational vaccine effectiveness studies in the context of outbreaks and pandemics. Such studies were an important part of the COVID-19 pandemic response, but were not always well conducted and it is important to consolidate learning from the pandemic.
- WHO will convene experts to discuss results and lessons learned from the global Solidarity platform trials for COVID-19 vaccines and therapeutics, sponsored by WHO.
- WHO will convene experts to discuss development and validation of correlates of protection for priority pathogens, potentially to allow vaccine efficacy to be predicted by immunogenicity data in certain cases.


Coordinate and facilitate worldwide research efforts to develop vaccines and therapeutics to address future outbreaks and pandemics.

The central role of research in future outbreak and pandemic response, as well as the dependence of rapid and trustworthy results upon international collaboration, free of political considerations, is widely recognized. WHO has the mandate and ability to coordinate such public health preparation and response on a global level.

WHO will continue to:

- convene consultations on ethical and regulatory approaches to vaccines and therapeutics against priority pathogens
- facilitate the pandemic treaty discussions. They will also contribute to building global plans for pandemic/outbreak medical and non-medical countermeasures
- further promote coordination of funders, researchers, regulators, developers, governments, NGOs, prescribers, and end-users via global forums, to create a transparent and open network of networks

Figure 4 shows the key steps involved in the development and evaluation of medical countermeasures (MCMs) – as part of WHO R&D Blueprint for Epidemics



© WHO/ Michael Duff

Filoviruses family research and innovation – a pathfinder

Filovirus outbreaks are a major challenge for African countries, and due to the lethal nature of the disease they cause, have considerable epidemic potential.

Based on previous experience, WHO and the Ministries of Health of the affected countries have been developing and implementing plans to speed the deployment of candidate vaccines and therapeutics for clinical studies in the context of future outbreaks.

Although in the most recent outbreak of Sudan virus in Uganda, novel candidate vaccines were available for the initiation of efficacy studies in record time (within 79 days), WHO’s goal is to make vaccines available for clinical evaluation within days 7-15 of outbreak identification in a subsequent outbreak, as has been done during Ebola Zaire outbreaks since 2016. For Zaire Ebola virus (ZEBOV) since 2016, ring vaccination has started 4-13 days after the outbreak has been reported to WHO.

Since 2022, WHO has been facilitating the formation of a research consortium led by Ministries of Health designated researchers. This is prepared to rapidly deploy filovirus candidate vaccines and therapeutics and will generate necessary clinical efficacy data in a future filovirus outbreak, integrated in the outbreak response. It will use pre-approved multiphase CORE protocols whose implementation will be led by researchers and institutions designated by Ministries of Health.

The R&D Blueprint for Epidemics and the Marburg Virus Vaccine (MARVAC) Consortium experts and collaborators launched a new filovirus research roadmap entitled Agenda for Filovirus Research and Monitoring (AFIRM).

WHO and MARVAC are planning a workshop to build on this new filovirus agenda and the important lessons learned such as the Uganda experience.

The planned objectives of the workshop are to:

- foster collaboration for evaluating filovirus candidate vaccines and therapeutics within outbreak responses, led by Ministries of Health and national research teams
- give the opportunity to national researchers and authorities to discuss existing trial protocols for candidate filovirus vaccines and therapeutics towards final consensus on key trial design attributes
- support a framework for an OPEN collaborative network of designated filovirus researchers in “at risk” countries with MARVAC members and other stakeholders. The framework aims to support clinical research preparedness and ensure that clinical research is integrated promptly into future outbreak responses

It is anticipated that representatives of all countries at risk of filovirus outbreaks will attend, including:

- Ministry of Health representative
- Ministry of Health-designated research institutions and primary investigators (PIs) who will lead the research integrated in the outbreak response
- Ministry of Health national regulatory authority (NRA) and ethics committee
- Members of the MARVAC Consortium
- Other invited experts

The workshop will be hosted by the Ministry of Health and organized by the three levels of WHO – global, regional and country.

Clinical management

Optimizing clinical management of COVID-19 patients and clinical care in large-scale health emergencies

Introduction

The Clinical Characterization and Management Working Group of the R&D Roadmap has brought together approximately 60 clinicians and researchers from around the world with the shared objective of accelerating the generation and dissemination of knowledge about the optimal clinical management of patients with COVID-19.

Our activities in the past year build on projects previously established and reported. In addition, working group members have been active in many other areas, including responses to other outbreaks of emerging and re-emerging infectious diseases, sharing this overall goal, and harmonized with, though not coordinated by, the working group. This work has evolved in three broad areas.

© iStock/ljubaphoto

Achievements

Follows are the main achievements in clinical management research for COVID-19/other key diseases and pathogens in the past 12 months:

1 Development of metrics for the characterization and stratification of COVID-19

Following on from our earlier creation of a Minimal Common Outcome Measure set for COVID-19 (Lancet ID, 2020), we have used a Delphi process to produce a clinical case definition of Post-COVID Condition (Lancet

Infect Dis. 2022 Apr;22(4):e102-e107) and developed a core outcome set for studies of Post-COVID Condition (Lancet Respir Med 10(7):715-724). Work to develop revised severity criteria for COVID-19 is ongoing.

2 Developing guidance and providing advice on emerging issues in the ethics of infectious diseases

We developed a novel method for the rapid pooling and reporting of data from recently finished and ongoing clinical trials – the prospective meta-analysis (PMA) – and a working sub-group – the REACT Working Group – to develop these.

We coordinated the publication of these in JAMA, working with the editorial team there to expedite publication, as well as to facilitate simultaneous publication of the participating trials in JAMA or its affiliated journals, as appropriate.

We further worked with the guidelines working group and the BMJ to incorporate these as well as the living COVID-19 guidelines. We followed up our PMA on

the use of corticosteroids (JAMA 2020) and interleukin-6 receptor antagonists (JAMA 2021) with a PMA on full-dose anticoagulation (manuscript submitted, under review), and of SGLT2 inhibitors (manuscript submitted, under review). An additional PMA on antiplatelet agents (ASA and P2Y12 inhibitors) has been discussed but deferred, pending completion of the two active meta-analyses.

In addition, we worked with partners to use the Living Network Meta-Analysis approach to evaluate therapeutics for COVID-19 on a rolling basis and rapidly inform the WHO COVID-19 clinical practice guidelines. This has led to 13 updates of the WHO living guidelines.

© WHO/Esther Ruth Mbabazi



3 Clinical studies of oxygen availability and respiratory support strategies in low and middle-income countries (LMICs)

A critical challenge during the pandemic, particularly in LMICs, was the ability to provide oxygen and respiratory support to patients with severe COVID-19. Compounding that challenge was a paucity of information on what resources were available and how they were being used.

We have undertaken an analysis of the availability of medicinal oxygen during the pandemic (under review) and initiated the WHO O2CoV2 study, a prospective cohort study of oxygen use, respiratory resources,

and clinical outcomes in more than 3,000 patients from 23 different LMICs.

Data were shared with study investigators at online meetings 1-3 May 2023. They will be reported, and used to inform the design of a planned collaborative platform trial to evaluate the relative clinical and resource effectiveness of differing strategies for respiratory support for severe acute respiratory infections (planned for 2024).

4 Access to investigational products for high-threat pathogens (HTPs) under the MEURI framework as an adjunct to randomized controlled trials

Since mid-2022, the WHO Clinical Research Working Group has supported the implementation of MEURI protocols during three outbreaks: i) Access to tecovirimat for mpox under an emergency use protocol,

ii) access to antivirals, including mAbs for Sudan virus in Uganda (descriptive analysis ongoing), and iii) access to antivirals for Marburg virus in Equatorial Guinea (manuscript submitted, under review).

5 Collection of standardized individual clinical and facility level data using the WHO Clinical Platform to inform public health response

Since the inception of the pandemic, WHO has launched the Clinical Platform that now hosts over one million anonymized hospitalized patient files and has informed multiple clinical characterization and management reports for COVID-19 (see bibliography) around the world. This is as well as periodically updating the COVID-19 clinical dashboard that provides the public with interactive sessions with global and regional data.

More recently, WHO expanded the scope of this platform to provide standardized clinical case record forms and a data platform for other emerging infectious diseases (EIDs), including cholera, filoviruses (generic), mpox and acute hepatitis of unknown origin. Contribution of data is ongoing in all of these areas.

6 Key performance indicators

Development of transparent and trustworthy key performance indicators (KPIs) is important to monitor and evaluate interventions. This was indeed the case during the pandemic where large-scale investments were made to scale up medical oxygen production at national and sub-

national levels. The Oxygen Emergency Task Force (part of the ACT-A) partners asked WHO to provide guidance on this aspect. WHO conducted a Delphi process to publish the first global KPIs on the medical oxygen ecosystem.

Future priorities

As the pandemic has waned, we have begun to shift our focus to address longer term needs for an effective future pandemic response, and to consider how the lessons learned during the COVID-19 pandemic can be applied to advance a global health goal of continuously improving and equitable health care for all, informed by clinical science that is integrated into the provision of that care.

The following next steps that pertain to each of the numbered achievements show how this can be applied in the future:

- Develop and apply standard methods to develop disease severity classification for other emerging infectious diseases (EIDs).
- Apply rapid evidence synthesis and transformation into clinical practice guidelines for other EIDs to improve care in a timely fashion.
- Develop and implement a WHO interventional trial on non-invasive respiratory interventions for severe acute respiratory infections/acute hypoxemic respiratory failure in LMICs using a collaborative approach amongst clinical platform trial networks.
- Develop a standard approach to the operationalization of expanded access protocols to ensure MEURI principles are maintained.
 - i) Develop a pan-respiratory pathogen clinical surveillance tool to augment epidemiologic data and inform readiness and response for circulating respiratory pathogens with epidemic and pandemic potential.
 - ii) Develop and implement observational, multicountry and multisite cohort studies for EIDs to enhance our understanding of clinical evolution and clinical management to improve clinical both short and longer term outcomes.
- Develop other key performance indicators (KPIs) for other key interventions that support scalable safe clinical care during health emergencies.

Infection prevention and control (IPC)

Readiness and response research and innovation (RI) for public health emergencies

Introduction

The COVID-19 pandemic highlighted significant gaps in the understanding of how transmission modes influence prevention measures and what are the most effective practical tools for protection and control in the context of emergencies due to novel high-threat pathogens (HTPs) of epidemiologic concern.

© iStock/Ridofranz

Objectives

In collaboration with experts from many countries, the WHO Infection Prevention and Control (IPC) team focused on the following research areas:

- Understanding risk factors in exposures to SARS-CoV-2 and other pathogens in the health care work environment.
- Rethinking existing IPC medical devices and equipment based on key enabling technologies.
- Defining pragmatic protocols for guiding local implementers in executing safe and effective IPC practices.
- Working with laboratory experts to bridge knowledge gaps on how to deactivate novel pathogens.
- Establishing research and innovation (RI) priorities which should be brought to the attention of the international community.

Achievements

Follows are the main achievements in IPC research for COVID-19/other key diseases and pathogens in the past 12 months.

- Peer-reviewed publications of COVID-19 IPC work**

With respect to COVID-19, the team supported and/or coordinated studies resulting in 13 peer-reviewed publications in the last year.¹
- Global case control study assessed SARS-CoV-2 infection risk factors for health workers**

The IPC team led a global case control study assessing risk factors for health workers, which included data from 121 health care sites across 21 countries and is now under peer review for publication. Its findings indicate that SARS-CoV-2 infection risk was associated with non-adherence to personal protective equipment (PPE), not performing hand hygiene consistently, and being in close contact with infected patients; however, the study suggests that there was no difference in infection risk between the type of masks worn for routine care.
- Tested innovative approaches with facepiece respirators² in the community**

A novel surveillance approach was piloted in community settings using poly-vinyl alcohol strips embedded in filtering facepiece respirators to enable capture of exhaled breath as a non-invasive testing approach for SARS-CoV-2.
- Delivered a major trial comparing medical masks versus filtering facepiece respirators**

WHO supported the data analysis portion of a randomized controlled trial (RCT)³ comparing medical masks versus filtering facepiece respirators for health workers providing care to COVID-19 patients.

5 Conducted virtual tabletop simulations⁴ to aid learning

A study on virtual tabletop simulations for helping IPC teams implementing international guidance into their specific clinical contexts was conducted, demonstrating that simulation tools can provide significant benefits to IPC and safety improvements worldwide.

6 Delivered key studies⁵ on decontamination procedures

Studies on decontamination procedures were conducted, including the use of Methylene Blue (MB) photochemical treatment, demonstrating the efficacy of MB + light (ultraviolet, phosphorescent or sunlight) in decontaminating medical masks, filtering facepiece respirators, and other PPE items contaminated with a range of dangerous pathogens.

7 Assessed the safety of reusing decontaminated medical masks and other protective equipment

Researchers also assessed the safety of reusing medical masks and filtering facepiece respirators decontaminated with MB, finding no persistent risk of chemical exposure to the wearer when MB is applied for decontamination at recommended levels. In the study, 13 face shield designs were tested in the laboratory and among 600 health workers in middle-income countries (MICs); users reported preferences towards face shields due to good communication, secure fixture, good visibility, comfort and fashion.

8 Various key studies - including scoping review on barriers⁶ to PPE implementation

A scoping review on barriers to PPE implementation and interventions concluded that effective PPE measures implementation involves multilevel transdisciplinary complexity and relies on context-driven implementation strategies, which should leverage solid collaboration among local and international health bodies. Finally, a live systematic literature review commissioned by WHO to assess risk factors for SARS-CoV-2 infection in health workers⁷ is on its 18th update in 2023.

9 Analysing innovative methods - including using drones⁸ to improve access to IPC supplies

A simulation study demonstrated how a scalable fleet of drones can be used to improve accessibility of essential supplies, equipment and remote care in remote areas. A systematic literature review was also delivered and published exploring the use of key enabling technologies (i.e. robots, internet of things and artificial intelligence - AI) for IPC.

10 IPC studies and work beyond COVID-19

Beyond COVID-19, other pathogen thematic research areas included: i) mpox deactivation protocol to provide reference standards for disinfection of surfaces, laundering of linens, and hand hygiene in health care and community settings where patients with mpox are cared for; ii) better understanding of contextual factors linked to IPC measures in relation to Ebola disease management in health facilities and Ebola treatment units (ETUs) through an ethnographic study, survey, and in-depth interviews of health workers in multiple countries; iii) systematic literature reviews to support evidence based IPC recommendations for COVID-19, mpox, Ebola and Marburg disease; iv) two systematic reviews to understand the burden of health care-associated (HAI) infection and antimicrobial resistance in primary care facilities, as well as effectiveness of interventions to prevent pathogens spread in these settings; v) a position paper describing IPC research needs for IPC for Ebola disease and Marburg disease is under development through a research prioritization exercise with contributions from an expert panel.

11 Working group for IPC in public health emergencies

A working group for IPC in public health emergencies has been established with a mandate to identify best response and implementation approaches and define immediate and longer term IPC research priorities and implementation considerations.

12 IPC Hub continuing to monitor IPC implementation worldwide

At the same time, the WHO IPC Hub has been progressing a programme of work for monitoring IPC implementation worldwide. The first WHO global survey on IPC programme at the national level conducted in 2021-2022 showed that only 3.8% of 106 participating countries met all the WHO IPC minimum requirements; however, it also showed improvement of several IPC indicators compared with 2017-2018.

Future priorities

Plans for the coming year for the World Health Emergencies (WHE) IPC programme of work are to strengthen IPC preparedness, operational readiness and response in the context of public health emergencies, including:

- IPC technical guidelines for Ebola and Marburg disease, and mpox
- health care-associated infection (HAI) cluster and outbreak investigation handbook for health facilities for epidemic-prone respiratory infections
- a scientific brief on IPC and water, sanitation and hygiene (WASH) innovations in emergencies

Plans for the coming year for the IPC Technical and Clinical Hub programme of work to strengthen IPC in primary health care (PHC) include the launch of a suite of WHO resources with a focus on PHC. These are:

- an assessment tool on IPC minimum requirements for PHC care facilities⁹
- an infographic and inventory document to facilitate PHC workers' access to all available WHO resources for the prevention of surgical site infection¹⁰
- a training package for improving IPC in PHC and to pilot implementation of an IPC improvement package

Public health and social measures (PHSM)

Providing global evidence on the effectiveness and impact of PHSM for emergency preparedness and response

Introduction

Public health and social measures (PHSM) are an essential part of critical interventions during health emergencies alongside medical countermeasures. PHSM refer to a broad array of non-pharmaceutical interventions implemented by governments, individuals and communities to reduce the risk and scale of transmission of epidemic and pandemic-prone infectious diseases.

© iStock/FG Trade

Objectives

- Conduct global monitoring and reviews of PHSM data and research to support countries in accessing and using multidisciplinary and context-specific knowledge about PHSM to strengthen understanding about PHSM effectiveness, unintended negative consequences and implementation strategies.
- Strengthen PHSM research methodology and capacity to support countries in conducting research using a harmonized conceptual understanding of PHSM and addressing methodological, legal, ethical and political challenges of PHSM research.
- Increase precision in PHSM decision-making to support countries in developing their own equitable, context-specific PHSM policies that are informed by robust evidence while taking into account epidemiological and socioeconomic impacts.
- Systematically integrate PHSM into existing health emergency management plans, policies, financing, governance and leadership in all relevant sectors at national, subnational and local levels across the health emergency spectrum of action.

Achievements

Follows are the main achievements for 2023-2024 in PHSM research in this area:

1 Global research agenda 2021-2030

WHO is developing a global research agenda on PHSM during health emergencies to strengthen the global evidence base on its effectiveness and impact. This research agenda is developed through a multistep, consultative process. Urgent research priorities for PHSM in the context of COVID-19 have been compiled through a global public survey, following the identification of six research themes at the global technical consultation on PHSM in 2021.

2 Conceptual framework of PHSM

WHO is developing a conceptual framework of PHSM to have a shared language, structured thinking and understanding of how PHSM operate to reduce risk and scale of transmission, to enable a comprehensive description of measures, their stringency, target population, settings, outcomes and other factors influencing their effectiveness. The initial draft framework was published in 2023.

WHO is developing a global research agenda on PHSM during health emergencies to strengthen the global evidence base on their effectiveness and impact.

3 A series of global evidence reviews

Preliminary results of the global evidence reviews on i) the effectiveness and impact of PHSM, and ii) social protection policies to mitigate the unintended negative consequences of PHSM during the COVID-19 pandemic are available.

4 PHSM 2023-2025 planning

A WHO high-level global PHSM workplan was developed with six WHO regions to set the pace of global actions and uphold the sense of urgency, quality and scale needed to address future health emergencies through PHSM in a systematic and evidence-informed manner.



Future priorities

To support countries in PHSM implementation during future health emergencies that is informed by the best available evidence on its effectiveness and impact, as well as equitable and context-specific, the PHSM initiative is focusing on the following research activities in 2023-2024:

- **Develop PHSM study protocols:** To ensure the high-quality and timely generation of data on the effectiveness of PHSM during health emergencies, WHO is developing study protocols for several diseases and interventions. The protocols will be accompanied by key considerations to address ethical and implementation challenges in conducting effectiveness research for emergency preparedness and response.
- **Develop global guidance on PHSM monitoring:** WHO is developing a global multi-hazards guidance and online toolkit for monitoring PHSM policies and implementation to facilitate systematic and harmonious data collection and use for PHSM decision-making across countries.
- **Launch of the global PHSM research database:** It will contain the latest global, multilingual, multidisciplinary literature including living systematic reviews and visualization of indexed literature against the global PHSM research agenda and conceptual framework. This facilitates timely monitoring of the implementation of the global PHSM research agenda and functions as the living mapping of PHSM research.
- **Finalization of the global research agenda:** The second public survey to identify research priorities for PHSM using a multi-hazards approach was launched in October 2023 and the complete research agenda for 2021-2030 will be published thereafter.




The delivery of effective medical countermeasures and wider policies to combat a disease outbreak is underpinned by a wide range of research areas. They all coordinate and work together enabling the global research effort before and during an outbreak.

Enabling research

Regulatory science	70
Biological standardization	74
Ethics	78
Community-centred readiness and response	82
Tackling infodemics	86
WHO Initiative on Trust and Pandemic Preparedness	90
Good participatory practice (GPP-EP)	94

Enabling research: Global network of expert groups/committees coordinated by the WHO R&D Blueprint for Epidemics



Regulatory science

Regulatory systems are integral to the public health response: working together to accelerate equitable access to vital medical products

Introduction

Efficient and effective regulatory systems are cornerstones in providing affordable, timely and equitable access to quality-assured diagnostics, medicines and vaccines at all times. But they are even more important during epidemics and pandemics. The COVID-19 pandemic has shown us the critical role of regulators in ensuring the continued supply of existing medicines as well as evaluating the quality, safety and efficacy of investigational treatments and vaccines for emergency use.

© WHO/Natalie Naccache

Achievements

Follows are the main achievements in regulatory science research for COVID-19/other key diseases and pathogens in the past 12 months:

1 Facilitating procurement decision-making across the globe to enable greater access to vital medical countermeasures against COVID-19

In a world where 70% of national regulatory authorities (NRAs) have inadequate or weak regulatory systems, the Department of Regulation and Prequalification (RPQ) at WHO has facilitated procurement decision-making of the COVAX Facility, the Global Fund, UN agencies and Member States from low and middle-income countries (LMICs) by assessing investigational diagnostics and vaccines using the WHO emergency use

listing (EUL) procedure, and prequalifying medical products. By the end of 2022, RPQ prequalification teams had recommended 42 in vitro diagnostics and 11 COVID-19 vaccines for EUL, and prequalified nine medicines and three biologicals for COVID-19 treatments, as well as 87 cold-chain equipment and immunization devices.

2 Providing vital support for LMICs in expediting regulatory clearance for life-saving COVID-19 vaccines, diagnostics and treatments

In parallel, WHO regulatory teams assisted NRAs in nearly 150 LMICs to issue approximately 5,500 expedited regulatory clearance for EUL listed COVID-19 vaccines. This was through regulatory reliance and a special EUL mechanism to share regulatory information with NRAs under a confidentiality agreement. According to a study published in 2022,¹ ten EUL COVID-19 vaccines contributed to the delivery of 842 million doses of vaccines in LMICS in 2021, averting between 5.1 million and 7.6 million deaths.

With WHO's behind-the-scenes support, over 1.95 billion doses of COVID-19 vaccines have been delivered to 146 countries through COVAX Facility to date. In addition, 40 million quality-assured diagnostic tests and over 32,000 treatment courses of COVID-19 antivirals were distributed through the pandemic response consortium to LMICs. RPQ pharmacovigilance team supported

countries and regions with robust guidelines, tools, and innovations for the safety surveillance of COVID-19 vaccines, and, through the Global Advisory Committee on Vaccine Safety (GACVS), provided swift and timely guidance on emerging safety signals.

Strengthening regulatory systems and building capacity for well-trained regulatory experts requires substantial time, investment and commitment within each country. Thus, coordinated efforts to support NRAs during the interepidemic period are essential steps towards building resilient systems against future outbreaks and pandemics. Furthermore, well-functioning regulatory systems are an essential foundation for successful execution of technology transfers, as well as sustainable and consistent local production of diagnostics, medicines and vaccines.

3 Supported national regulatory authorities (NRAs) in LMICs through technical assistance, training and benchmarking, towards functional maturity in medical products regulation


In the past two years, 12 NRAs have reached functional maturity level in medical products regulation and there are numerous other NRAs undertaking the self-benchmarking. Meanwhile, thousands of regulators from

around the world have participated in the WHO Department of Regulation and Prequalification (RPQ) subject-specific training programmes to gain in-depth knowledge and build expertise.

Future priorities

WHO has declared COVID-19 to no longer be a public health emergency of international concern (PHEIC). However COVID-19 remains a global health threat. Leveraging the lessons learned from the COVID-19 pandemic, we also need to prepare for other outbreaks and epidemics. Given this, here are the main priorities for 2023-2024 in regulatory science research – and the work of RPQ teams – in this area:

- Continuing to assess quality, safety and efficacy of vaccines, diagnostics, medicines and biologicals that are essential for COVID-19, as well as for diseases affecting LMICs, promoting and providing relevant training for implementing good regulatory practices² and good reliance practices³ to build strong, efficient and sustainable regulatory systems.
- Continuing assisting NRAs in particular in LMICs to assess weakness in their regulatory systems through the WHO Global Benchmarking Tool.⁴
- Contributing further to coordinated regulatory harmonization, conversion and collaboration efforts through the WHO Coalition of Interested Parties (CIP).⁵
- Expanding the collaborative registration procedure (CRP)⁶ to enable market entry and national marketing authorizations for prequalification products. Further support countries and regions to enhance their ability to collect, assess and act on safety data and to implement WHO Global Safety Advisory Committees⁷ recommendations.
- Providing specialized technical assistance for strengthening sustainable local production and technology transfer to improve access to quality, safe and effective health products.
- Documenting and analysing the unprecedented agility, flexibility, innovative regulatory approaches and collaborative efforts of a number of regulatory agencies and networks, for example, the International Coalition of Medicines Regulatory Authorities (ICMRA)⁸ during the COVID-19 pandemic, to identify bottlenecks and develop coordinated strategies to build resilient and efficient regulatory mechanisms against outbreaks and pandemics for the future.



Biological standardization

Helping increase access to life-saving vaccines, treatments and diagnostics

Introduction

The core focus of biological standardization is to provide international standards to facilitate convergence of global regulatory requirements, accelerate approval processes, and increase access to diagnostic, preventive and therapeutic medicinal products.

© iStock/BrianAJackson

Achievements

Follows are the main achievements in biological standardization research for COVID-19/other key diseases and pathogens in the past 12 months:

1 Delivery of key international measurement standards

International written and measurement standards have been developed through global collaborative effort to facilitate development and regulatory convergence of vaccines, diagnostics and therapeutics, relevant to priority pathogens and beyond.

Measurement standards help assay validation and assessment towards assured quality, and enable comparison of results from different assays or vaccine clinical trials.

The use of the WHO International Standards of SARS-CoV-2 Antibody is important for interpreting results from vaccine clinical trials by providing the basis for the expression of the antibody titres in International Unit (IU).

In particular, from the results from efficacy trials for various vaccine candidates, for example, correlate of protection can be defined as IU/mL. Faced with an evolving antigenically diverse pathogen, there are challenges in maintaining the continuity of the unitage while still providing biologically relevant reference preparations.

WHO international measurement standards have been established to support the development and evaluation of diagnostic,

preventative and therapeutic products for infectious diseases including priority pathogens:

- Second WHO International Standard of Anti-SARS-CoV-2 immunoglobulin
- First WHO International Standard of Antibodies to SARS-CoV-2 variants of concern
- First WHO International Reference Panel of Antibodies to SARS-CoV-2 variants of concern
- First WHO International Standard of SARS-CoV-2 antigen
- First WHO International Standard of Lassa virus RNA for NAT-based assays
- First WHO International Standard of Anti-chikungunya virus immunoglobulin G
- First WHO International Standard of Rift Valley fever virus antibodies for use in neutralization assays (serum)
- First WHO International Standard of Rift Valley fever virus antibodies for use in binding assays (serum)

2 Delivery of training and support tools

Following the establishment of WHO standards, continuous support has been provided to users by, for example, organizing trainings and webinars. A WHO manual for the preparation of reference materials for use as secondary standards in antibody testing focusing on SARS-CoV-2 has been developed. Such need for WHO support was reinforced by the

unprecedented level of demand for the First WHO International Standard for Anti-SARS-CoV-2 immunoglobulin. This manual provides guidance on the preparation, characterization, calibration, storage and distribution of antibody secondary standards. A future implementation workshop to provide help to users is also being planned.

3 Production of key guidelines

Recognizing the paucity of regulatory advice specific to the evaluation of monoclonal antibodies and related products for use against infectious pathogens, guidelines for the production and quality control of monoclonal antibodies and related products intended for medicinal use; and guidelines on the non-clinical and clinical evaluation of monoclonal antibodies and related products intended for the prevention or treatment of infectious diseases, have been developed in broad consultation with worldwide stakeholders.

This is to facilitate harmonization of global regulatory requirements, accelerate approval

processes, and increase access to such products that play an important role in rapid response to public health emergencies caused by emerging infectious agents, while continuing to assure their safety and efficacy.

Other relevant WHO guidance that has been developed includes:

- Guidelines on evaluation of biosimilars
- WHO global model regulatory framework for medical devices including in vitro diagnostic medical devices



© WHO/Medicines Patent Pool/Rodger Bosch

Future priorities

During the COVID-19 pandemic, a number of standards have been developed and updated to assist regulators and manufacturers in the evaluation of the quality, safety and efficacy of vaccines, monoclonal antibodies and other biologicals. As part of the preparation for future outbreaks and pandemic situations, the following priorities for 2023-2024 in setting standards by the Norms and Standards for Biologicals team have been defined:

- Review of needs for new or replacement standards for public health emergencies and organization of activities with the aim to meet the needs of WHO Member States.
- Timely development of international measurement standards for emerging disease pathogens by WHO collaborating centres coordinated by the Norms and Standards for Biologicals team.
- Review and establishment of standards for public health emergencies through the Expert Committee on Biological Standardization.
- Development of guidelines on regulatory preparedness for authorization and post-authorization activities for human pandemic and other public health emergency vaccines in importing countries.
- Preparation of a key document with special consideration for COVID-19 monoclonal antibodies as an addendum to the WHO guidelines on the nonclinical and clinical evaluation of monoclonal antibodies and related products intended for the prevention or treatment of infectious diseases.
- Continuous provision of technical assistance to countries to facilitate regulatory evaluation of vaccines and biotherapeutic products.
- Promotion of science-based regulation of biologicals with a focus on standardization of vaccines, monoclonal antibodies and other biologicals for public health emergencies.
- Organization of the activities to facilitate implementation of the standards for public health emergencies into regulatory and manufacturing practices.

International written and measurement standards have been developed through global collaborative effort to facilitate development and regulatory convergence of vaccines, diagnostics and therapeutics, relevant to priority pathogens and beyond.

Ethics

Prioritizing pivotal ethics work before and during pandemics and outbreaks

Introduction

The WHO Expert Group on the Ethics and Governance of Infectious Disease Outbreaks and Other Emergencies of Public Health Importance aims to examine and produce guidance with respect to the ethical and justice considerations and dimensions associated with preventing, preparing for, responding to, and recovering from, such events.

© iStock/SDI Productions

Objectives

Follows are the objectives of the WHO Expert Group on the Ethics and Governance of Infectious Disease Outbreaks and Other Emergencies of Public Health Importance:

- Develop and revise WHO guidance on ethics and governance matters and related tools for infectious disease outbreaks, including on research, public health measures, and equitable allocation.
- Discuss and advise on ethical and governance aspects of preparedness for emergencies of public health importance and infectious disease outbreaks, as needed.
- Where needed, help facilitate the implementation of related WHO ethical and governance guidance documents into policy and practice.
- Support WHO and Member States in responding to ethical and governance issues as they arise in terms of preparedness and response for emergencies of public health importance and infectious disease outbreaks.

Achievements

Follows are the achievements of the WHO Expert Group on the Ethics and Governance of Infectious Disease Outbreaks and Other Emergencies of Public Health Importance for COVID-19 and other key diseases and pathogens in the past 12 months:

- ### 1 Updating ethics guidance on COVID-19

The working group has updated earlier guidance documents, e.g. on ethical considerations for mandatory vaccination, in light of evolving evidence and developments on COVID-19.
- ### 2 Developing guidance and providing advice on emerging issues in the ethics of infectious diseases

The working group has initiated the generation of new ethics guidance on emerging issues of importance, for example the ethics of social listening and infodemic management. It has recently published a guidance document on ethical issues in mpox. The group has also provided advice in response to inquiries from various WHO units and initiatives, for example on allocation principles for distributing scarce malaria vaccines, as well as the distribution of therapeutics within the ACT-Accelerator.
- ### 3 Generating evidence on ethics committees during COVID-19

In a global empirical study and a dedicated satellite meeting at the Global Summit of National Ethics Committees 2022 in Lisbon, the working group mapped the experiences of ethics review committees worldwide during the COVID-19 pandemic. It has thereby laid the foundations for an evidence-based assessment and improvement of ethics capacities for future epidemic outbreaks.

4 Bridging gaps between ethics and public health decision-making

Following up on the WHO Pandemic Ethics and Policy Summit hosted by the Expert Group in December 2021, a meeting report has been published and a programme of work is being developed which identifies priority issues in bridging gaps between ethics advice and its implementation in public health decision-making.

5 Breaking new ground in research ethics during public health emergencies

The working group has published a comprehensive update of the ethical framework for the use of unproven clinical interventions outside clinical trials during public health emergencies (the MEURI ethical framework), a practice that has surged during the COVID-19 pandemic.

6 Outreach and engagement

A range of video presentations and panel discussions on current ethical issues in infectious disease outbreaks were made available through the Epidemic Ethics Network at <https://epidemicethics.tghn.org/seminars/>

Future priorities

Follows are the main priorities for 2023-2024 in ethics research in this area:

- Updating WHO guidance on the ethics of infectious disease outbreaks in light of lessons learned from COVID-19.
- Providing ethics guidance on the transition from the COVID-19 pandemic to the endemic stage.
- Monitoring and integrating advice on ethics and justice in epidemic and pandemic preparedness into relevant WHO initiatives (e.g. the Pandemic Treaty), and revisions (e.g. of the International Health Regulations - IHR).
- Generating ethics-to-policy tools for translating, integrating and implementing ethics in public health decision-making, response efforts, and ethical preparedness.
- Convening global stakeholders to develop new research ethics oversight and governance models for implementation under the WHO clinical trials resolution.
- Exploring models of “ethical governance” to support future global and regional mechanisms for the delivery of medical countermeasures in infectious disease outbreaks.
- Continuing the implementation of WHO quality assurance, norms and standards in the development of WHO ethics guidance documents.

Bridging the gap between ethics and decision-making

Research and health policy during the COVID-19 pandemic raised a number of important ethical issues and questions – for example around the allocation of vaccines, therapeutics and diagnostics across the world.

But policy decisions during the pandemic did not always engage meaningfully with the ethics dimension.

To improve the role of ethics in policy-making, mutual learning must occur between ethicists and policy-makers. This should involve the inclusion of ethicists in policy-making processes, and ethicists integrating and operationalizing advice more effectively, e.g. into checklists, where appropriate.

This was one of the main findings of a summit convened by the Expert Group and the WHO Health Ethics and Governance Unit during the pandemic (December 2021). The event was attended by experts from all WHO regions and served as a catalyst for much needed empirical, theoretical and

normative work to better understand and improve “ethics to policy” input in pandemic prevention, preparedness and response.

The WHO Director-General, in his opening remarks, highlighted that “ethics is fundamental in every area of health” and urged policy-makers to “keep ethics at the heart of decision-making”.

Many examples of the successful inclusion of ethicists at the policy table locally, regionally, nationally, and internationally were cited.

Participants drew attention to a number of key moral failures and global health injustices during the pandemic and beyond, such as the hoarding of vaccines and administration of booster shots in rich countries, while other parts of the world had to wait for their first doses.

Further information is available in the [Meeting Report of the WHO Pandemic Ethics & Policy Summit](#).



Community-centred readiness and response

Data driving action

Introduction

Health emergencies start and end at local levels.

Pandemics and outbreaks have a more significant impact on resource-poor areas, where people face challenges such as fractured infrastructure, weak governance, fragile health systems, food insecurity, and limited access to clean water. Community-centred approaches bring together the knowledge, expertise and assets of local communities and key stakeholders to develop acceptable, feasible and relevant preparedness and response actions.

This approach considers the social and behavioural aspects of health emergencies alongside biomedical perspectives. To achieve inclusive, accountable and equitable community-centred action, responders require rapid and practical social and behavioural data and analytics.

Models emerged, and were tested, during the COVID-19 pandemic and have been successfully applied to other health emergencies.

These include partnerships that strengthened risk communication and community engagement (RCCE),¹ as well as for rapid integrated outbreak analytics at a local level.²

Infrastructure for providing routine social and behavioural evidence production, along with advancements in rapid methods for evidence production, have further contributed to policy and response improvement.^{3,4,5}

The achievements reported here result from activities across all levels of WHO, partnerships with academic networks and initiatives from operational partners, including through the Global Outbreak Alert and Response Network (GOARN) supported initiatives, such as the RCCE Collective Service⁶ and Integrated Outbreak Analytics (IOA).⁷

Objectives

- Learn from the COVID-19 pandemic with regards to integrating community-centred approaches to build readiness for future shocks.
- Build fit-for-purpose structures and capacity for social research to inform action in a future public health emergency.
- Systematic, institutional inclusion of social evidence for readiness and response.

Achievements

Community-centred research drives readiness and response action that is acceptable, feasible and relevant to affected populations. It is most impactful when owned and delivered at local and national levels.

Follows are the achievements in the past 12 months across the three levels of WHO:

1 Conducted 150+ rapid studies to strengthen practice

Over the past 12 months alone, 150+ rapid studies were conducted to strengthen RCCE practices, including among marginalized groups, for COVID-19, mpox, Sudan Ebola

Virus Disease (SVD), Marburg Virus Disease (MVD), cholera, the conflict in Ukraine and earthquakes in Turkey and Syria, and other health emergencies.

Community-centred approaches bring together the knowledge, expertise and assets of local communities and key stakeholders to develop acceptable, feasible and relevant preparedness and response actions.

2 Developing systems and process for routine use of data to drive practice

Infrastructure for data-driven social approaches were developed - including the Collective Service Data for Action platform.⁸ Technologies for person-centred risk communication interventions, such as rapid testing of public health messages were also created.

Advances were made in a promising operational model for rapid production and use of evidence from multiple perspectives to strengthen local level response to health emergencies through Integrated Outbreak Analytics (IOA).

3 Delivered evidence syntheses on social/behavioural dynamics in health emergencies

Evidence syntheses to identify gaps⁹ and key considerations for social and behavioural dynamics of health emergencies were

delivered. Briefings and best practice approaches,^{10,11,12,13,14} including for IOA were also produced.

4 Expanded partnerships and collaborations to drive change through evidence and analytics

New collaborations were forged including engagement of civil society organizations in research that led to policy change.¹⁵ For example, one organization conducted operational research on the prevalence of

COVID-19 infections among health workers, resulting in national standard operating procedures (SOPs) for protecting health workers in emergencies, setting a flagship example to countries in the region.

5 Key work of working and advisory groups

Over 15 advisory and working groups convened to inform readiness and response at all three levels of WHO.

Future priorities

Follows are the main priorities for 2023-2024 in community-centred research in this area:

- Integrate lessons from recent health emergencies into updated technical guidance, including for RCCE and best practice in rapid evidence production.
- Advance methods, technologies, infrastructure and capacity for evidence-informed technical expertise to drive community-centred readiness and response via IOA and other initiatives.
- Consolidate tools and products for effective RCCE, for example, community conversation kits, an evidence-informed intervention for frontline health workforce to communicate with affected populations.



Tackling infodemics

Promoting a resilient and healthier information environment

Introduction

An infodemic is an overwhelming amount of information, including mis- and disinformation, that accompanies health emergencies such as outbreaks and other health crises.

Infodemics contain questions, concerns, information voids (where people seek credible, accurate information but cannot find it), and circulating mis- and disinformation. When people's questions and concerns about a health topic are not addressed, and when they cannot find accurate health information that is relevant to them and in acceptable formats when they need it, it is more likely that their attention will turn to sources of health information that are less credible.

A digitized information environment has sped up information exchange through digital media which affects also offline conversations and can cause information overload and confusion. In the digitized information environment, individuals can be part of multiple online and offline communities simultaneously, thus concurrently discussing topics with others from local and global contexts in communities with which they share some common interests, values, or activities.

At the same time, the digitized information environment is designed to promote content and narratives that are closely aligned with people's interests, values and identities. In such a noisy context, circulating narratives can challenge how effectively and rapidly health authorities can respond to health emergencies, not only through infodemic management strategies, but also through communications, community engagement, and design, delivery and quality of health services.

It has therefore become imperative to find ways to clearly discern and demonstrate the burden of infodemics on our individual and collective health outcomes so that interventions may be created to mitigate its harms.

Infodemic management helps us i) understand the information environment in which individuals and communities live and interact, ii) gain insights into affects people's health perceptions and behaviour, iii) diagnose possible harmful patterns that emerge in the information environment, and iv) provide recommendations and strategies to mitigate those harms.

WHO is developing tools to provide an evidence-based response to the infodemic to strengthen epidemic and pandemic response activities and is fostering the growth of the field of infodemiology.

In future, all emergencies and pandemics will be accompanied by infodemics that will be better addressed with the tools and insights developed today.

Objectives

Aligned with the WHO public health infodemiology research agenda, WHO's specific objectives contribute to infodemiology by:

- promoting an infodemiology research agenda
- Measure the burden of infodemic
- connecting research to practice through a WHO infodemic management training programme and evidence-based infodemiologist's toolbox
- promoting implementation science, evidence generation and publication in infodemiology-related topics
- developing an evidence map and gap analysis for frameworks of interventions and infodemiology
- promoting the development of ethical frameworks for infodemiology applied to social listening and infodemic management

Achievements

Follows are the main achievements in research to tackle infodemics for COVID-19/other key diseases and pathogens in the past 12 months:

- 1 Promotion of public health research agenda for managing infodemics.
- 2 Calls for papers on infodemiology.
- 3 Establishment of five working areas of collaboration towards measurement of burden of infodemic.
- 4 1300+ infodemic managers from 142 countries now trained in infodemiology and evidence-based approaches to infodemic management and actively participating in a community of research and practice.
- 5 WHO principles and strategies to mainstream infodemiology and infodemic management into training and learning programmes at universities, professional associations and applied professional programmes such as field epidemiology programmes.
- 6 OpenWHO channel on infodemic management with eight courses, including infodemiology methods.
- 7 Evidence mapping and gap analysis reviewing implementation of the public health research agenda, infodemic management frameworks and interventions.
- 8 Ongoing development of methods and tools for automated social listening of conversations in social media and other digital public data sources.
- 9 Ongoing development of evidence-based scalable social inoculation interventions.
- 10 Tools and protocol for measuring information diet and linking it to health outcomes.
- 11 Ongoing delivery of tools for analysis of digital information environment, such as Early AI-supported Response with Social Listening (EARS) platform, piloted for COVID-19 and COVID-19 vaccines, now recalibrated to respiratory pathogen social listening.
- 12 A manual for how to develop infodemic insights report in six steps for field responders, with accompanying job aids and training programme.
- 13 A risk assessment approach to assess narratives for risk to health and wellbeing, and prioritize emergency response and strategies.
- 14 Methodology for developing a social listening taxonomy for infodemic monitoring and integrated analysis, including taxonomies for COVID-19, mpox and respiratory pathogens.
- 15 Ongoing development of an ethical framework for social listening and infodemic management.

- 16 Analysis of lived experience and impact of COVID-19 infodemic on field responders.
- 17 Infodemic insights informing outbreak response of COVID-19, mpox, mass gatherings (e.g. the Olympics and Football World Cup) and other emergencies.
- 18 Development of analytical methods and deep dive analyses on specific topics (e.g. pandemic fatigue, trust in evidence and health information, stigmatization of vulnerable populations, etc.).
- 19 Policy brief on COVID-19 infodemic management.
- 20 (ongoing) Analysis of current use of social media analysis tools in health, with recommendations for future tool requirements.

Future priorities

Despite widespread recognition of the importance of infodemic management in response to the COVID-19 pandemic, mpox, and other outbreaks and health emergencies since then, there is still much to learn about the use, implementation and effectiveness of infodemic management tools, methods and interventions, and how they are integrated into the emergency preparedness and response.

Promoting the science of infodemiology aims to strengthen the global evidence base on infodemic management to inform the development of action-oriented guidance, support options, mechanisms and tools for infodemic managers and emergency programme managers.

Follows are the main priorities for 2023-2024 in tackling infodemics in this area:

- Boost global research collaborations and networks in measuring information exposure and burden of infodemic.
- Establish a global network for research and training in infodemiology.
- Advocate for research in areas of research gaps that have been identified in the evidence gap map, with particular attention paid to health system impacts and emergency preparedness.
- Continue developing practical tools for field responders in rapidly generating evidence to inform infodemic resilience strategies and infodemic response in emergencies.
- Develop policy analyses and recommendations to build health system and community resilience to future infodemics.
- Review the evolution of infodemic management teams globally, and related professionalization of the functions in health authorities.
- Identify five strategies each that can be scaled before and during emergencies to build resilience to infodemics and support a more effective infodemic management response by health authorities.

WHO Initiative on Trust and Pandemic Preparedness



The COVID-19 pandemic has highlighted trust as an important determinant of successful pandemic response and leadership, a prerequisite for the uptake of interventions and behaviour change among communities, and a crucial factor contributing to community resilience.

A recent study looking at the factors influencing infection rates across countries found that those with the lowest COVID-19 infection rates had the highest levels of trust.¹ This included both trust in governments and interpersonal trust.

Trust is multifaceted, dynamic and complex: it can wax and wane as an epidemic or pandemic evolves. Furthermore, trust is highly context-specific, influenced by social, historical and political factors. In order to embed trust as a critical element of pandemic preparedness at both global and national levels, it will be necessary to deepen and develop the global health community's understanding of trust and translate this understanding into concrete actions that build trust prior to epidemics and pandemics and sustain it during emergencies.

To deliver on this need, the WHO Department for Epidemic and Pandemic Preparedness and Prevention is leading a new initiative on trust and pandemic preparedness.

Objectives

- Build the research and evidence base in line with the [global architecture for health emergency prevention, preparedness, response and resilience](#) for trust in the context of epidemics and pandemics including defining the dimensions of trust, the contextualization and localization of trust, the factors that erode trust, and the interventions that protect and sustain trust.
- Support an inclusive, Member State-led process to develop a **"Trust Platform"**, that includes a global community of research and practice and tools to measure and build trust.

Achievements

Follows are the main achievements in research relating to the parameters of the Trust Initiative for COVID-19/other key diseases and pathogens in the past 12 months:

1 Launch of a WHO webinar series on trust and pandemic preparedness

WHO has launched a new series of webinars discussing determinants, interventions and experiences around trust in the context of pandemic preparedness. To date, three webinars featuring multidisciplinary experts reaching several thousand people took place on:

- trust and pandemics²
- the shifting landscape of trust – history, leadership and communities³
- the digital information ecosystem and trust⁴

2 Establishment of a working group on trust and pandemic preparedness

Led by the Department of Epidemic and Pandemic Preparedness and Prevention, a working group consisting of global experts researching multifaceted aspects of trust, as well as members from departments across the WHO, is being formed. The working

group will shape the priority activities of the initiative and ensure seamless collaboration across research institutions, implementing partners, and relevant WHO departments.

Future priorities

Follows are the main priorities for 2023-2024 for the WHO Initiative on Trust and Pandemic Preparedness:

- Advance global research on the role of trust for pandemic preparedness: The purpose of this workstream is to collate, synthesize and generate the evidence necessary to define the dimensions of trust in the context of epidemics and pandemics. This workstream will include a diverse and representative community of researchers.
- Build a global community of research and practice: The purpose of this workstream is to ensure that all relevant stakeholders, including Member States, WHO staff at all three levels, partners and researchers, are invited to co-develop and shape the WHO Initiative on Trust and Pandemic Preparedness through consultation processes, information-sharing sessions, and co-hosting of events. The workstream will also deliver a community of practice for exchange of good practice, to support implementation of the initiative and to ensure localization of the tools.
- Develop tools to measure trust in the context of pandemic preparedness: The purpose of this workstream is to translate the findings of the research workstream and the engagement workstream into two tools:
 - the Trust Pulse - a high-level index to measure in real-time levels of trust
 - the Pandemic Trust Implementation Tool - a set of interventions that can be adapted/ localized at a national and community level to build trust prior to epidemics and pandemics, and to sustain trust during emergencies

The pandemic has highlighted trust as an important determinant of successful pandemic response and leadership, a prerequisite for the uptake of interventions and behaviour change among communities, and a crucial factor contributing to community resilience.





Good participatory practice for clinical trials of new or re-emerging pathogens (GPP-EP)

Evidence-driven community engagement in clinical trials

Good participatory practice for clinical trials of new or re-emerging pathogens (GPP-EP) provides principle-based guidance to effectively engage stakeholders in the design and conduct of prevention and treatment trials for emerging and re-emerging pathogens.

Clinical trials of medical countermeasures for new or re-emerging pathogens can produce significant breakthroughs in discovering life-saving medicines, diagnostics, and vaccines during public health emergencies.

These trials are delivered in tough emergency contexts with accelerated timelines to produce results as quickly as possible. Multi-stakeholder engagement during the design, deployment and dissemination of clinical trials is key for implementation to be acceptable, relevant and trusted.

With the increasing frequency and complexity of health emergencies caused by emerging pathogens, such as novel viruses or other infectious agents, it is essential to establish transparent and respectful practices that engage communities and safeguard their rights.

Learning lessons from HIV prevention trials, in 2016 WHO developed GPP-EP to normalize and standardize this work for clinical trials of novel medical countermeasures delivered during public health emergency events. WHO has taken significant steps to promote GPP-EP through a programme of work centred on practical approaches to implementation and uptake.

Objectives

- Provide focused, bespoke technical support for GPP-EP for clinical trials delivered in public health emergencies.
- Develop a suite of generic tools, training and communications products in readiness for rapid adaptation and use in future public health emergency-related clinical trials.
- Build network of expert GPP-EP practitioners.

Achievements

Follows are the main achievements in GPP-EP for COVID-19/other key diseases and pathogens in the past 12 months:

1 Delivered practical evidence-informed materials to be rapidly activated in new trials

Practical tools, materials, and online training materials were created for implementing guidance and evidence-informed good participatory practice for new or re-emerging pathogens (GPP-EP) in clinical trials conducted in low-resource settings. The resources were developed and pre-positioned for rapid adaptation for future trials.^{1,2}

2 GPP-EP activity delivered to engage stakeholders/communities on the Solidarity Trial Vaccines (STV)

Coordination, and delivery of GPP-EP for the Solidarity Trial Vaccines (STV), an international multicentre, multi-vaccine, adaptive, shared placebo, event-driven, individually randomized controlled clinical trial that aimed to evaluate the efficacy and safety of promising new COVID-19 vaccines. The trial recruited over 20,000 people in the Philippines, Colombia, Mali, Kenya and Sierra Leone in 2022.

3 GPP-EP activity delivered to engage stakeholders/communities on the Tokomeza Ebola trial

Trial specific materials and bespoke training programme were developed and delivered in Uganda in readiness for the launch of the Tokomeza Ebola trial, a ring-vaccination adaptive clinical trial to evaluate the safety and efficacy of promising vaccine candidates against Sudan ebolavirus.

4 Strategic and practical GPP-EP counsel delivered around Lassa fever

Highlighted GPP-EP relevance and strategic entry points for development of research protocols for Lassa fever clinical trials.

5 Key work of working and advisory groups

Regular meetings were held for the GPP-EP technical advisory group and working groups to inform readiness and response for GPP-EP.

Future priorities

Follows are the main priorities for 2023-2024 for GPP-EP:

- Learn from GPP-EP work delivered for COVID-19 and other emergency-relevant clinical trials around the world.
- Integrate lessons to update GPP-EP tools and products to drive best practice in public health emergency clinical trials, particularly those using novel trial designs.
- Expand network of GPP-EP practitioners.



NON-PROFIT CENTRES

2023



Building on the global research response to the pandemic to combat the next one

Building on our defences to get ahead of the next global threat

Throughout history, research has played a fundamental role in combatting deadly diseases that have threatened people and communities across the world.

During the dark, devastating and uncertain times at the start of the COVID-19 pandemic, science gave the world hope that we would see better days and humanity could be saved. And it delivered across a wide range of research areas. Crucially it gave us effective vaccines and treatments in record time.

But as the pages of this report show, its achievements were also instrumental across the whole emergency response. For example, research confirmed how the virus was transmitted, provided vital evidence that underpinned infection prevention and control (IPC) and informed the public and policymakers about variants - their transmissibility, virulence and how best to protect ourselves from them.

There is no doubt that all these measures working together helped save millions of lives. And it showcased, possibly for the first time, every aspect of research and innovation being fully utilized in an emergency response.


While COVID-19 still inflicts a significant toll in many parts of the world, the pandemic

has now moved out of the acute phase and was recently declared an established and ongoing health issue which no longer constitutes a public health emergency of international concern (PHEIC). There can be no doubt that global research has played a key role in delivering this historic milestone.

However, the fact remains that outbreaks of deadly new pathogens will happen again in future: we cannot prevent them. What we can do is learn from history and build on the research knowledge and structures gained during the pandemic to fortify us against future ones.

As we saw in Section One, WHO is collaborating closely with key global and national organizations to agree and deliver mechanisms and activities to bolster our resilience against other deadly pathogens and the next pandemic.

Our main enemy is complacency. We must use this post-pandemic window of opportunity wisely and tirelessly to 'get ahead' of the next global threat - global resilience to outbreaks and pandemics will only come with global agreements and major monetary, human resource and knowledge investment. The work has started but must continue at pace.



Ten priority research activities/themes to combatting future outbreaks and pandemics

We now bring the focus right back to the specific future role that research and innovation can play in preparing and responding to the next epidemic or pandemic.

And by bringing together global research infrastructure activities with national capacity-building initiatives, we outline ten key areas that can enhance, prioritize and build the role of research in defending the

world from future disease and pathogen threats.

Many of these activities link with, and form part of, the broader framework of health emergency preparedness and response within the a possible new pandemic convention, agreement or other international instrument and other global policy initiatives in this area.

1

Increase resources for research and innovation (RI) worldwide

Additional resources for research and innovation are needed to purchase vaccines, treatments and diagnostics, as well as fund logistics to ensure rapid distribution and access of products.

Funding should be available pre-pandemic - with the ability to be rapidly scaled in the

event of a large-scale health emergency. In addition, we need to identify how current research funding organizations can efficiently focus their resources to address pivotal research questions to combat new or re-emerging outbreaks.

2

If there is uncertainty give randomization the opportunity to yield trustworthy evidence

Randomized studies are feasible where there is uncertainty about the benefits of medical countermeasures. A key assumption underlying the need for large-scale randomized evidence is that it is often necessary for reliable assessment of moderate effects on mortality or severe disease.

During epidemics and pandemics, trials need to generate data to answer important public health questions (actionable information). It is important to continue to help develop robust CORE protocols for trials for priority viral and bacterial family diseases.

3

Expand the use of simple large platform trials employing core protocols

If trials are collaborative, it is important to use simplified procedures and focus on the questions of public health importance. The adaptive nature of these trials introduces a level of flexibility that enables the swift inclusion of promising new therapeutic agents into the clinical evaluation process, while also permitting the discontinuation of underperforming interventions based on interim evaluations.

Platform trials contribute significantly to the establishment of an efficient research ecosystem that can enhance clinical trial capacity, ensuring long-term sustainability in a manner that is both coordinated and collaborative across diverse institutions spanning different countries.

Simple trials serve as a pivotal conduit for bridging the gap between clinical trials and frontline health care providers and patients. The integration of trials into health care delivery systems and the outbreak response teams serves to enhance the involvement and engagement of frontline health care providers, patients and communities.

In so doing, platform trials have the potential to bolster trust in clinical trial processes and foster increased participation in clinical trials across countries both during interludes between epidemics and in the epidemic period itself.

4

Consider generating large-scale randomized evidence during epidemics and pandemics

Open-label randomized controlled trials (RCTs) during outbreaks are feasible and desirable where there is uncertainty about the benefits of vaccines and treatments. Moreover, when the supply of doses may be limited, RCTs are a fair way to distribute them. A key assumption underlying the use of large-scale randomized evidence is that it is often necessary for reliable assessment of moderate effects on mortality or severe disease.

One main requirement in such studies is that they should not interfere with ordinary

vaccination or administration of the intervention. No additional duties should be added for health care workers in managing and delivering vaccinations or treatments with participating individuals. Follow-up depends on what is locally possible.

Huge, randomized comparisons need not be expensive, and could nimbly and rapidly resolve some uncertainties. Preparedness during the years between pandemics should involve revising trial regulations to make open-label randomized studies as easy as mass vaccination.

5

Adopting a 'One Health' approach that encompasses the human-animal-environment interface is critical to global health security

Health emergency preparedness and response is multisectoral, and future research must engage communities and stakeholders across the 'One Health' spectrum, i.e. human, animal and environmental domains.

Environmental degradation and ecosystem loss (through global deforestation, for example) combined with the trade in wildlife and wildlife products can greatly increase the risk of spillover events with epidemic and pandemic potential.

At a research level it is imperative that we:

- increase our collective understanding

of key issues such as the evolution of pathogens in animal hosts, the modes and drivers of transmission between animals and humans, and new interfaces between humans and animals in a changing environment. Doing this will help us to develop stronger health emergency preventive strategies as well as bolster our preparedness, response and resilience.

- develop early warning systems that link three ways (human, animal and environment) and beyond to help detect spillovers of disease in humans, domestic animals and wildlife at the point when containing them is still an option.

6

Interconnected global laboratory capacity for pathogen/genomic surveillance

Across the globe, we need better, more coordinated global epidemic intelligence and surveillance achieved by:

- enhancing and expanding laboratory capacity/networks
- providing incentives for sharing pathogens, biological samples and genomic data
- harnessing the latest technology driving innovations to increase availability of key

data, develop state-of-the-art analytic tools and predictive models for risk analysis, and link communities of practice around the world

- providing access to surge capacity during emergencies through agreements to utilize regional and/or global auxiliary capacity
- addressing surveillance 'black spots'

7

Research for community protection and to promote trust

Global trust has been shown to be a vital determinant of pandemic preparedness and response. It can help encourage understanding and uptake of research and policy interventions to reduce pathogen transmission and promote the health and wellbeing of local communities.

More broadly, we need to integrate evidence from social sciences and infodemiology into health emergency preparedness and response, including:

- advancing global research to drive equitable, ethical policy and practice for

community protection, including on the role of trust

- boosting global research collaborations and networks to strengthen national and local capacity for evidence to drive key International Health Regulations (IHR) capacities of risk communication and community engagement (RCCE) and infodemic management
- building engagement and communications initiatives with the public around a strong evidence base which takes into account local cultural issues, context and audiences

8

Agile, well-resourced national health systems to protect health workers and patients

Strong and agile national health systems with robust primary health care (PHC) services are key to detecting cases, saving lives and protecting livelihoods in a health emergency.

Future research must support clinical care that is safe, scalable and equitable. Innovative and effective infection prevention

and control (IPC) that protects patients, health workers and communities is key within this.

Resilient health systems must be agile, flexible and sufficiently resourced to surge their capacity during a health emergency while maintaining essential services.

9

Strengthen research capability in every country and incorporate research systems into their emergency preparedness and response systems for epidemic infectious diseases

To enhance the capability to proactively address future outbreaks and promptly identify emerging epidemics for effective response, including the successful execution of priority research, it is imperative to prioritize the strengthening of key health systems elements (e.g. surveillance, outbreak investigation, and diagnostic capabilities) in all countries.

it is important to aid the establishment of sustainable foundational capacities at the


intersection of health care systems and research so as to better equip countries for both research during interepidemic periods and the facilitation of fundamental research during epidemics and pandemics. Such proactive measures can significantly contribute to global health security by effectively responding to and researching emerging health threats.

10

Build equitable global manufacturing capacity that is pandemic-ready

Manufacturing capacity to deliver effective vaccines, treatments and diagnostics rapidly needs to be more equitably distributed across the world.

This can be achieved through strengthened regulatory, legal and enabling frameworks to scale manufacturing platforms for emergency use medical countermeasures with robust agreements for technology transfer.



Publications and further resources

References, peer-reviewed publications and WHO publications

Research in the interepidemic period

Vaccines and therapeutics

Peer-reviewed publications

Vaccine research

- Cross RW, Longini IM, Becker S, Bok K, Boucher D, Carroll MW, et al. An introduction to the marburg virus vaccine consortium, Marvac. PLOS Pathogens 2022;18. doi:10.1371/journal.ppat.1010805. <https://doi.org/10.1371/journal.ppat.1010805>
- Fleming TR, Krause PR, Nason M, Longini IM, Henao-Restrepo AM. COVID-19 vaccines trials: The use of active controls and non-inferiority studies. Clin Trials. 2021 Jun;18(3):335-342. <https://doi.org/10.1177/1740774520988244>.
- Fleming TR, Nason M, Krause PR, Longini IM, Henao-Restrepo AM. COVID-19 vaccine trials: The potential for “hybrid” analyses. Clin Trials. 2021 Aug;18(4):391-397. <https://doi.org/10.1177/17407745211018613>.
- Krause PR, Arora N, Dowling W, Muñoz-Fontela C, Funnell S, Gaspar R, et al. Making more covid-19 vaccines available to address global needs: Considerations and a framework for their evaluation. Vaccine 2022;40:5749-51. doi:10.1016/j.vaccine.2022.07.028. <https://doi.org/10.1016/j.vaccine.2022.07.028>
- Krause PR, Fleming TR, Peto R, Longini IM, Figueroa JP, Sterne JAC, Cravioto A, Rees H, Higgins JPT, Boutron I, Pan H, Gruber MF, Arora N, Kazi F, Gaspar R, Swaminathan S, Ryan MJ, Henao-Restrepo AM. Considerations in boosting COVID-19 vaccine immune response. Lancet. 2021 Oct 9;398(10308):1377-1380. [https://doi.org/10.1016/S0140-6736\(21\)02046-8](https://doi.org/10.1016/S0140-6736(21)02046-8).
- Krause PR, Fleming TR, Longini IM, Peto R, Briand S, Heymann DL, Beral V, Snape MD, Rees H, Ropero AM, Balicer RD, Cramer JP, Muñoz-Fontela C, Gruber M, Gaspar R, Singh JA, Subbarao K, Van Kerkhove MD, Swaminathan S, Ryan MJ, Henao-Restrepo AM. SARS-CoV-2 Variants and vaccines N Engl J Med. 2021 Jul 8;385(2):179-186. <https://doi.org/10.1056/NEJMSr2105280>.
- Krause PR, Arora N, Dowling W, Muñoz-Fontela C, Funnell S, Gaspar R, Gruber MF, Hacker A, Henao-Restrepo AM, Plotkin S, Rees HV, Smith DK, Swaminathan S. Making more COVID-19 vaccine available to address global needs: Considerations and a framework for their evaluation. Vaccine. 2022 Sep 22;40(40):5749-5751. <https://doi.org/10.1016/j.vaccine.2022.07.028>
- Longini IM, Yang Y, Fleming TR, Muñoz-Fontela C, Wang R, Ellenberg SS, et al. A platform trial design for preventive vaccines against Marburg virus and other emerging infectious disease threats. Clinical Trials 2022;19:647-54. doi:10.1177/17407745221110880. <https://doi.org/10.1177/17407745221110880>
- Muñoz-Fontela C, Dowling WE, Funnell SGP, Gsell PS, Riveros-Balta AX, Albrecht RA, Andersen H, Baric RS, Carroll MW, Cavaleri M, Qin C, Crozier I, Dallmeier K, de Waal L, de Wit E, Delang L, Dohm E, Duprex WP, Falzarano D, Finch CL, Frieman MB, Graham BS, Gralinski LE, Guilfoyle K, Haagmans BL, Hamilton GA, Hartman AL, Herfst S, Kaptein SJF, Klimstra WB, Knezevic I, Krause PR, Kuhn JH, Le Grand R, Lewis MG, Liu WC, Maisonnasse P, McElroy AK, Munster V, Oreshkova N, Rasmussen AL, Rocha-Pereira J, Rockx B, Rodríguez E, Rogers TF, Salguero FJ, Schotsaert M, Stittelaar KJ, Thibaut HJ, Tseng CT, Vergara-Alert J, Beer M, Brasel T, Chan JFW, García-Sastre A, Neyts J, Perlman S, Reed DS, Richt JA, Roy CJ, Segalés J, Vasan SS, Henao-Restrepo AM, Barouch DH. Animal models for COVID-19. Nature. 2020 Oct;586(7830):509-515. <https://doi.org/10.1038/s41586-020-2787-6>.
- WHO Ad Hoc Expert Group on the Next Steps for Covid-19 Vaccine Evaluation; Krause PR, Fleming TR, Longini IM, Peto R, Beral V, Bhargava B, Cravioto A, Cramer JP, Ellenberg SS, Figueroa JP, Halloran E, Henao-Restrepo AM, Ryan MJ, Levine MM, Nason M, Nohynek HM, Plotkin S, Rees H, Singh JA, Swaminathan S. Placebo Controlled Trials of Covid-19 Vaccines – Why We Still Need Them. N Engl J Med. 2021 Jan 14;384(2):e2. <https://doi.org/10.1056/NEJMp2033538>.

Therapeutics research

- Consortium, W. S. T., 2021. Repurposed Antiviral Drugs for Covid-19 – Interim WHO Solidarity Trial Results. The New England Journal of Medicine, 384(6), pp. 497-511.
- Consortium, 2022. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses [https://doi.org/10.1016/S0140-6736\(22\)00519-0](https://doi.org/10.1016/S0140-6736(22)00519-0)

WHO publications

Vaccines research

- A WHO-Strategic Research Agenda for Filovirus Research and Monitoring (WHO-AFIRM) [https://www.who.int/publications/m/item/a-who-strategic-research-agenda-for-filovirus-research-and-monitoring----\(who-afirm\)](https://www.who.int/publications/m/item/a-who-strategic-research-agenda-for-filovirus-research-and-monitoring----(who-afirm))
- Accelerating the licensure of Lassa vaccines: Generating robust evidence on vaccine efficacy and safety. HYPERLINK “<https://www.who.int/news-room/events/detail/2022/10/25/default-calendar/save-the-date---accelerating-the-licensure-of-lassa-vaccines--generating-robust-evidence-on-vaccine-efficacy-and-safety>”Accelerating the licensure of Lassa vaccines: Generating robust evidence on vaccine efficacy and safety (who.int)
- Improving Vaccine Effectiveness Studies: A Vital step before the next pandemic HYPERLINK “<https://www.who.int/news-room/events/detail/2023/09/14/default-calendar/improving-vaccine-effectiveness-studies--a-vital-step-before-the-next-pandemic>”Improving Vaccine Effectiveness Studies: A vital step before the next pandemic (who.int)
- Integrating Research into Outbreaks: How can we prepare for the next Marburg outbreak? HYPERLINK “<https://www.who.int/news-room/events/detail/2023/03/10/default-calendar/who-consultation---integrating-research-into-outbreaks--how-can-we-prepare-for-the-next-marburg-outbreak>”Integrating Research into Outbreaks: How can we prepare for the next Marburg outbreak? (who.int)
- Lassa Fever Research and Development (R&D) Roadmap HYPERLINK “[https://www.who.int/publications/m/item/lassa-fever-research-and-development-\(r-d\)-roadmap](https://www.who.int/publications/m/item/lassa-fever-research-and-development-(r-d)-roadmap)”Lassa Fever Research and Development (R&D) Roadmap (who.int)
- Solidarity Trials Core Protocol - Ring vaccination trial to evaluate the efficacy and safety of a Sudan ebolavirus vaccine in Uganda <https://www.who.int/publications/m/item/solidarity-trials-core-protocol---ring-vaccination-trial-to-evaluate-the-efficacy-and-safety-of-a-sudan-ebolavirus-vaccine-in-uganda>
- Solidarity Trials Core Protocol - Randomized trial to evaluate the efficacy and safety of select therapeutic agents in the treatment of Ebola Disease <https://www.who.int/publications/m/item/solidarity-trials-core-protocol---randomized-trial-to-evaluate-the-efficacy-and-safety-of-select-therapeutic-agents-in-the-treatment-of-ebola-disease>
- WHO Working Group on vaccine prioritization - review of Sudan ebolavirus vaccine candidates <https://www.who.int/news-room/events/detail/2022/11/07/default-calendar/who-working-group-meeting-on-sudan-ebolavirus-candidate-vaccines---review-of-uganda-outbreak-and-existing-vaccine-candidates>
- WHO Sudan ebolavirus candidate therapeutics working group meeting on RCT protocol <https://www.who.int/news-room/events/detail/2022/11/04/default-calendar/who-sudan-ebolavirus-therapeutics-working-group-meeting-on-rct-protocol>
- WHO Sudan ebolavirus therapeutics subgroup meeting on candidate treatments to consider for inclusion in an RCT <https://www.who.int/news-room/events/detail/2022/11/02/default-calendar/who-sudan-ebolavirus-therapeutics-sub-group-meeting-on-candidate-treatments-to-consider-for-inclusion-in-an-rct>
- WHO Sudan ebolavirus vaccines working group - RCT design and operational considerations <https://www.who.int/news-room/events/detail/2022/10/28/default-calendar/who-sudan-ebolavirus-vaccines-working-group-meeting---rct-design-and-operational-considerations>
- WHO Working Group on vaccine prioritization - review of Sudan ebolavirus vaccine candidates <https://www.who.int/news-room/events/detail/2022/10/26/default-calendar/who-working-group-meeting-on-sudan-ebolavirus-candidate-vaccines---review-of-uganda-outbreak-and-existing-vaccine-candidates>
- WHO Sudan ebolavirus therapeutics and trial design subgroups meeting on RCT <https://www.who.int/news-room/events/detail/2022/10/21/default-calendar/who-sudan-ebolavirus-therapeutics-and-trial-design-sub-groups>
- WHO Sudan ebolavirus therapeutics subgroup meeting on trial design <https://www.who.int/news-room/events/detail/2022/10/13/default-calendar/who-sudan-ebolavirus-therapeutics-sub-group-meeting-on-trials-designs>
- WHO Working Group on vaccine prioritization - review of Sudan ebolavirus vaccine candidates <https://www.who.int/news-room/events/detail/2022/10/13/default-calendar/who-working-group-meeting-on-sudan-ebolavirus-candidate-vaccines---review-of-uganda-outbreak-and-existing-vaccine-candidates>
- WHO Sudan ebolavirus therapeutics subgroup meeting on candidate treatments to consider for inclusion in an RCT <https://www.who.int/news-room/events/detail/2022/10/11/default-calendar/who-working-group-meeting-on-sudan-ebolavirus-candidate-vaccines---review-of-uganda-outbreak-and-existing-vaccine-candidates>
- WHO Sudan ebolavirus therapeutics subgroup meeting on candidate treatments to consider for inclusion in an RCT <https://www.who.int/news-room/events/detail/2022/10/07/default-calendar/who-working-group-meeting-on-sudan-ebolavirus-candidate-vaccines---review-of-uganda-outbreak-and-existing-vaccine-candidates>
- WHO Sudan ebolavirus vaccines working group - RCT design <https://www.who.int/news-room/events/detail/2022/10/07/default-calendar/who-working-group-meeting-on-sudan-ebolavirus-candidate-vaccines---rct-design>
- WHO Sudan ebolavirus candidate therapeutics working group meeting on review of existing evidence <https://www.who.int/news-room/events/detail/2022/08/28/default-calendar/who-working-group-meeting-on-sudan-ebolavirus-candidate-vaccines---review-of-uganda-outbreak-and-existing-vaccine-candidates>

- WHO Sudan ebolavirus vaccines working group - updates from vaccine developers and RCT design <https://www.who.int/news-room/events/detail/2022/08/23/default-calendar/who-working-group-meeting-on-sudan-ebolavirus-candidate-vaccines---updates-from-vaccine-developers-and-rct-design>
- WHO Sudan ebolavirus vaccines working group - review of Uganda outbreak and existing vaccine candidates <https://www.who.int/news-room/events/detail/2022/08/20/default-calendar/who-working-group-meeting-on-sudan-ebolavirus-candidate-vaccines---review-of-uganda-outbreak-and-existing-vaccine-candidates>
- WHO Technical Advisory Group - candidate vaccine prioritization. Summary of the evaluations and recommendations on the four Marburg vaccines <https://www.who.int/publications/m/item/who-technical-advisory-group---candidate-vaccine-prioritization.--summary-of-the-evaluations-and-recommendations-on-the-four-marburg-vaccines>

Therapeutics research

- Research and Development (R&D) Roadmaps (who.int) <https://www.who.int/teams/blueprint/r-d-roadmaps>

Epidemiology

References

- Bergeri I, Lewis HC, Subissi L, et al. Early epidemiological investigations: World Health Organization UNITY protocols provide a standardized and timely international investigation framework during the COVID-19 pandemic. *Influenza Other Respir Viruses*. 2022 Jan;16(1):7-13. <https://doi.org/10.1111/irv.12915>. Epub 2021 Oct 5. PMID: 34611986; PMCID: PMC8652791.
- Bergeri I, Whelan MG, Ware H, Subissi L, Nardone A, Lewis HC, et al. Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies. *PLoS medicine*. 2022;19(11):e1004107.
- Lewis HC, Ware H, Whelan M et al. UNITY Studies Collaborator Group. SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021. *BMJ Glob Health*. 2022 Aug;7(8):e008793. <https://doi.org/10.1111/irv.1291510.1136/bmjgh-2022-008793>. PMID: 35998978; PMCID: PMC9402450.
- Lewis HC, Marcato AJ, Meagher N, et al. Transmission of SARS-CoV-2 in standardised first few X cases and household transmission investigations: A systematic review and meta-analysis. *Influenza Other Respi Viruses*. 2022; 16(5): 803-819. <https://doi.org/10.1111/irv.1291510.1111/irv.13002>
- Price DJ, Spirkoska V, Marcato AJ, et al. Household transmission investigation: Design, reporting and critical appraisal. *Influenza Other Respir Viruses*. 2023 Jun 15;17(6):e13165. <https://doi.org/10.1111/irv.13165>. PMID: 37333946; PMCID: PMC10271595.
- World Health Organization Seroepidemiology Technical Working Group. ROSES-S: statement from the World Health Organization on the reporting of seroepidemiologic studies for SARSCoV-2. *Influenza Other Respi Viruses*. 2021;15(5):561-568. <https://doi.org/10.1111/irv.12870>
- Horby PW, Laurie KL, Cowling BJ, et al.; CONWISE Steering Committee. CONWISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement. *Influenza Other Respir Viruses*. 2017 Jan;11(1):2-14. Price DJ, Spirkoska V, Marcato AJ, et al. Household transmission investigation: Design, reporting and critical appraisal. *Influenza Other Respir Viruses*. 2023 Jun 15;17(6):e13165. doi: 10.1111/irv.13165. PMID: 37333946; PMCID: PMC10271595.10.1111/irv.12411. Epub 2016 Aug 9. PMID: 27417916; PMCID: PMC5155648.
- Hennessey, K., Pezzoli, L. & Mantel, C. A framework for seroepidemiologic investigations in future pandemics: insights from an evaluation of WHO's Unity Studies initiative. *Health Res Policy Sys* 21, 34 (2023). <https://doi.org/10.1186/s12961-023-00973-z>

Peer-reviewed publications

- Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C, Selemon A, Whelan M, Premji Z, Issa H, Cheng B, Raddad LJA, Buckeridge DL, Van Kerkhove MD, et al Subissi L. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. *Lancet ID*. Jan 2023 doi: [https://doi.org/10.1016/S1473-3099\(22\)00801-5](https://doi.org/10.1016/S1473-3099(22)00801-5)
- Bergeri I, Whelan M, et al Van Kerkhove MD. *Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies*. *PLoS Medicine* Nov 2022. <https://doi.org/10.1371/journal.pmed.1004107>
- Bergeri I, Lewis HC, Subissi L, Nardone A, Valenciano M, Cheng B, Glonti K, Williams B, Abejirinde IO, Simniceanu A, Cassini A, Grant R, Rodriguez A, Vicari A, Al Ariqi L, Azim T, Wijesinghe PR, Rajatonirina SC, Okeibunor JC, Le LV, Katz M, Vaughan A, Jorgensen P, Freidl G, Pebody R, Van Kerkhove MD. *Early epidemiological investigations: World Health Organization UNITY protocols provide a standardized and timely international investigation framework during the COVID-19 pandemic*. *Influenza Other Respir Viruses*. 2021 Oct 5. <https://doi.org/10.1111/irv.12915>.
- Cohen HA et al. *Global profile of SARS-CoV-2 emerging variants: Insights from integrated surveillance can guide on future public health risk assessments* (submitted)

- Durski KN, Vojnov L, Cognat S, Carter L, Cunningham J, Moussy F, Prat I, Ströher U, Nahapetyan K, Mendez-Rico J, Zwetyenga J, von Eije KJ, Perkins M, Ali Ahmed Y, Konings F, Yesurajan Inbanathan F, Subissi L, Barakat A, Herring B, Ryan MJ, Balkhy H, Van Kerkhove MD, and the WHO COVID-19 Laboratory Diagnostics Team. *WHO's role in SARS-CoV-2 laboratory diagnostics: an end-to-end approach*, *Weekly epidemiological record*. 2021, 96, 125-132
- Ford N, Holmer HK, Chou R, Villeneuve PJ, Baller A, Van Kerkhove M, Allegranzi B. *Mask use in community settings in the context of COVID-19: A systematic review of ecological data*. *EClinicalMedicine*. 2021 Aug;38:101024. <https://doi.org/10.1016/j.eclinm.2021.101024>.
- Grant R, Sacks JA, Abraham P, et al. *When to update COVID-19 vaccine composition*. *Nat Med*. 2023 Apr;29(4):776-780. <https://doi.org/10.1038/s41591-023-02220-y>.
- Han AX, Toporowski A, Sacks JA, Perkins M, Briand S, Van Kerkhove M, Hannay E, Carmona S, Rodriguez B, Parker E, Nichols BE, Russell CA. *Low testing rates limit the ability of genomic surveillance programs to monitor SARS-CoV-2 variants: a mathematical modelling study*. medRxiv. 2022 May 23:2022.05.20.22275319. <https://doi.org/10.1101/2022.05.20.22275319>. Preprint.
- Konings, F., Perkins, M.D., Kuhn, J.H. et al Van Kerkhove MD. *SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourse*. *Nat Microbiol* (2021). <https://doi.org/10.1038/s41564-021-00932-w>.
- Krause PR, Fleming TR, Longini IM, Peto R, Briand S, Heymann DL, Beral V, Snape MD, Rees H, Ropero AM, Balicer RD, Cramer JP, Muñoz-Fontela C, Gruber M, Gaspar R, Singh JA, Subbarao K, Van Kerkhove MD, Swaminathan S, Ryan MJ, Henao-Restrepo AM. *SARS-CoV-2 Variants and Vaccines*. *N Engl J Med*. 2021 Jul 8;385(2):179-186
- Khan AA, Alahmari AA, Almuzaini Y, Alamri F, Alsofayan YM, Aburas A, Al-Muhsen S, Van Kerkhove M, Yezli S, Ciottone GR, Assiri AM, Jokhdar HA. *Potential Cross-Reactive Immunity to COVID-19 Infection in Individuals With Laboratory-Confirmed MERS-CoV Infection: A National Retrospective Cohort Study From Saudi Arabia*. *Front Immunol*. 2021 Sep 17;12:727989. <https://doi.org/10.3389/fimmu.2021.727989>.
- Lewis HC, Ware H, Whelan M UNITY Studies Collaborator Group, et al *SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021* *BMJ Global Health* 2022;7:e008793
- Lewis HC, Marcato AJ, Meagher N, Valenciano M, et al. *Transmission of SARS-CoV-2 in standardised first few X cases and household transmission investigations: A systematic review and meta-analysis*. *ISIRV*, 2022. <https://doi.org/10.1111/irv.13002>
- Ma X, Li Z, Whelan MG, Kim D, Cao C, Yanes-Lane M, Yan T, Jaenisch T, Chu M, Clifton DA, Subissi L, Bobrovitz N, Arora RK. *Serology Assays Used in SARS-CoV-2 Seroprevalence Surveys Worldwide: A Systematic Review and Meta-Analysis of Assay Features, Testing Algorithms, and Performance*. *Vaccines (Basel)*. 2022 Nov 24;10(12):2000. doi: 10.3390/vaccines10122000
- Munblit D, Nicholson T, Akrami A, Apfelbacher C, Chen J, De Groote W, Diaz JV, Gorst SL, Harman N, Kokorina A, Olliaro P, Parr C, Preller J, Schiess N, Schmitt J, Seylanova N, Simpson F, Tong A, Needham DM, Williamson PR; PC-COS project steering committee. *A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study*. *Lancet Respir Med*. 2022 Jul;10(7):715-724. [https://doi.org/10.1016/S2213-2600\(22\)00169-2](https://doi.org/10.1016/S2213-2600(22)00169-2). Epub 2022 Jun 14.
- Relan P et al. *Severity and outcomes of Omicron variant of SARS-CoV-2 compared to Delta variant and severity of Omicron sublineages: A systematic review and metanalysis*. (submitted)
- Relan P, Motaze NV, Kothari K, Askie L, Le Polain O, Van Kerkhove MD, Diaz J, Tirupakuzhi Vijayaraghavan BK. Severity and outcomes of Omicron variant of SARS-CoV-2 compared to Delta variant and severity of Omicron sublineages: a systematic review and metanalysis. *BMJ Glob Health*. 2023 Jul;8(7):e012328. <https://doi.org/10.1136/bmjgh-2023-012328>.
- Subissi L., von Gottberg, A., Thukral, L. et al. *An early warning system for emerging SARS-CoV-2 variants*. *Nat Med*, 2022. <https://doi.org/10.1038/s41591-022-01836-w>
- Utunen H, Van Kerkhove MD, Tokar A, O'Connell G, Gamhewage GM, Fall IS. *One Year of Pandemic Learning Response: Benefits of Massive Online Delivery of the World Health Organization's Technical Guidance*. *JMIR Public Health Surveill*. 2021 Apr 21;7(4):e28945. <https://doi.org/10.2196/28945>.
- Van Kerkhove MD. *COVID-19 in 2022: controlling the pandemic is within our grasp*. *Nat Med*. 2021 Dec;27(12):2070.
- Van Kerkhove MD, Ryan MJ, Ghebreyesus TA. *Preparing for "Disease X"*. *Science*. 2021 Oct 13:eabm7796. <https://doi.org/10.1126/science.abm7796>.
- Van Kerkhove MD. *Share all SARS-CoV-2 data immediately* *Science*. 2023 Apr 7;380(6640):11. <https://doi.org/10.1126/science.adi0490>. Epub 2023 Apr 6.
- Venter, M. (2023). Why the world needs more transparency on the origins of novel pathogens. *Nature*, 618(7963), 27-29. <https://www.nature.com/articles/d41586-023-01722-6>
- Worp N, Subissi L, Perkins MD, Van Kerkhove MD, Agrawal A, Chand M, van Beek J, Oude Munnink BB, Koopmans MPG. *Lancet Microbe*. 2023 Aug 25:S2666-5247(23)00179-9. [https://doi.org/10.1016/S2666-5247\(23\)00179-9](https://doi.org/10.1016/S2666-5247(23)00179-9). Online ahead of print.PMID: 37640039 Free article. Review.
- W, Curley S, Subissi L, Ströher U, Perkins MD, Cunningham J. *Comprehensive, Comparative Evaluation of 35 Manual SARS-CoV-2 Serological Assays*. *Dimech. Microbiol Spectr*. 2023 Jun 15;11(3):e0510122. <https://doi.org/10.1128/spectrum.05101-22>. Epub 2023 May 9.PMID: 37158743 Free PMC article.
- Wong MK et al Van Kerkhove MD *COVID-19 mortality and progress towards vaccinating older adults ---worldwide, 2020-2022*, *MMWR Morb Mortal Wkly Rep* 2023;72:113-118. DOI: <http://dx.doi.org/10.15585/mmwr.mm7205a1>

WHO publications

- WHO Global Situational Alert System: a mixed methods multistage approach to identify country-level COVID-19 alerts. McMenamin M, Kolmer J, Djordjevic I, Campbell F, Laurenson-Schafer H, Abbate JL, Abdelgawad BM, Babu A, Balde T, Batra N, Bélorgeot VD, Brindle H, Dorji T, Esmail M, Hammermeister Nezu I, Hernández-García L, Hassan M, Idoko F, Karmin S, Kassamali ZA, Kato M, Matsui T, Duan M, Motaze V, Ogundiran O, Pavlin BI, Riviere-Cinamond A, Ryan K, Schmidt T, Sedai T, Van Kerkhove MD, Zakaria T, Höhle M, Mahamud AR, le Polain de Waroux O; WHO Global Situational Alert System Group. *BMJ Glob Health*. 2023 Jul;8(7):e012241. <https://doi.org/10.1136/bmjgh-2023-012241>. PMID: 37495371 Free PMC article.3
- The World Health Organization's public health intelligence activities during the COVID-19 pandemic response, December 2019 to December 2021
- Togami Eri, Griffith Bridget, Mahran Mostafa, Nezu Ingrid H, Mirembe Bernadette B, Kaasik-Aaslav Kaja, Alexandrova-Ezerska Lidia, Babu Amarnath, Sedai Tika Ram, Kato Masaya, Abbas Heidi, Sadek Mahmoud, Nabeth Pierre, MacDonald Lauren E., Hernández-García Lucía, Pires Jeffrey, Ildefonso Stefany, Stephen Mary, Lee Theresa Min-Hyung, Impouma Benido, Matsui Tamano, Moon Sangjun, Phenxay Manilay, Biaukula Viema, Ochirpurev Ariuntuya, Schnitzler Johannes, Fontaine Julie, Djordjevic Irena, Brindle Hannah, Kolmer Jessica, McMenamin Martina, Peron Emilie, Kassamali Zyleen, Greene-Cramer Blanche, Hamblion Esther, Abdelmalik Philip, Pavlin Boris I, Mahamud Abdi Rahman, Morgan Oliver. *Euro Surveill*. 2022;27(49):pii=2200142. <https://doi.org/10.2807/1560-7917.ES.2022.27.49.2200142>
- SAGO Report. <https://www.who.int/publications/m/item/scientific-advisory-group-on-the-origins-of-novel-pathogens-report>
- SAGO Statement SAGO statement on newly released SARS-CoV-2 metagenomics data from China CDC on GISAID. <https://www.who.int/news/item/18-03-2023-sago-statement-on-newly-released-sars-cov-2-metagenomics-data-from-china-cdc-on-gisaid>
- SAGO Statement. Recommendations to better understand the origins of and factors for the emergence and re-emergence of mpox <https://www.who.int/publications/m/item/recommendations-to-better-understand-the-origins-of-and-factors-for-the-emergence-and-reemergence-of-mpox>

Health emergency intelligence and surveillance

Peer-reviewed publications

- Morgan, O.W., Abdelmalik, P., Perez-Gutierrez, E. et al. How better pandemic and epidemic intelligence will prepare the world for future threats. *Nat Med* 28, 1526–1528 (2022) <https://doi.org/10.1038/s41591-022-01900-5>
- Morgan Oliver, Pebody Richard. The WHO Hub for Pandemic and Epidemic Intelligence; supporting better preparedness for future health emergencies. *Euro Surveill*. 2022;27(20):pii=2200385 <https://doi.org/10.2807/1560-7917.ES.2022.27.20.2200385>
- Technical contributors to the Pandemic and Epidemic Intelligence Innovation Forum February meeting and report. Innovations in public health surveillance: updates from a forum convened by the WHO Hub for Pandemic and Epidemic Intelligence, 2 and 3 February 2022. *Euro Surveill*. 2022;27(15):pii=2200302 <https://doi.org/10.2807/1560-7917.ES.2022.27.15.2200302>

Research integrated in the outbreak response

Clinical management

Peer-reviewed publications

- Cross, R. W., et al. (2022). "An introduction to the Marburg virus vaccine consortium, MARVAC." *PLoS Pathog* 18(10): e1010805. <https://doi.org/10.1371/journal.ppat.1010805>
- Godolphin, P. J., et al. (2022). "Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis." *PLoS One* 17(7): e0270668. <https://doi.org/10.1371/journal.pone.0270668>
- Munblit, D., et al. (2022). "A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study." *Lancet Respir Med* 10(7): 715-724. [https://doi.org/10.1016/S2213-2600\(22\)00169-2](https://doi.org/10.1016/S2213-2600(22)00169-2)

- Pryanka Relan, Laura Alejandra Velez, Stacey L Rowe, Constance McDonough-Thayer and Janet Victoria Diaz (2022) "Using an intra-organizational multidisciplinary team to strengthen the accessibility, use and sustainability of medicinal oxygen during the COVID-19 pandemic." *Frontiers in Health Services*, section Implementation Science. Under peer review
- Alvarez, C. et al. Associated Factors for Mortality in a COVID-19 Colombian Cohort by Epidemic Wave: Is the Predominance of Mu Variant Relevant? <https://doi.org/10.2139/ssrn.4297049>
- Bertagnolio, S. et al. Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19. [https://doi.org/10.1016/S2352-3018\(22\)00097-2](https://doi.org/10.1016/S2352-3018(22)00097-2)
- Damen, A. et al. Validation of prognostic models predicting mortality or ICU admission in patients with COVID-19 in low- and middle-income countries: a global individual participant data meta-analysis" for publication to *Lancet Global Health*. Submitted
- Gonçalves, B. et al. An international observational study to assess the impact of the Omicron variant emergence on the clinical epidemiology of COVID-19 in hospitalised patients – PubMed. <https://doi.org/10.7554/eLife.80556>
- OPAS/BRA, Estudo de caracterização clínica e manejo de pacientes hospitalizados com Covid-19: contribuindo com o SUS e a Plataforma Clínica Global da OMS. http://apsredes.org/wp-content/uploads/2022/12/OPAS_Tapia_balanco.pdf
- Lindsey Kjaldgaard, et al. Virus kinetics and biochemical derangements among children with Ebolavirus disease. <https://doi.org/10.1016/j.eclinm.2022.101638>.
- Joan B. Soriano, et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus" [https://doi.org/10.1016/S1473-3099\(21\)00703-9](https://doi.org/10.1016/S1473-3099(21)00703-9).
- Daniel Munblit, et al. Studying the post-COVID-19 condition: research challenges, strategies, and importance of Core Outcome Set development. <https://doi.org/10.1186/s12916-021-02222-y>.
- Ya Gao, et al. Effects of therapies for Ebola virus disease: a systematic review and network meta-analysis. [https://doi.org/10.1016/S2666-5247\(22\)00123-9](https://doi.org/10.1016/S2666-5247(22)00123-9).
- Argawal, et al. A living WHO guideline on drugs for covid-19. <https://doi.org/10.1136/bmj.m3379>
- Owen, et al. WHO Living Guidelines on antivirals for COVID-19 are evidence-based. [https://doi.org/10.1016/S0140-6736\(22\)02306-6](https://doi.org/10.1016/S0140-6736(22)02306-6).
- Lamontagne, et al. A living WHO guideline on drugs to prevent covid-19. <https://doi.org/10.1136/bmj.p692>
- Janet Prvu Bettger, Andrea Thoumi, Victoria Markevich, Wouter De Groote, et al. COVID-19: maintaining essential rehabilitation services across the care continuum. <https://doi.org/10.1136/bmjgh-2020-002670>
- Simon Décar, Wouter De Groote, Chiara Arienti, et al. Scoping review of rehabilitation care models for post COVID-19 condition. <https://doi.org/10.2471/BLT.22.288105>
- Stefano NEGRINI, Carlotta KIEKENS, Claudio CORDANI, Chiara ARIENTI, Wouter DE GROOTE. Cochrane "evidence relevant to" rehabilitation of people with post COVID-19 condition. What it is and how it has been mapped to inform the development of the World Health Organization recommendations. <https://doi.org/10.23736/S1973-9087.22.07793-0>
- Allotey J, Chatterjee S, Kew T, Gaetano A, Stallings E, Fernández-García S, Yap M, Sheikh J, Lawson H, Coomar D, Dixit A, Zhou D, Balaji R, Littmoden M, King Y, Debenham L, Llavall AC, Ansari K, Sandhu G, Banjoko A, Walker K, O'Donoghue K, van Wely M, van Leeuwen E, Kostova E, Kunst H, Khalil A, Brizuela V, Broutet N, Kara E, Kim CR, Thorson A, Oladapo OT, Zamora J, Bonet M, Mofenson L, Thangaratinam S; PregCOV-19 Living Systematic Review Consortium. SARS-CoV-2 positivity in offspring and timing of mother-to-child transmission: living systematic review and meta-analysis. *BMJ*. 2022 Mar 16;376:e067696. <https://doi.org/10.1136/bmj-2021-067696>.
- Allotey J, Stallings E, Bonet M et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. *BMJ* 2020;370:m3320. <https://doi.org/10.1136/bmj.m3320>
- Maza-Arnedo F, Paternina-Caicedo A, Sosa CG, de Mucio B, Rojas-Suarez J, Say L, Cresswell JA, de Francisco LA, Serruya S, Lic DCFP, Urbina L, Hilaire ES, Munayco CV, Gil F, Rousselin E, Contreras L, Stefan A, Becerra AV, Degraff E, Espada F, Conde V, Mery G, Castaño VHÁ, Umbarila ALT, Romero ILT, Alfonso YCR, Lovato Silva R, Calle J, Díaz-Viscensini CM, Frutos VNB, Laguardia EV, Padilla H, Ciganda A, Colomar M. Maternal mortality linked to COVID-19 in Latin America: Results from a multi-country collaborative database of 447 deaths. *Lancet Reg Health Am*. 2022 Aug;12:100269. <https://doi.org/10.1016/j.lana.2022.100269>
- Smith ER, Oakley E, He S, Zavala R, Ferguson K, Miller L, Grandner GW, Abejirinde IO, Afshar Y, Ahmadzia H, Aldrovandi G, Akelo V, Tippett Barr BA, Bevilacqua E, Brandt JS, Broutet N, Fernández Buhigas I, Carrillo J, Clifton R, Conry J, Cosmi E, Delgado-López C, Divakar H, Driscoll AJ, Favre G, Flaherman V, Gale C, Gil MM, Godwin C, Gottlieb S, Hernandez Bellolio O, Kara E, Khagayi S, Kim CR, Knight M, Kotloff K, Lanzone A, Le Doare K, Lees C, Litman E, Lokken EM, Laurita Longo V, Magee LA, Martinez-Portilla RJ, McClure E, Metz TD, Money D, Mullins E, Nachega JB, Panchara A, Playle R, Poon LC, Raiten D, Regan L, Rukundo G, Sanin-Blair J, Temmerman M, Thorson A, Thwin S, Tolosa JE, Townsend J, Valencia-Prado M, Visentin S, von Dadelszen P, Adams Waldorf K, Whitehead C, Yang H, Thorlund K, Tielisch JM. Protocol for a sequential, prospective meta-analysis to describe coronavirus disease 2019 (COVID-19) in the pregnancy and postpartum periods. *PLoS One*. 2022 Jun 16;17(6):e0270150. <https://doi.org/10.1371/journal.pone.0270150>

- Smith ER, Oakley E, Grandner GW, Rukundo G, Farooq F, Ferguson K, Baumann S, Adams Waldorf KM, Afshar Y, Ahlberg M, Ahmadzia H, Akelo V, Aldrovandi G, Bevilacqua E, Bracero N, Brandt JS, Broutet N, Carrillo J, Conry J, Cosmi E, Crispi F, Crovetto F, Del Mar Gil M, Delgado-López C, Divakar H, Driscoll AJ, Favre G, Fernandez Buhigas I, Flaheerman V, Gale C, Godwin CL, Gottlieb S, Gratacós E, He S, Hernandez O, Jones S, Joshi S, Kalafat E, Khagayi S, Knight M, Kotloff KL, Lanzone A, Laurita Longo V, Le Doare K, Lees C, Litman E, Lokken EM, Madhi SA, Magee LA, Martinez-Portilla RJ, Metz TD, Miller ES, Money D, Mounghmaithong S, Mullins E, Nachega JB, Nunes MC, Onyango D, Panchaud A, Poon LC, Raiten D, Regan L, Sahota D, Sakowicz A, Sanin-Blair J, Stephansson O, Temmerman M, Thorson A, Thwin SS, Tippet Barr BA, Tolosa JE, Tug N, Valencia-Prado M, Visentin S, von Dadelszen P, Whitehead C, Wood M, Yang H, Zavala R, Tielsch JM. Clinical risk factors of adverse outcomes among women with COVID-19 in the pregnancy and postpartum period: a sequential, prospective meta-analysis. *Am J Obstet Gynecol*. 2023 Feb;228(2):161-177. <https://doi.org/10.1016/j.ajog.2022.08.038>
- Smith ER, Oakley E, Grandner GW, Ferguson K, Farooq F, Afshar Y, Ahlberg M, Ahmadzia H, Akelo V, Aldrovandi G, Tippet Barr BA, Bevilacqua E, Brandt JS, Broutet N, Fernández Buhigas I, Carrillo J, Clifton R, Conry J, Cosmi E, Crispi F, Crovetto F, Delgado-López C, Divakar H, Driscoll AJ, Favre G, Flaheerman VJ, Gale C, Gil MM, Gottlieb SL, Gratacós E, Hernandez O, Jones S, Kalafat E, Khagayi S, Knight M, Kotloff K, Lanzone A, Le Doare K, Lees C, Litman E, Lokken EM, Laurita Longo V, Madhi SA, Magee LA, Martinez-Portilla RJ, McClure EM, Metz TD, Miller ES, Money D, Mounghmaithong S, Mullins E, Nachega JB, Nunes MC, Onyango D, Panchaud A, Poon LC, Raiten D, Regan L, Rukundo G, Sahota D, Sakowicz A, Sanin-Blair J, Söderling J, Stephansson O, Temmerman M, Thorson A, Tolosa JE, Townson J, Valencia-Prado M, Visentin S, von Dadelszen P, Adams Waldorf K, Whitehead C, Yassa M, Tielsch JM; Perinatal COVID PMA Study Collaborators. Adverse maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection: an individual participant data meta-analysis. *BMJ Glob Health*. 2023 Jan;8(1):e009495. <https://doi.org/10.1136/bmjgh-2022-009495>
- 3. Bôtto-Menezes, C.H.A., Safe, I.P., da Cunha Ferreira, A.C. et al. Myopericarditis associated with acute Zika virus infection: a case report. *BMC Infect Dis* 22, 508 (2022). <https://doi.org/10.1186/s12879-022-07454-8>

Maternal health - social sciences and health systems

- Cecatti JG, Bahamondes L, Ali M, Alangea DO, Brizuela V, Nahyuha Chomi E, Kouanda S, Karmaliani R, Ladak L, Lumbiganon P, Emefa M, Jen S, Kuganantham H, Kim C; WHO HRP Social Science Research Team. Issues related to pregnancy, pregnancy prevention and abortion in the context of the COVID-19 pandemic: a WHO qualitative study protocol. *BMJ Open*. 2022 Oct 6;12(10):e063317. <https://doi.org/10.1136/bmjopen-2022-063317>
- Kouanda S, Nahyuha Chomi E, Kim C, Jen S, Bahamondes L, Cecatti JG, Lumbiganon P, Emefa M, Brizuela V, Kuganantham H, Seuc AH, Ali M; WHO HRP Social Science Research Team. Health systems analysis and evaluation of the barriers to availability, utilisation and readiness of sexual and reproductive health services in COVID-19-affected areas: a WHO mixed-methods study protocol. *BMJ Open*. 2022 Jun 1;12(6):e057810. <https://doi.org/10.1136/bmjopen-2021-057810>
- Kabra R, Joshi B, Elisaria E, Akande TM, Allagh KP, Olumide A, Tandon D, Prusty R, Ramesh M, Shamba D, Kiarie J. Mixed methods study to determine the impact of the COVID-19 pandemic on availability, utilization, and readiness of family planning and contraceptive services at selected primary health care facilities in Africa and Asia: A study protocol. *JMIR Res Protoc*. 2023 Jan 26. <https://doi.org/10.2196/43329>
- Carabali M, Maxwell L, Levis B, Shreedhar P; ZIKV IPD-MA Consortium. Heterogeneity of Zika virus exposure and outcome ascertainment across cohorts of pregnant women, their infants and their children: a metadata survey. *BMJ Open*. 2022 Nov 22;12(11):e064362. <https://doi.org/10.1136/bmjopen-2022-064362>
- Gómez Ponce de Leon R, Bahamondes MV, Ali M et al. Potential of LARC to recover loss in satisfied demand for modern contraception after the COVID-19 pandemic: a case scenario analysis of Brazil and Mexico. *Rev Panam Salud Publica*. 2022 Jun 3;46:e41. <https://doi.org/10.26633/RPSP.2022.41>. PMID: 35677216; PMCID: PMC9168421.
- VanBenschoten H, Kuganantham H, Ali M, et al. Impact of the COVID-19 pandemic on access to and utilisation of services for sexual and reproductive health: a scoping review. *BMJ Glob Health*. 2022 Oct;7(10):e009594. <https://doi.org/10.1136/bmjgh-2022-009594>. PMID: 36202429; PMCID: PMC9539651. 3.

Maternal health - vaccines

- Agustin Ciapponi, Mabel Berrueta, Ariel Bardach, Agustina Mazzoni, Fernando J Argento, Jamile Ballivian, Daniel Comandé, Erin Goucher, Beate Kampmann, Edward P.K. Parker, Veronica Pingray, Federico Rodriguez Cairolí, Victoria Santa María, Andy Stergachis, Xu Xiong, Sabra Zarea, Pierre M Buekens. Safety, immunogenicity, and effectiveness of COVID-19 vaccines for pregnant persons: a protocol for a living systematic review and meta-analysis. *PROSPERO* 2021 CRD42021281290 Available from: https://www.crd.york.ac.uk/prosperto/display_record.php?ID=CRD42021281290 | https://www.crd.york.ac.uk/prosperto/display_record.php?ID=CRD42021281290 | doi: 10.26633/RPSP.2022.41 | doi: 10.1136/bmjgh-2022-009594
- Global uncertainty in the diagnosis of neurological complications of SARS-CoV-2 infection by both neurologists and non-neurologists: An international inter-observer variability study April 2023 *Journal of the Neurological Sciences* 449:120646 <https://doi.org/10.1016/j.jns.2023.120646>

WHO publications

- Drugs to prevent COVID-19: living guideline. [Drugs to prevent COVID-19: living guideline \(who.int\)](https://www.who.int/publications/item/drugs-to-prevent-covid-19-living-guideline)
- Therapeutics and COVID-19: living guideline. [Therapeutics and COVID-19 \(who.int\)](https://www.who.int/publications/item/therapeutics-and-covid-19-living-guideline)

- Clinical management of COVID-19: living guideline. [Clinical management of COVID-19 \(who.int\)](https://www.who.int/publications/item/clinical-management-of-covid-19-living-guideline)
- Clinical characterization of mpox including monitoring the use of therapeutic interventions: statistical analysis plan: [Clinical characterization of mpox including monitoring the use of therapeutic interventions: statistical analysis plan, 13 October 2023 \(who.int\)](https://www.who.int/publications/item/clinical-characterization-of-mpox-including-monitoring-the-use-of-therapeutic-interventions-statistical-analysis-plan-13-october-2023)
- Atlas for mpox lesions. Clinical management of [Mpox \(monkeypox\) \(who.int\)](https://www.who.int/publications/item/atlas-for-mpox-lesions)
- Paediatric Drug Optimization (PADO) for COVID-19 Meeting report. [https://www.who.int/publications/item/9789240068193](https://www.who.int/publications/item/pado-for-covid-19-meeting-report)
- A clinical case definition for post COVID-19 condition in children and adolescents by expert consensus. [Post COVID-19 condition \(who.int\)](https://www.who.int/publications/item/post-covid-19-condition)
- Neurology and COVID-19 Scientific Brief <https://www.who.int/publications/item/WHO-2019-nCoV-Sci-Brief-Neurology-2021>
- Foundations of medical oxygen systems. [Foundations of medical oxygen systems \(who.int\)](https://www.who.int/publications/item/foundations-of-medical-oxygen-systems)
- Developing key performance indicators for the medical oxygen ecosystem through Delphi consensus. Developing key performance indicators for the medical oxygen ecosystem through Delphi consensus ([who.int](https://www.who.int/publications/item/developing-key-performance-indicators-for-the-medical-oxygen-ecosystem-through-delphi-consensus)) https://app.powerbi.com/links/PE7uEdYZ1x?ctid=f610c0b7-bd24-4b39-810b-3dc280afb590&pbi_source=linkShare
- Severity of disease associated with Omicron variant as compared with Delta variant in hospitalized patients with suspected or confirmed SARS-CoV-2 infection. [https://www.who.int/publications/item/9789240051829](https://www.who.int/publications/item/severity-of-disease-associated-with-omicron-variant)
- COVID-19 Pregnancy module - Statistical analysis plan. [https://www.who.int/publications/item/WHO-2019-nCoV-Clinical-Pregnancy-Analytic-plan-2022.1](https://www.who.int/publications/item/covid-19-pregnancy-module)
- COVID-19 Pediatric subgroup - Statistical analysis plan. Under clearance process
- COVID-19 Pediatric report. Under clearance process
- Generic protocol: a prospective cohort study investigating maternal, pregnancy and neonatal outcomes for women and neonates infected with SARS-CoV-2, 1 November 2022. [https://www.who.int/publications/item/WHO-2019-nCoV-pregnancy-and-neonates-2022.1](https://www.who.int/publications/item/generic-protocol)

Posters

- Preparation and administration of REGN-EB3 for Ebola virus disease (EVD). <https://apps.who.int/iris/rest/bitstreams/1487555/retrieve>
- Preparation and administration of mAb114 for Ebola virus disease (EVD). https://www.who.int/publications/item/WHO-EVD-therapeutics-mAb114-Poster_B-2022.1
- Neutralizing monoclonal antibody cocktail REGN-EB3 for Ebola virus disease (EVD) https://www.who.int/publications/item/WHO-EVD-therapeutics-REGN-EB3-Poster_A-2022.1
- Neutralizing monoclonal antibody mAb114 for Ebola virus disease (EVD). https://www.who.int/publications/item/WHO-EVD-therapeutics-mAb114-Poster_A-2022.1
- Nirmatrelvir-ritonavir for non-severe COVID-19. <https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Therapeutics-Nirmatrelvir-ritonavir-Poster-B-2023.1>
- Remdesivir for non-severe COVID-19. <https://apps.who.int/iris/rest/bitstreams/1449314/retrieve>
- Molnupiravir for non-severe COVID-19. <https://apps.who.int/iris/rest/bitstreams/1449298/retrieve>
- Administration of Nirmatrelvir-ritonavir for COVID-19. <https://apps.who.int/iris/rest/bitstreams/1487561/retrieve>
- Safety and monitoring for patients receiving Nirmatrelvir-ritonavir for COVID-19. <https://apps.who.int/iris/rest/bitstreams/1487558/retrieve>
- Safety and monitoring in patients receiving remdesivir for COVID-19. <https://apps.who.int/iris/rest/bitstreams/1449370/retrieve>
- Administration of Remdesivir for COVID-19. <https://apps.who.int/iris/rest/bitstreams/1449346/retrieve>
- Safety and monitoring for patients receiving Molnupiravir for COVID-19. <https://apps.who.int/iris/rest/bitstreams/1449358/retrieve>
- Administration of Molnupiravir for COVID-19. <https://apps.who.int/iris/rest/bitstreams/1449323/retrieve>
- AMR and COVID-19: preliminary findings from the WHO Global Clinical Platform for COVID-19. <https://www.eccmid.org/abstracts>

Q&As

- Coronavirus disease (COVID-19): Post COVID-19 condition. [https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-\(covid-19\)-post-covid-19-condition](https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition)
- Coronavirus disease (COVID-19): Corticosteroids, including dexamethasone. <https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-covid-19-dexamethasone>

- Coronavirus disease (COVID-19). <https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-covid-19>
- Coronavirus disease (COVID-19): Hydroxychloroquine. [https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-\(covid-19\)-hydroxychloroquine](https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-hydroxychloroquine)
- Q&As. Coronavirus disease (COVID-19): Contraception and family planning. <https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-covid-19-contraception-and-family-planning>

Dashboard

- Clinical Platform: COVID-19 dashboard. <https://app.powerbi.com/>

Case Report Form

- Cholera case report form. <https://www.who.int/tools/global-clinical-platform/cholera>
- Viral haemorrhagic fever case report form. <https://www.who.int/tools/global-clinical-platform/viral-haemorrhagic-fever>
- Severe acute hepatitis of unknown aetiology in children case report form. <https://www.who.int/publications/i/item/WHO-UnkHep-Clinical-CRF-2022.1>
- Mpox case report form <https://www.who.int/publications/m/item/monkeypox-minimum-dataset-case-reporting-form-%28crf%29#:~:text=The%20full%20form%20serves%20as%20a%20tool%20for,the%20purposes%20of%20global%20situational%20awareness%20and%20reporting.>

Country and region reports

- Report on clinical characterization of COVID-19 – Ecuador.
- Clinical features, outcomes and prognostic factors of COVID-19 hospitalized children and adults during pre-Delta, Delta and Omicron SARS-CoV-2 waves in the WHO AFRO Region. Under clearance process

Abstract

- Maternal health and vaccines
- Characteristics of people with tuberculosis reported to the WHO Global Clinical Platform of COVID-19 and associations with outcome to be presented
- People with HIV remain at higher risk of dying from COVID-19 in the Omicron era <https://www.aidsmap.com/news/jul-2023/people-hiv-remain-higher-risk-dying-covid-19-omicron-era>
- High in-hospital mortality in SARS-CoV-2 infected patients living with HIV during pre-Delta, Delta and Omicron variant waves: finding from the WHO Global Clinical Platform for COVID-19 <https://programme.ias2023.org/Abstract/Abstract/?abstractid=5988>
- Ongoing Living Update of Potential COVID-19 Therapeutics Options: Summary of Evidence. Rapid Review <https://iris.paho.org/handle/10665.2/52719>
- Living Systematic Review of Therapeutic Options for Post Acute or Post COVID-19 Condition <https://iris.paho.org/handle/10665.2/57278>
- A Guide for Evidence-Informed Decision-Making, Including in Health Emergencies <https://iris.paho.org/handle/10665.2/55828>
- Guidelines for the Prophylaxis and Management of Patients with NON-SEVERE COVID-19 in Latin America and the Caribbean. Abridged version, third edition <https://iris.paho.org/handle/10665.2/57304>
- Guidelines for the Care of Adult Patients with Severe or Critical COVID-19 in the Americas. Abridged version, 4th edition <https://iris.paho.org/handle/10665.2/57275>
- Considerations on the Use of Antivirals, Monoclonal Antibodies, and Other Interventions for the Management of COVID-19 Patients in Latin America and the Caribbean <https://iris.paho.org/handle/10665.2/55968>
- ECCMID poster 2023: AMR & COVID-19: preliminary findings from the WHO Global Clinical Platform for COVID-19

Infection prevention and control (IPC)

References

- 1 The Issue cover for Volume 50, Issue 8 August 2022 Volume 50 Issue 8p839-968 WHO Special issue: Personal protective equipment research and innovation in the context of the World Health Organization COVID-19 R&D Blueprint programme. [https://www.ajicjournal.org/issue/S0196-6553\(21\)X0019-3](https://www.ajicjournal.org/issue/S0196-6553(21)X0019-3)
- 2 <https://doi.org/10.1016/j.ajic.2022.03.015>
- 3 <https://doi.org/10.7326/M22-1966>
- 4 <https://doi.org/10.1016/j.ajic.2021.12.026>
- 5 <https://doi.org/10.1016/j.ajic.2022.03.015>, <https://doi.org/10.1016/j.ajic.2022.03.003>, <https://doi.org/10.1016/j.ajic.2022.02.016>, <https://doi.org/10.1016/j.ajic.2022.01.024>, <https://doi.org/10.1016/j.ajic.2022.02.019>.

- 6 Personal protective equipment implementation in healthcare: A scoping review. <https://doi.org/10.1016/j.ajic.2022.01.013>
- 7 (Chou et al. 2023)
- 8 Pilot studies exploring the use of drones for the capillary delivery of PPE and diagnostic tests to remote areas. <https://doi.org/10.1016/j.ajic.2022.03.004>
- 9 <https://www.who.int/publications/i/item/WHO-UHL-IHS-IPC-2023.2>
- 10 <https://www.who.int/multi-media/details/surgical-site-infection-prevention-in-the-primary-health-care-setting>

Peer-reviewed publications

- Kabra, Kareem B., et al. "Inactivation strategies for SARS-CoV-2 on surgical masks using light-activated chemical dyes." American journal of infection control 50.8 (2022): 844-848. <https://doi.org/10.1016/j.ajic.2022.03.015>
- Flemons, Kristin, et al. "The use of drones for the delivery of diagnostic test kits and medical supplies to remote First Nations communities during COVID-19." American Journal of Infection Control 50.8 (2022): 849-856. <https://doi.org/10.1016/j.ajic.2022.03.004>
- Moon, Madison, et al. "Personal protective equipment research and innovation in the context of the World Health Organization COVID-19 R&D Blueprint program." American Journal of Infection Control 50.8 (2022): 839-843. <https://doi.org/10.1016/j.ajic.2022.05.007>
- Lendvay, Thomas S., et al. "Methylene blue applied to N95 respirators and medical masks for SARS-CoV-2 decontamination: What is the likelihood of inhaling methylene blue?" American Journal of Infection Control 50.8 (2022): 857-862. <https://doi.org/10.1016/j.ajic.2022.03.003>
- Scholte, Florine EM, et al. "Exploring inactivation of SARS-CoV-2, MERS-CoV, Ebola, Lassa, and Nipah viruses on N95 and KN95 respirator material using photoactivated methylene blue to enable reuse." American journal of infection control 50.8 (2022): 863-870. <https://doi.org/10.1016/j.ajic.2022.02.016>
- Wielick, Constance, et al. "Of masks and methylene blue—The use of methylene blue photochemical treatment to decontaminate surgical masks contaminated with a tenacious small nonenveloped norovirus." American Journal of Infection Control 50.8 (2022): 871-877. <https://doi.org/10.1016/j.ajic.2022.01.024>
- Brainard J, Hall S, van der Es M, Sekoni A, Price A, Padoveze MC, Ogunsola FT, Nichiata LYI, Hornsey E, Crook B, Cirino F, Chu L, Hunter PR. A mixed methods study on effectiveness and appropriateness of face shield use as COVID-19 PPE in middle income countries. Am J Infect Control. 2022 Aug;50(8):878-884. <https://doi.org/10.1016/j.ajic.2022.01.019>
- Fadaak, Raad, Nicole Pinto, and Myles Leslie. "Considering context: Adaptive elements of a simulation program to improve primary care safety during the COVID-19 pandemic in Alberta, Canada." American Journal of Infection Control 50.8 (2022): 885-889. <https://doi.org/10.1016/j.ajic.2021.12.026>
- Gallichotte, Emily N., et al. "Detection of SARS-CoV-2 in exhaled air using non-invasive embedded strips in masks." American Journal of Infection Control 50.8 (2022): 890-897. <https://doi.org/10.1016/j.ajic.2022.01.010>
- Cordeiro, Luciana, et al. "Personal protective equipment implementation in healthcare: A scoping review." American journal of infection control 50.8 (2022): 898-905. <https://doi.org/10.1016/j.ajic.2022.01.013>
- Vos, Kevin A., Paul MK Gordon, and Belinda Heyne. "Methylene blue in combination with sunlight as a low cost and effective disinfection method for coronavirus-contaminated PPE." American Journal of Infection Control 50.8 (2022): 906-908. <https://doi.org/10.1016/j.ajic.2022.02.019>
- Price A, Lin YL, Levin AS, Tumietto F, Almeida R, Almeida A, Ciofi-Silva CL, Fontana L, Oliveira N, Parisi NF, Mainardi GM, Cordeiro L, Roselli M, Shepherd P, Morelli L, Mehrabi N, Price K, Chan W, Srinivas S, Harrison TK, Chu M, Padoveze MC, Chu L. Perceived Workload Using Separate (Filtering Facepiece Respirator and Face Shield) and Powered Air-Purifying Respirator and Integrated Lightweight Protective Air-Purifying Respirator: Protocol for an International Multisite Human Factors Randomized Crossover Feasibility Study. JMIR Res Protoc. 2022 Dec 1;11(12):e36549 <https://doi.org/10.2196/36549>
- Piaggio, Davide, et al. "The use of Smart Environments and Robots for Infection Prevention Control: a systematic literature review." American Journal of Infection Control (2023). <https://doi.org/10.1016/j.ajic.2023.03.005>
- Infection prevention and control risk factors in health workers infected with SARS-CoV-2 in Jordan: A case control study <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9269456/>
- Baller A, Padoveze MC, Mirindi P, Hazim CE, Lotemo J, Pfaffmann J, Ndiaye A, Carter S, Chabrat MD, Mangala S, Banzua B, Umutoni C, Niang NR, Kabego L, Ouedraogo A, Houdjo B, Mwesha D, Ousman KB, Kolwaite A, Blaney DD, Choi MJ, Pallawo R, Legand A, Park B, Formenty P, Montgomery JM, Gueye AS, Allegranzi B, Yao NKM, Fall IS. Ebola virus disease nosocomial infections in the Democratic Republic of the Congo: a descriptive study of cases during the 2018-2020 outbreak. Int J Infect Dis. 2022 Feb;115:126-133. doi: 10.1016/j.ijid.2021.11.039. Epub 2021 Dec 7. PMID: 34883237; PMCID: PMC8755545. <https://doi.org/10.1016/j.ijid.2021.11.039>

WHO publications

- How Bangladesh Rapidly Scaled up IPC Programmes in the World's Largest Refugee Camp at Cox's Bazar, <https://www.who.int/southeastasia/news/feature-stories/detail/bangladesh-ipc-scale-up>
- World Health Organization. (2023). Infection prevention and control in the context of coronavirus disease (COVID-19): a living guideline, 13 January 2023, <https://apps.who.int/iris/handle/10665/365576>

- Clinical management and infection prevention and control for monkeypox: interim rapid response, 10 June 2022, <https://www.who.int/publications/i/item/WHO-MPX-Clinical-and-IPC-2022.1>

Public health and social measures (PHSM)

Peer-reviewed publications

- Enria D, Feng Z, Fretheim A, Ihekweazu C, Ottersen T, Schuchat A, Ungchusak K, Briand S, Haldane V, Lamichhane J, Ludolph R, Mathis M, Nguyen T, Shindo N. Strengthening the evidence base for decisions on public health and social measures. *Bull World Health Organ.* 2021 Sep 1;99(9):610-610A. <https://doi.org/10.2471/BLT.21.287054>. PMID: 34475594; PMCID: PMC8381089.
- Rehfuess, E. A., Movsisyan, A., Pfadenhauer, L. M., Burns, J., Ludolph, R., Michie, S., & Strahwald, B. (2023). Public health and social measures during health emergencies such as the COVID-19 pandemic: An initial framework to conceptualize and classify measures. *Influenza and Other Respiratory Viruses*, 17(3), e13110. <https://doi.org/10.1111/irv.13110>
- Ramona Ludolph, Ryoko Takahashi, Zubin Cyrus Shroff, Monika Kosinska, Tanja Schmidt, Huda Haidar Anan, Fatima Arifi, Abdoulaye Yam, Kumanan Rasanathan, Abraham Aseffa, Phuong Nam Nguyen, Masaya Kato, Aarti Garg, Dorji Tshewang, Andrea Villalobos, Victoria Haldane, Tim Nguyen and Sylvie Briand (in print). Closing the evidence gap: towards a global research agenda on using public health and social measures during health emergencies. in print (WHO Bulletin)

WHO publications

- Public health and social measures information flyer: <https://www.who.int/publications/m/item/phsm-information-flyer>
- Report of the WHO global technical consultation on public health and social measures during health emergencies: <https://www.who.int/publications/i/item/9789240043213>
- COVID-19 and the social determinants of health and health equity: evidence brief: <https://www.who.int/publications/i/item/9789240038387>
- Considerations for implementing and adjusting public health and social measures in the context of COVID-19, Interim guidance – 30 March 2023: <https://www.who.int/publications/i/item/who-2019-ncov-adjusting-ph-measures-2023.1>
- How do public health and social measures work during health emergencies (explainer video, available in all UN languages). <https://www.who.int/activities/measuring-the-effectiveness-and-impact-of-public-health-and-social-measures#>

Enabling research

Regulatory science

References

- 1 Source: *Global impact of the first year of COVID-19 vaccination: a mathematical modelling study*, The Lancet (2022)
- 2 Annex 11 WHO Technical Report Series 1033 <https://apps.who.int/iris/bitstream/handle/10665/340323/9789240020900-eng.pdf>
- 3 Annex 10 WHO Technical Report Series 1033 <https://apps.who.int/iris/bitstream/handle/10665/340323/9789240020900-eng.pdf>
- 4 Global Benchmarking Tool: <https://www.who.int/tools/global-benchmarking-tools>
- 5 WHO Coalition of Interested Parties: <https://www.who.int/teams/regulation-prequalification/regulation-and-safety/rss/cip>
- 6 WHO Collaborative Registration Procedures: <https://www.who.int/teams/regulation-prequalification/regulation-and-safety/facilitated-product-introduction>
- 7 WHO Safety Advisory Committees: <https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance/safety-advisory-committees>
- 8 International Coalition of Medicines Regulatory Authorities: <https://icmra.info/drupal/en>

Peer-reviewed publications

- A Vaz, MR Santos, L Gwaza, EM González, MP Lewandowska, S Azatyan, A Saint-Raymond. WHO collaborative registration procedure using stringent regulatory authorities' medicine evaluation: reliance in action? *Expert Rev Clin Pharmacol.* 2022. <https://doi.org/10.1080/17512433.2022.2037419>.
- A Saint-Raymond, M Valentin, N Nakashima, N Orphanos, G Santos, G Balkamos, S Azatyan. Reliance is key to effective access and oversight of medical products in case of public health emergencies. *Expert Rev Clin Pharmacol.* 2022. <https://doi.org/10.1080/17512433.2022.2088503>.
- Fukushima, A., Iessa, N., Balakrishnan, M.R. et al. Smartphone-based mobile applications for adverse drug reactions reporting: global status and country experience. *BMC Med Inform Decis Mak* 22, 118 (2022). <https://doi.org/10.1186/s12911-022-01832-7>
- Patience P. Shabangu, Rutendo J.Kuwana, Admire Dube. Collaborative reliance in medicine safety and quality regulation: Investigation of experiences in handling N-nitrosamine impurities among ZaZiBoNa participating countries. September 2022. <https://doi.org/10.3389/fmed.2022.975032>
- Wayne Dimech, Francois Lamoury, Xavier C Ding, Leticia Megias Lastra, Giuseppe Vincini, Anita Sands. Policy analysis: User monitoring of in-vitro diagnostic medical devices used for near-patient testing of infectious diseases. August 2022. <https://doi.org/10.1515/cclm-2020-0031>
- Zuzana Kusynová, Youssra Bais, Hendrika A van den Ham, Aukje K Mantel-Teeuwisse, Gisele Etame-Loe, Eliangiringa Kaale, Serigne Omar Sarr, Fatima Guiet-Mati, Pernelle Bourdillon-Esteve. Improved knowledge on substandard and falsified (SF) medical products through a dedicated course for pharmacy students at three universities in sub-Saharan Africa. February 2023. <https://doi.org/10.1136/bmjgh-2022-009367>

WHO publications

Local Production and Assistance

- WHO Convenes Workshop on Achieving Quality and Sustainable Local Vaccine Production in Africa to Improve Access <https://www.who.int/news/item/01-05-2023-who-convenes-workshop-on-achieving-quality-and-sustainable-local-vaccine-production-in-africa-to-improve-access>
- Virtual cGMP Training Marathon for Vaccine Manufacturing: Questions & Answers. <https://www.who.int/publications/i/item/WHO-MHP-RPQ-LPA-2023.1>
- WHO Vaccine Manufacturing Workshop for the South-East Asia and Western Pacific Regions: Meeting Report <https://apps.who.int/iris/bitstream/handle/10665/359113/9789240052017-eng.pdf>
- Vaccine manufacturers and regulators complete training on CTD format and requirements for vaccine dossiers to improve access in a WHO virtual workshop. <https://www.who.int/news/item/03-07-2022-vaccine-manufacturers-and-regulators-complete-training-on-ctd-format-and-requirements-for-vaccine-dossiers-to-improve-access-in-a-who-virtual-workshop>
- Virtual Workshop on Documentation Format Requirements and Principles of Assessment for WHO Prequalification and Emergency Use Listing of Vaccines. <https://www.who.int/news/item/14-06-2022-more-info-virtual-cgmp-training-marathon-for-vaccine-manufacturing--sustaining-a-gmp-compliant-environment>
- Specialized Technical Assistance – Medicines. <https://www.who.int/news-room/articles-detail/specialized-technical-assistance-medicines>
- Specialized Technical Assistance – IVDs. <https://www.who.int/news-room/articles-detail/specialized-technical-assistance-ivds>
- Specialized Technical Assistance – Vaccines. <https://www.who.int/news-room/articles-detail/specialized-technical-assistance-vaccines>
- WHO missions to address gaps and compliance for the local production of quality COVID-19 vaccines in the Arab Republic of Egypt. <https://www.who.int/news/item/21-09-2022-more-info-virtual-cgmp-training-marathon-for-vaccine-manufacturing-sustaining-a-gmp-compliant-environment>
- Republic of Ghana receives WHO mission to support sustainable local production of quality-assured vaccines <https://www.who.int/news/item/19-05-2022-more-info-virtual-cgmp-training-marathon-for-vaccine-manufacturing--sustaining-a-gmp-compliant-environment>
- COVID-19 vaccine ecosystem for sustainable local production of quality-assured vaccines in the Islamic Republic of Iran <https://www.who.int/news/item/28-04-2022-more-info-virtual-cgmp-training-marathon-for-vaccine-manufacturing--sustaining-a-gmp-compliant-environment>

Incidents and substandard/falsified medical products

- The WHO Member State mechanism on substandard and falsified medical products. <https://www.who.int/publications/i/item/WHO-MHP-RPQ-REG-2022.01>
- Member State mechanism on substandard and falsified medical products. <https://apps.who.int/gb/SF/index.html>
- Review of product information for selected antiretroviral medicines circulating in five African countries. <https://www.who.int/publications/i/item/9789240050884>

- Medical Product Alert N°2/2022: Falsified DESREM (Remdesivir) identified in the WHO Regions of the Americas and South-East Asia. <https://www.who.int/news/item/09-03-2022-medical-product-alert-n-2-2022-falsified-desrem-remdesivir>
- Steering Committee meeting of the WHO Member State mechanism on SF Medical Products. <https://www.who.int/news-room/events/detail/2022/07/05/default-calendar/steering-committee-meeting-of-the-who-member-state-mechanism-on-sf-medical-products>

Pharmacovigilance

- VigiMobile, a new app for field reporting of adverse events following immunization (AEFI). <https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance#>
- Global vaccine safety blueprint 2.0 (GVS2.0) 2021-2023. <https://www.who.int/publications/i/item/9789240036963>
- Summary and recommendations from the second joint meeting of the WHO GACVS and the WHO ACSOMP, December 2022. https://cdn.who.int/media/docs/default-source/medicines/pharmacovigilance/2022-december-accomp-recommendations.pdf?sfvrsn=a2465f84_3&download=true
- Recommendations from the first joint meeting of the WHO GACVS and the WHO ACSOMP, June 2022 https://cdn.who.int/media/docs/default-source/medicines/pharmacovigilance/2022-accomp-recommendations.pdf?sfvrsn=ed257c37_2&download=true
- Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19). <https://www.who.int/publications/i/item/9789240061989>
- WHO pharmaceuticals newsletter – No. 1, 2023. <https://www.who.int/publications/i/item/9789240070240>
- WHO pharmaceuticals newsletter – No. 4, 2022. <https://www.who.int/publications/i/item/9789240062245>
- WHO pharmaceuticals newsletter – No. 3, 2022. <https://www.who.int/publications/i/item/9789240057883>
- WHO pharmaceuticals newsletter – No. 2, 2022. <https://www.who.int/publications/i/item/9789240053083>
- WHO pharmaceuticals newsletter – No. 1, 2022. <https://www.who.int/publications/i/item/9789240042452>
- Safety monitoring of molnupiravir for treatment of mild to moderate COVID-19 infection in low and middle-income countries using cohort event monitoring: a WHO study. https://www.who.int/publications/i/item/WHO-2019-nCoV-Therapeutics-safety_monitoring-molnupiravir-2022.1
- Good information practices criteria - Vaccine Safety Net (VSN) criteria <https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance/vaccine-safety-net/eligibility-criteria>
- WHO statement regarding COVID-19 immunization errors in children. <https://www.who.int/news/item/30-08-2022-statement-covid-19-immunization-errors-children>

Regulatory network

- Paediatric Regulatory Network (PRN)
- Report of the Paediatric Regulatory Network meeting, 14-15 April 2021. <https://www.who.int/publications/i/item/9789240050280>

Regulatory systems strengthening

- WHO global benchmarking tool plus medical devices rev. VI+ MD ver. 1 – National Regulatory System
- WHO Global Benchmarking Tool (GBT) for Evaluation of National Regulatory System of Medical Products - Revision VI <https://www.who.int/publications/i/item/9789240020245>
- Manual for benchmarking of the national regulatory system of medical products and formulation of institutional development plans. https://www.who.int/publications/m/item/Benchmarking_manual_V2_09Mar2021
- WHO global benchmarking tool plus medical devices rev. VI+ MD ver. 1 – National Regulatory System. <https://www.who.int/publications/m/item/01-GBT-MD-rev-VI-MD-ver-1-RS>
- WHO global benchmarking tool plus medical devices rev. VI+ MD ver. 1 – Registration and Marketing Authorization. <https://www.who.int/publications/m/item/02-GBT-MD-rev-VI-MD-ver-1-MA>

Biological standardization

Peer-reviewed publications

- Knezevic, I, Liu MA, Peden K, Zhou T, Na Kang H. (2021) Development of mRNA Vaccines: Scientific and Regulatory Issues. *Vaccines* 9, no. 2: 81. <https://doi.org/10.3390/vaccines9020081>.
- Kristiansen PA, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K, Plotkin S, Knezevic I. WHO International Standard for anti-SARS-CoV-2 immunoglobulin. *Lancet* 2021; 397: 1347-8 (<https://www.thelancet.com/action/showPdf?pii=S0140-6736%2821%2900527-4>).
- Funnell SGP, Afrough B, Baczenas JJ, Berry N, Bewley KR, Bradford R, Florence C, le Duff Y, Lewis M, Moryarty RV, O'Connor SL, Osman KL, Pullan S, Rashid S, Richards KS, Stemple KJ, Knezevic I. A cautionary perspective regarding the isolation and serial propagation of SARS-CoV-2 in Vero cells. *npj Vaccines* (2021) 6:83; <https://doi.org/10.1038/s41541-021-00346-z> (<https://rdcu.be/cmlhQ>).

- Knezevic I, Mattiuzzo G, Page M, Minor P, Griffiths E, Nuebling M, Moorthy V. WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community. *The Lancet Microbe* (2021); [https://doi.org/10.1016/S2666-5247\(21\)00266-4](https://doi.org/10.1016/S2666-5247(21)00266-4). (<https://www.sciencedirect.com/science/article/pii/S2666524721002664>).
- Liu MA, Zhou T, Sheets R, Meyer H and Knezevic I. WHO informal consultation on regulatory considerations for evaluation of the quality, safety and efficacy of RNA-based prophylactic vaccines for infectious diseases, 20-22 April 2021, *Emerging Microbes & Infections* (2022), 11:1, 384-391, <https://doi.org/10.1080/22221751.2022.2026742>.
- Wadhwa M, Kang H-N, Thorpe R, Knezevic I and selected meeting participants. WHO Informal consultation on revision of guidelines on evaluation of similar biotherapeutic products, virtual meeting, 30 June – 2 July 2021. *Biologicals*. 2022; 76:1-9 (<https://www.sciencedirect.com/science/article/pii/S1045105622000197?via%3Dihub>).
- Kurki P, Kang H-N, Ekman N, Knezevic I, Weise M, Wolff-Holz E. Regulatory evaluation of biosimilars: refinement of principles based on the scientific evidence and clinical experience. *BioDrugs*. 2022;36:359-371(<https://doi.org/10.1007/s40259-022-00533-x>).
- Knezevic I, Mattiuzzo G, Page M, Nuebling M, Griffiths E, Minor P. Complexity of serological assays and misunderstandings of WHO International Units. *Clinical Chemistry and Laboratory Medicine (CCLM)* (2022) (<https://doi.org/10.1515/cclm-2022-0660>).

WHO publications

- Evaluation of the quality, safety and efficacy of messenger RNA vaccines for the prevention of infectious diseases: regulatory considerations, Annex 3, TRS No 1039 15 April 2022. <https://www.who.int/publications/m/item/annex-3-mRNA-vaccines-trs-no-1039>
- WHO Manual for the preparation of reference materials for use as secondary standards in antibody testing, TRS 1043, Annex 2. <https://www.who.int/publications/m/item/who-manual-for-reference-material-for-antibody-testing-annex-2>
- WHO Guidelines for the production and quality control of monoclonal antibodies and related products intended for medicinal use, TRS 1043, Annex 4. <https://www.who.int/publications/m/item/guideline-for-the-safe-production-and-quality-control-of-monoclonal-antibodies-annex-4>
- Guidelines on the nonclinical and clinical evaluation of monoclonal antibodies and related products intended for the prevention or treatment of infectious diseases: WHO TRS 1048: <https://iris.who.int/bitstream/handle/10665/373128/9789240078116-eng.pdf?sequence=1>
- Guidelines on evaluation of Biosimilars, TRS 1043, Annex 3. <https://www.who.int/publications/m/item/guidelines-on-evaluation-of-biosimilars--trs-1043--annex-3>
- WHO Global Model Regulatory Framework for medical devices including in vitro diagnostic medical devices, TRS 1045, Annex 3. <https://www.who.int/publications/m/item/who-global-model-regulatory-framework-for-medical-devices-including-in-vitro-diagnostic-medical-devices--annex-3>
- Other Guidelines/Recommendations such as: Guidelines on nonclinical evaluation of vaccines, Guidelines on nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines, Guidelines on clinical evaluation of vaccines: regulatory expectations, are available: <https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/vaccine-standardization/>

Ethics

Peer-reviewed publications

- Downar, J., Smith, M. J., Godkin, D., Frolic, A., Bean, S., Bensimon, C., Bernard, C., Huska, M., Kekewich, M., Ondrusek, N., Upshur, R., Zlotnik-Shaul, R., & Gibson, J. (2022). A framework for critical care triage during a major surge in critical illness. *Canadian Journal of Anesthesia/Journal Canadien d'anesthésie*, 69(6), 774-781. <https://doi.org/10.1007/s12630-022-02231-2>
- Emanuel, E. J., Upshur, R. E. G., & Smith, M. J. (2022). What Covid Has Taught the World about Ethics. *New England Journal of Medicine*, 387(17), 1542-1545. <https://doi.org/10.1056/NEJMp2210173>
- Faden, R., Cravioto, A., Hombach, J., Kaslow, D. C., Kochhar, S., Nohynek, H., Wilder-Smith, A., Crane, M. A., & Omer, S. B. (2022). Who to vaccinate first? A peek at decision-making in a pandemic. *Nature*, 607(7918), 235-238. <https://doi.org/10.1038/d41586-022-01899-2>
- Jackson, C., Habibi, R., Forman, L., Silva, D. S., & Smith, M. J. (2022). Between rules and resistance: Moving public health emergency responses beyond fear, racism and greed. *BMJ Global Health*, 7(12), e009945. <https://doi.org/10.1136/bmjgh-2022-009945>
- Katz, R. A., Salamanca-Buentello, F., Silva, D. S., Upshur, R. E., & Smith, M. J. (2022). R&D during public health emergencies: The value(s) of trust, governance and collaboration. *BMJ Global Health*, 7(3), e007873. <https://doi.org/10.1136/bmjgh-2021-007873>
- Mastroleo, I., & Daly, T. (2023). The New Role of Ethics Committees in Emergency Use of Unproven Interventions Outside Research. In Valdes, Erick & Lecaros, Juan Alberto (Eds.), *Handbook of Bioethical Decisions* (Vol. 2). Springer. <https://rgdoi.net/10.13140/RG.2.2.33413.63201>

- McIntyre, P. B., Aggarwal, R., Jani, I., Jawad, J., Kochhar, S., MacDonald, N., Madhi, S. A., Mohsni, E., Mulholland, K., Neuzil, K. M., Nohynek, H., Olayinka, F., Pitisuttithum, P., Pollard, A. J., & Cravioto, A. (2022). COVID-19 vaccine strategies must focus on severe disease and global equity. *Lancet* (London, England), 399(10322), 406–410. [https://doi.org/10.1016/S0140-6736\(21\)02835-X](https://doi.org/10.1016/S0140-6736(21)02835-X)
- Moon, S., Armstrong, J., Hutler, B., Upshur, R., Katz, R., Atuire, C., Bhan, A., Emanuel, E., Faden, R., Ghimire, P., Greco, D., Ho, C. W., Kochhar, S., Schaefer, G. O., Shamsi-Gooshki, E., Singh, J. A., Smith, M. J., & Wolff, J. (2022). Governing the Access to COVID-19 Tools Accelerator: Towards greater participation, transparency, and accountability. *The Lancet*, 399(10323), 487–494. [https://doi.org/10.1016/S0140-6736\(21\)02344-8](https://doi.org/10.1016/S0140-6736(21)02344-8)
- Muralidharan, A., Schaefer, G. O., Johnson, T., & Savulescu, J. (2022). Funder priority for vaccines: Implications of a weak Lockean claim. *Bioethics*, 36(9), 978–988. <https://doi.org/10.1111/bioe.13075>
- Nampewo, Z., Mike, J. H., & Wolff, J. (2022). Respecting, protecting and fulfilling the human right to health. *International Journal for Equity in Health*, 21(1), 36. <https://doi.org/10.1186/s12939-022-01634-3>
- Silva, D. S., & Smith, M. J. (2023). Is the Cure Worse than the Disease? The Ethics of Imposing Risk in Public Health. *Asian Bioethics Review*, 15(1), 19–35. <https://doi.org/10.1007/s41649-022-00218-1>
- Singh, J. A., Kochhar, S., Wolff, J., Atuire, C., Bhan, A., Emanuel, E., Faden, R., Ghimire, P., Greco, D., Ho, C., Moon, S., Shamsi-Gooshki, E., Touré, A., Thomé, B., Smith, M. J., & Upshur, R. E. G. (2022). WHO guidance on COVID-19 vaccine trial designs in the context of authorized COVID-19 vaccines and expanding global access: Ethical considerations. *Vaccine*, 40(14), 2140–2149. <https://doi.org/10.1016/j.vaccine.2022.02.038>
- Smith, M. J. (2022). Evaluating potential unintended consequences of COVID-19 vaccine mandates and passports. *BMJ Global Health*, 7(7), e009759. <https://doi.org/10.1136/bmjgh-2022-009759>
- Smith, M. J., & Emanuel, E. J. (2023). Learning from five bad arguments against mandatory vaccination. *Vaccine*. <https://doi.org/10.1016/j.vaccine.2023.04.046>
- Voo, T. C., & Mastroleo, I. (2023). Boundaries Between Research, Surveillance and Monitored Emergency Use. In S. Bull, M. Parker, J. Ali, M. Jonas, M. Vasantha, C. Saenz, M. J. Smith, T. C. Voo, J. De Vries, & K. Wright (Eds.), *Research ethics in epidemics and pandemics: A casebook*. Springer.
- Voo, T. C., Savulescu, J., Schaefer, O., Ho Zhi Ling, A., & Tam, C. C. (2022). COVID-19 differentiated measures for unvaccinated individuals: The need for clear goals and strong justifications. *Vaccine*, 40(36), 5333–5337. <https://doi.org/10.1016/j.vaccine.2022.06.051>
- Voo, T. C., Smith, M. J., Mastroleo, I., Dawson, A., & WHO Ethics & COVID-19 Working Group. (2022). COVID-19 vaccination certificates and lifting public health and social measures: Ethical considerations. *Eastern Mediterranean Health Journal*, 28(6), 454–458. <https://doi.org/10.26719/emhj.22.023>
- Wolff, J. (2022). The Three Waves of Pandemic Ethics. *The Philosophers Magazine*. <https://mail.philosophersmag.com/essays/271-the-three-waves-of-pandemic-ethics>
- Wolff, J., Elitzer, D., Petherick, A., Tudor, M., & Tyner, K. (2022). COVID-19 and Authoritarianism: Two Strategies of Engaging Fear. *Global Justice : Theory Practice Rhetoric*, 13(02), 78–98. <https://doi.org/10.21248/gjn.13.02.259>
- Pratt B, Parker M, Bull S. (2022). Equitable Design and Use of Digital Surveillance Technologies During COVID-19: Norms and Concerns. *Journal of Empirical Research on Human Research Ethics*. <https://doi.org/10.1177/15562646221118127>
- Marteau TM, Parker MJ, & Edmunds WJ. (2022). "Science in the time of COVID: Reflections on the Events Research Programme in England" *Nature Communication* 13, 4700. <https://doi.org/10.1038/s41467-022-32366-1>
- Parker M. (2023). "Ethical hotspots in infectious disease surveillance for global health security: social justice and pandemic preparedness". In Wilkinson, D and Savulescu, J. *Pandemic Ethics: From COVID-19 to Disease X* Oxford: Oxford University Press.
- Ngwenya N, Ilo Van Nuil J, Nyirenda D et al. "A network of empirical ethics teams embedded in research programmes across multiple sites: opportunities and challenges in contributing to COVID-19 research and responses" *Wellcome Open Res* 2022, 7:48. <https://doi.org/10.12688/wellcomeopenres.17548.1>
- Atuire, C. A., & Bull, S. (2022). COVID-19 heightens the imperative to decolonize global health research. *Global Justice: Theory Practice Rhetoric*, 13(02), <https://doi.org/10.21248/gjn.13.02.257>
- Modlin, C., Sugarman, J., Chongwe, G., Kass, N., Nazzawa, W., Tegli, J., Shrestha, P., & Ali, J. (2023). Towards achieving transnational research partnership equity: Lessons from implementing adaptive platform trials in low- and middle-income countries. *Wellcome Open Research*, 8, 120. <https://doi.org/10.12688/wellcomeopenres.18915.1>
- Singh, J. A. (2023). Adaptive clinical trials in public health emergency contexts: Ethics considerations. *Wellcome Open Research*, 8, 130. <https://doi.org/10.12688/wellcomeopenres.19057.1>
- Singh, J. A. (2023). Governance of adaptive platform trials. *Wellcome Open Research*, 8, 141. <https://doi.org/10.12688/wellcomeopenres.19058.1>
- Saxena, A., Baker, B. K., Banda, A., Herlitz, A., Miller, J., Karrar, K., ... & Hassoun, N. (2023). Pandemic preparedness and response: beyond the Access to COVID-19 Tools Accelerator. *BMJ Global Health*, 8(1), e010615. <https://doi.org/10.1136/bmjgh-2022-010615>
- Davies, A., Ormel, I., Bernier, A., Harriss, E., Mumba, N., Gobat, N., Schwartz, L., & Cheah, P. Y. (2023). A rapid review of community engagement and informed consent processes for adaptive platform trials and alternative design trials for public health emergencies. *Wellcome Open Research*, 8, 194. <https://doi.org/10.12688/wellcomeopenres.19318.1>

WHO publications

- Bridging the gap between ethics and decision-making in pandemics: Report of the WHO Pandemic Ethics and Policy Summit, 6 December 2021. <https://www.who.int/publications/i/item/9789240065086>
- Global Network of WHO Collaborating Centres for Bioethics: Progress report 2019-2021. <https://www.who.int/publications/i/item/9789240047297>
- The research ethics review committee of WHO regional office for South-East Asia (SEARO-ERC). <https://www.who.int/publications/i/item/9789290229278>
- COVID-19 and mandatory vaccination: Ethical considerations (May 2022 revised version). <https://www.who.int/publications/i/item/WHO-2019-nCoV-Policy-brief-Mandatory-vaccination-2022.1>
- Emergency use of unproven clinical interventions outside clinical trials: ethical considerations. <https://www.who.int/publications/i/item/9789240041745>
- World Health Organization. Ethics and Adaptive Platform Trial Design in Public Health Emergencies: Meeting Report, 18-19 July 2022, Geneva, Switzerland. Geneva: World Health Organization, 1 October 2023. <https://www.who.int/publications/i/item/9789240079670>

Community-centred readiness and response

References

- <https://www.rcce-collective.net/>
- Carter SE et al. How to improve outbreak response: a case study of integrated outbreak analytics from Ebola in Eastern Democratic Republic of the Congo. *BMJ Global Health*, 2021, 6(8).
- Data Portal – Collective Service ([rcce-collective.net](https://www.rcce-collective.net/))
- [Monitoring behavioural insights related to COVID-19 - PubMed \(nih.gov\)](#)
- [Global survey on COVID-19 beliefs, behaviours and norms - PubMed \(nih.gov\)](#)
- The Collective Service is a collaborative partnership between WHO, IFRC, UNICEF and supported by GOARN, that brings together a wide range of organizations engaged in policy, practice, and research for RCCE to ensure expert driven, collaborative, consistent and localized RCCE support reaches governments and partners involved in the national response to COVID-19 and beyond – <https://www.rcce-collective.net/>
- Integrated Outbreak Analytics (IOA) was developed during the 10th (2018-20) Ebola outbreak in the DRC. It is an approach that brings together multiple data types, disciplines, and sources to better understand and explain outbreak dynamics and their impacts on communities. It is focused on collaborative partnership across operational and academic actors in support of outbreak response and on rapid, operational analytics to support decision-making.
- [Studies & Data Tracker – COVID-19 \(rcce-collective.net\)](#)
- [Social dimensions of mPox: gaps and priority questions \(who.int\)](#)
- [IOA Field Exchange Volume 3, June 2022 – World | ReliefWeb](#),
- [IOA Field Exchange Volume 4, September 2022 – World | ReliefWeb](#)
- [IOA Field Exchange Volume 5, December 2022 – World | ReliefWeb](#)
- <https://apps.who.int/iris/handle/10665/362782>
- <https://apps.who.int/iris/handle/10665/366353>
- Community assets and civil society outreach in critical times: an initiative to engage civil society organizations in the COVID-19 response (who.int) <https://iris.who.int/handle/10665/362782>

WHO publications/wider research activity

- Clinical Trials for new or re-emerging pathogens: GPP enriched online training programme
- Davies et al, (2023) A rapid review of community engagement and informed consent processes for adaptive platform trials and alternative design trials for public health emergencies. [A rapid review of community engagement and ... | Wellcome Open Research](#)
- Bernier et al (in preparation) Rapid review: Implementation and evaluation of good participatory practices for clinical trials of (re-)emerging pathogens.
- Social dimensions of MPox
- Face coverings for COVID-19: evidence synthesis
- Public Health and Social Measures policy brief: update of evidence

- Case studies – protocol for best practice synthesis
- Rapid Review of Rapid Qualitative Research Tools in Urgent Epidemic Settings, including COVID-19. Giles Vernick, Yeoh et al (in development) Rapid Review of Rapid Qualitative Research Tools in Urgent Epidemic Settings, including COVID-19
- Rapid Scoping Review: What is community resilience to public health emergencies? How can it be strengthened and measured?
- Community assets and civil society outreach in critical times: an initiative to engage civil society organizations in the COVID-19 response. <https://apps.who.int/iris/handle/10665/362782>
- Resilience to emergencies and civil society organization <https://apps.who.int/iris/handle/10665/366353>
- WHO Regional Office for Europe COVID-19 behavioural insights surveys
- Behavioural insights on refugee health service needs and access: Qualitative study to assess the health service needs and gaps and barriers and drivers of health service uptake among Ukrainian refugees in Czechia, Poland, Romania, Slovakia and Slovenia
- Risk Communication and Community Engagement in Action During Ukraine's War: A RCCE rapid needs assessment was conducted across the countries receiving Ukrainian refugees during the initial weeks of the war to examine the health needs, perceptions and concerns reported by Ukrainian refugees, along with the capacity of each country to respond to these needs. Conducted in 6 countries of the WHO European Region
- COVID-19 RCCE: Compendium of Case studies: a collection of case studies on risk communication and community engagement (RCCE) providing evidence of numerous results achieved and lessons learned since the start of the COVID-19 pandemic, in 17 countries of the WHO European Region
- Use of Sticky-Beak and A / B for Risk Communication message testing through Brand Lift Studies, starting from November 2020 to March 2023. For the "New Normal" Risk communication Campaign aiming at increasing uptake of PHSM, conducted regionally and translated to Ukrainian, Romanian and Czech, in November 2020
- Use of Sticky-Beak and A / B for Risk Communication message testing through the Brand Lift Study for the "WHO EURO Holiday Campaign", in January 2021, conducted regionally and translated to Czech, Polish, Romanian, Ukrainian and Serbian
- Use of Sticky-Beak and A / B for Risk Communication message testing through the Brand Lift Study for the "Health Workers Vaccination Campaign", in June 2021
- Use of Sticky-Beak and A / B for Risk Communication message testing through the Brand Lift Study of the "Vaccines for the Elderly Campaign", conducted regionally, translated to Bulgarian, Uzbekistan, and Armenian, in July 2021
- Use of Sticky-Beak and A / B for Risk Communication message testing through the Brand Lift Study of the "Do It All campaign". Conducted regionally, in October 2021
- Use of Sticky-Beak and A / B for Risk Communication message testing through the Brand Lift Study of the "MRNA Vaccines explained" conducted regionally in September 2021
- Use of Sticky-Beak and A / B for Risk Communication message testing through the Brand Lift Study of "Back To School PHSM" Campaign, conducted in Greece in October 2021
- Use of Sticky-Beak and A / B for Risk Communication message testing through the Brand Lift Study of the "COVID_19 vaccines' safety and effectiveness" campaign, conducted regionally in December 2021
- Use of Sticky-Beak and A / B for Risk Communication message testing through the Brand Lift Study of the "WHO EURO Back to School Campaign", conducted regionally in October 2021
- Use of Sticky-Beak and A / B for Risk Communication message testing through the Brand Lift Study of the "COVID-19 Vaccines and fertility campaign", conducted regionally and translated in Armenian, Bulgarians and Romanian, in March 2022
- Using TalkWalker Free Search, Google Trends, CrowdTangle for the development of Social Listening Reports for Risk Communication on the Earthquake response in Türkiye
- Use of MeltWater, TalkWalker, Crowdtangle, Google Trends digital tools for the development of Infodemic Management reports for all health emergencies (COVID-19, Ukraine Conflict, Mpox, Earthquake)
- Return of Investment of RCCE interventions: Collaboration with Bocconi University, Prof. David Stuckler examining expenditure or RCCE interventions based on infodemic management and debunking asset development as well as digital adds for asset promotion, in 6 Romania of the WHO European Region. The intervention is evaluated through data gathering to inform future interventions.
- Evaluation of community engagement intervention of the "COVID-19 health caravan Initiative" in North Macedonia conducted in 2022. The study evaluated the interventions and provided insights for the planning and development of future interventions for community engagement in other health emergencies.
- "Eliminating mpox in the European region – a response with communities at its heart;" is a case studies compendium detailing experience from 12 countries, with a focus on the engagement of CSOs who represent men who have sex with men (the most affected group in this outbreak). It offers a range of perspectives and records innovative and successful practice under headings such as surveillance, prevention and control measures, mass gathering and more . It is intended to offer inspiration to health authorities, civil society organizations, researchers and policy makers, and to galvanize efforts to eliminate the disease from the region.

- Building a chatbot in a pandemic.
- Rapid qualitative assessment of health-seeking behaviours and referrals towards cholera treatment centers (CTCs): Summary findings and recommendations from Salima, District (Malawi)
- 6 Ways to Incorporate Social Context and Trust in Infodemic Management (2020). <https://www.socialscienceinaction.org/resources/6-ways-to-incorporate-social-context-and-trust-in-infodemic-management/>
- Lessons Learned from 2014–2016 Ebola Outbreak in Guinea: A Review of RCCE Related Publications (2021). <https://www.socialscienceinaction.org/resources/lessons-learned-from-2014-2016-ebola-outbreak-in-guinea-a-review-of-rcce-related-publications/>
- Balancing Burial Rituals with Public Health Demands During the 2014 Guinean Ebola Epidemic (2020). <https://www.socialscienceinaction.org/resources/balancing-burial-rituals-with-public-health-demands-during-the-2014-guinean-ebola-epidemic/>
- Key Considerations: 2021 Outbreak of Ebola in Guinea, the Context of N'Zérékoré (2021). <https://www.socialscienceinaction.org/resources/key-considerations-2021-outbreak-of-ebola-in-guinea-the-context-of-nzerekore/>
- SSHAP Roundtable: 2021 Ebola Outbreak in Guinea (2021). <https://www.socialscienceinaction.org/resources/sshap-roundtable-2021-ebola-outbreak-in-guinea/>
- Community Resilience: Key Concepts and their Applications to Epidemic Shocks (2021). <https://www.socialscienceinaction.org/resources/community-resilience-key-concepts-and-their-applications-to-epidemic-shocks/>
- Key Considerations: Operational Considerations for Building Community Resilience for COVID-19 Response and Recovery (2021). <https://www.socialscienceinaction.org/resources/operational-considerations-for-building-community-resilience-for-covid-19-response-and-recovery/>
- Social Considerations for Monkeypox Response (2022). <https://www.socialscienceinaction.org/resources/social-considerations-for-monkeypox-response/>
- RCCE Strategies for Monkeypox Response (2022). <https://www.socialscienceinaction.org/resources/rcce-strategies-for-monkeypox-response/>
- Social dimensions of monkeypox: gaps and priority questions? (2022). <https://www.socialscienceinaction.org/resources/social-dimensions-of-monkeypox-gaps-and-priority-questions/>
- Key Considerations: Adherence to COVID-19 Preventive Measures in Greater Kampala, Uganda (2022). <https://www.socialscienceinaction.org/resources/key-considerations-adherence-to-covid-19-preventive-measures-in-greater-kampala-uganda/>
- Key Considerations: Adherence to COVID-19 Preventive Measures in Greater Kampala, Uganda (2022). <https://www.socialscienceinaction.org/resources/key-considerations-adherence-to-covid-19-preventive-measures-in-greater-kampala-uganda/>
- Rapid Appraisal of Key Health-Seeking Behaviours in Epidemics (2020). <https://www.socialscienceinaction.org/resources/rapid-appraisal-of-key-health-seeking-behaviours-in-epidemics/>
- Using Social Science in Response to the 2022 Ebola Outbreak in Uganda (2022). <https://www.socialscienceinaction.org/resources/using-social-science-in-response-to-the-2022-ebola-outbreak-in-uganda/>
- Key Considerations for RCCE in the 2022 Ebola Outbreak Response in Greater Kampala, Uganda (2022). <https://www.socialscienceinaction.org/resources/key-considerations-for-rcce-in-the-2022-ebola-outbreak-response-in-greater-kampala-uganda/>
- Key Considerations: Cross-Border Dynamics Between Uganda and Rwanda in the Context of the Outbreak of Ebola, 2022 (2022). <https://www.socialscienceinaction.org/resources/key-considerations-cross-border-dynamics-between-uganda-and-rwanda-in-the-context-of-the-outbreak-of-ebola-2022/>
- Key Considerations: Cross-Border Dynamics Between Uganda and Tanzania in the Context of the Outbreak of Ebola, 2022. <https://www.socialscienceinaction.org/resources/key-considerations-cross-border-dynamics-between-uganda-and-tanzania-in-the-context-of-the-outbreak-of-ebola-2022/>
- Key Considerations: Socio-Behavioural Insight For Community-Centred Cholera Preparedness And Response In Mozambique, 2023. <https://www.socialscienceinaction.org/resources/key-considerations-socio-behavioural-insight-for-community-centred-cholera-preparedness-and-response-in-mozambique-2023/>
- Cholera Questions Bank (2023). <https://www.socialscienceinaction.org/resources/cholera-questions-bank/>
- Guidance on Community Engagement in Cholera Outbreaks (2023).
- Social, behavioural and community dynamics related to the cholera outbreak in Malawi (2022). <https://www.rcce-collective.net/resource/social-behavioural-and-community-dynamics-related-to-the-cholera-outbreak-in-malawi/>
- Approaches to scaling up COVID-19 vaccination: Experiences from Malawi, Kenya and Uganda (2022). <https://www.rcce-collective.net/resource/approaches-to-scaling-up-covid-19-vaccination-experiences-from-malawi-kenya-and-uganda/>
- Supporting inclusive humanitarian assistance in Somalia: a rapid synthesis of the socio- behavioural evidence (2023).
- Data for Action Platform: Data tools and services contribute to the Collective Service data-driven RCCE response for public health emergencies. The integration of social science data and approaches for evidence-based decision-making during an emergency response is the foundation of the Collective Service data-driven work. With this in mind, in 2021,

the Collective Service established the Data for Action platform to provide a holistic approach to its data work. This included the sharing of data resources, expertise, and platforms; collaborating on inter-agency data standards and indicators; and advocating jointly at global, regional, and country levels for information sharing.

- Social Behavioral Dashboard (February 2021): Displays over +1 million data points through 47 indicators in 197 countries on COVID-19 and social behavioural change, which assist governments and partners to understand the key issues and concerns of communities regarding COVID-19. Users are located in Europe (45.11%), Americas (33.07%), Africa (12.94%), Asia (11.10%).
- Social Data Tracking: Since March 2020, 650+ studies and reports have been compiled within 197 countries. The Collective Service developed and launched the social data tracker dashboard in January 2022, which has been visited by 725 users.
- Community Feedback Mechanism (CFM) Tracker: Monitors CFMs led by Collective Service's partners to support RCCE response on PHE and other crises. The mapping initiated in 2022, helped to identify 135 mechanisms across 80 countries and 33 organizations. This tool has been viewed 945 times since February 2022.
- Inter-agency Community feedback monitoring in Eastern and Southern Africa: Led by the ESAR Inter-agency Working Group, a monthly community feedback monitoring has been conducted since June 2020. Thirty-five monthly reports have been generated and disseminated gathering feedbacks from 21 organizations allowing for operational recommendations to be made. The Collective Service supports the development of a Joint Report, which triangulates online and offline community feedback collected by different organizations
- Country-level Community Feedback Mechanism Support. Technical support on Community Feedback monitoring through capacity building, data management assistance and data visualization support. Community Feedback Mechanisms supported: DRC (Ebola, COVID-19), Eswatini (COVID-19), Zimbabwe (COVID-19), Lesotho (COVID-19), Uganda (Ebola), South Africa (Floods). Collective Service has also provided 4Ws mapping support for coordination at the regional and country level.
- Data Snapshots: The Data for Action team conducted a series of data snapshots presenting situations on SBC. Nine data snapshots have been produced on COVID-19 highlighting populations inequity on vaccine access and demand. Recent snapshots were produced on Monkeypox.
- REVIEW OF UNDERSTANDING THE DRIVERS OF NON-ADHERENCE TOWARDS COVID-19 PREVENTIVE MEASURES IN EAST AND SOUTHERN AFRICA. This was a multi-country study that provided evidence for the design and delivery of RCCE interventions
- Qualitative study on social-behavioural determinants of population compliance with PHMS and COVID-19 vaccine uptake.
- Determinants of refusal of COVID-19 cases to visit epidemiological treatment centres in Guinea
- Getting cured of COVID-19 within communities in Guinea
- Evaluation of satisfaction of patients cured of COVID-19 and hospitalized in the CT-EPI
- Analysis of COVID-19 case management system in Guinea: From diagnosis to follow up of patients discharged from treatment centres
- Community health practice and public health action in Guinea
- Behavioural and cultural insights for mpox control and elimination: policy brief No. 3, 30 November 2022. <https://www.who.int/europe/publications/i/item/WHO-EURO-2022-6784-46550-67554>
- Interim advice on Risk Communication and Community Engagement during the monkeypox outbreak in Europe, 2022 (2022). [Interim advice on Risk Communication and Community Engagement during the monkeypox outbreak in Europe, 2022](https://www.who.int/news-detail/20-04-2022-calling-for-youth-voices-to-reimagine-the-future-by-changing-our-present)
- Risk communication and community engagement for COVID-19 vaccination: implementation tool. [Risk communication and community engagement for COVID-19 vaccination: implementation tool](https://www.who.int/news-detail/20-04-2022-calling-for-youth-voices-to-reimagine-the-future-by-changing-our-present)
- Risk communication and community engagement for COVID-19 contact tracing: interim guidance. [Risk communication and community engagement for COVID-19 contact tracing: interim guidance](https://www.who.int/news-detail/20-04-2022-calling-for-youth-voices-to-reimagine-the-future-by-changing-our-present)
- COVID-19 An informative guide Advice for journalists. [COVID-19. An informative guide Advice for journalists](https://www.who.int/news-detail/20-04-2022-calling-for-youth-voices-to-reimagine-the-future-by-changing-our-present)
- [Advancing infodemic management in risk communication and community engagement in the WHO European Region Implementation guidance.](https://www.who.int/news-detail/20-04-2022-calling-for-youth-voices-to-reimagine-the-future-by-changing-our-present)
- [Engaging with faith partners in health emergencies: An interim implementation tool](https://www.who.int/news-detail/20-04-2022-calling-for-youth-voices-to-reimagine-the-future-by-changing-our-present)
- [Risk communication and community engagement: a compendium of case studies in times of COVID-19](https://www.who.int/news-detail/20-04-2022-calling-for-youth-voices-to-reimagine-the-future-by-changing-our-present)
- Risk communication and community engagement approaches during the monkeypox outbreak in Europe, 2022. [Risk communication and community engagement approaches during the monkeypox outbreak in Europe, 2022 \(who.int\)](https://www.who.int/news-detail/20-04-2022-calling-for-youth-voices-to-reimagine-the-future-by-changing-our-present)
- [Digital solutions to health risks raised by the COVID-19 infodemic: policy brief.](https://www.who.int/news-detail/20-04-2022-calling-for-youth-voices-to-reimagine-the-future-by-changing-our-present)
- HealthBuddy+: Access to trusted information on COVID-19 in local languages using an interactive web- and mobile-based application. [Innovating science HB+ case study w HQ](https://www.who.int/news-detail/20-04-2022-calling-for-youth-voices-to-reimagine-the-future-by-changing-our-present)
- Risk communication and community engagement for COVID-19 contact tracing: interim guidance, 2021. [Risk communication and community engagement for COVID-19 contact tracing: interim guidance \(who.int\)](https://www.who.int/news-detail/20-04-2022-calling-for-youth-voices-to-reimagine-the-future-by-changing-our-present)
- Focus Groups Discussions to collect qualitative data on COVID-19 vaccine acceptance amongst vulnerable groups, conducted in 7 countries with 112 participants in total.

- Vaccine Confidence Survey KAB study - two rounds of data collection in 2021 and 2022 to understand knowledge of COVID-19 vaccines and drivers of vaccine hesitancy in the Western Pacific Region. Conducted in 14 countries (including Pacific Island countries) with 24,117 respondents in total (circa 1000 respondents per country, per round, in non-PICs and 500 for PICs).
- Perceptions and Behavioural Insights on COVID-19 KAB - longitudinal, cross-sectional study - five rounds of data collection to observe COVID-19 including vaccination knowledge, attitudinal and behavioural shifts and trends between 2021 and 2022, conducted in 7 countries with 17,505 respondents in total (circa 500 respondents, per country, per round).
- WPRO COVID-19 Social Listening Report Regularly monitoring the latest social media trends and hot topics (including rumours and misinformation) in WPR, to identify the community's questions, concerns, information gaps, knowledge, attitudes, and behaviours, as well as any needs, challenges, and opportunities that arise. In 2022, a total of 28 reports were generated.
- WPRO Mpox Social Listening Report A total of 27 reports were produced on a weekly or bi-weekly basis.
- Desk-based and primary research conducted in 2021 to understand the role of closed messaging channels for risk communication and its potential in promoting health messages and engaging with communities during public health emergencies.
- COVID-19 Behavioural Insights survey A study conducted with Malaysian Research Institute on Ageing (MyAgeingTM), Persiaran MARDI-UPM, Universiti Putra Malaysia (UPM) to capture information gaps, knowledge, attitudes, and behaviours related to COVID-19. The study was launched in September 2020.
- COVID-19 Community perception survey. Four rounds of data collection from 2020 until 2022, jointly implemented with MRCS (Malaysian Red Crescent Society), IFRC and UN OCHA. This longitudinal study was aimed at following the perceptions of risk related to COVID-19 and COVID-19 vaccines and has help to inform both the communication activities as well as decision-making. [COVID-19: Community perceptions in Malaysia - Community Engagement Hub](https://www.who.int/news-detail/20-04-2022-calling-for-youth-voices-to-reimagine-the-future-by-changing-our-present)
- Community perception survey among undocumented migrant communities in Sabah. WHO engaged with a local non-governmental organization called "ANAK (Advocates for Non-discrimination and Access to Knowledge) to run a survey, focus group discussions and a WhatsApp quiz among migrant and other vulnerable communities in State of Sabah from November 2020 until February 2021. The aim of these activities was to understand the knowledge, attitudes and practices about COVID-19 among the communities, barriers to access healthcare and stigma and discrimination they might face.
- Social listening and infodemic management. Social listening mechanism was set up in 2020 to support the COVID-19 response in Malaysia and Brunei Darussalam. Based on localization of an innovative research methodology, a co-created bespoke infodemic taxonomy, and a linguistic based emotion matrix designed to capture citizens' emotions, external partner "Marble Global" was delivering daily snapshots with key insights to WHO and MOH, weekly reports through regular meetings and monthly analysis of key topics and trends that were shaping public's perceptions related to protective behaviours and vaccines. This system included rumours and mis/dis information alert and repository.
- Call for Innovations: Imagine The World Anew. This was an open call for innovations organized in early 2021 by WHO, Impact Hub KL, Social Entrepreneurship to Spur Health (SESH), Social Innovation in Health Initiative (SIHI) and the University of North Carolina. The purpose of this open call was to mobilize large numbers of youth in Malaysia, and through their voices, inform and contribute to the formulation of the national health policies related to COVID-19. The call for innovations had three categories under which people could apply: Youth-Led Social Innovations in Health, Youth messaging for COVID-19, Futures Thinking and Strategic Planning. <https://www.who.int/malaysia/news/detail/20-04-2021-calling-for-youth-voices-to-reimagine-the-future-by-changing-our-present>
- Research project with Wikimedia to raise health awareness in Malaysia WHO conducted online research with the Wikimedia Community User Group in Malaysia, to understand if there is a knowledge and information gap among the population on various health topics including about COVID-19. Based on the findings of the research, the team organized a first ever article writing competition seeking to increase awareness and coverage of multiple health topics in the Malay language on Wikipedia. <https://www.who.int/malaysia/news/detail/15-04-2021-who-partners-with-wikimedia-to-raise-health-awareness-in-malaysia>
- "Research study to assess the status of mental health among the semi-rural population in Malaysia, during the COVID-19 pandemic. The study was conducted with the Southeast Asia Community Observatory (SEACO) and the Jeffrey Cheah School of Medicine and Health Sciences at Monash University. The project had 3 objectives: to assess the status of mental health (anxiety and depression) during covid-19 pandemic among the semi-rural population in Malaysia and to identify the association of relational aspects such as social connectedness and loneliness, and mental health status; to explore the relationships and interactions of the mental health providers/community health workers (CHW) and the person seeking help in an existing community-based mental health programme; to identify the enablers and barriers to earning the communities' trust and to build long term relationship and shared interest". <https://www.who.int/malaysia/news/feature-stories/item/malaysia-trials-digital-community-to-protect-mental-health-during-covid-19>
- Mental Health and Psychosocial Support for COVID-19 positive patients. This project called "Homecare" aimed to provide support to the marginal and hard to reach communities including the B40 families, indigenous, migrants including refugees, asylum seekers and undocumented, as well as the stateless people. This project was implemented together with the Malaysian Red Crescent Society and the Ministry of Health in Malaysia. It had two main components during the summer of 2021 and through the peak of Delta cases in Malaysia: Mental Health and Psychosocial Support for COVID-19 positive patients, working closely with Malaysia COVID-19 Assessment Centre (CAC); to make outbound calls for cases under home monitoring identified by CAC as asymptomatic and in high-risk groups; to call and follow up with the patients to obtain information on their current health status and do constant monitoring.; to collect data and

evidence from the communities and inform and tailor decision-making and COVID-19 response. Distribution of COVID home kits that included oximeters, thermometers, medicines, info kits. (10.000).

- Behavioural insights (BI) research project to test the “Living with the virus” communications strategy in Malaysia. The objective of the BI intervention was to understand what the optimal content and format of “Living with the Virus” communications materials is, and to maximize comprehension and intention among the population to perform the desired behaviour/s during the COVID-19 pandemic. The project aimed to: investigate the effectiveness of current communications targeted to the population and in particular their impact on encouraging the desired “Living with the virus” behaviours; test the existing “Living with the virus” package of materials against alternative options informed by evidence and data; provide concrete recommendations to the Ministry of Health for the current “Living with the virus” communication materials, and; propose new content based on the findings for the next phase of public communication. <https://www.who.int/malaysia/news/feature-stories/item/using-behavioural-science-in-communication-to-improve-health-in-malaysia>
- Evaluation Study on Demand Generation for COVID-19 and Booster Vaccines among Vulnerable Populations. To strengthen the RCCE efforts of the DOH, WHO, and UNICEF, WHO Philippines, through a contracted institution, evaluated and measured the impact of the COVID-19 prevention and vaccine-related RCCE materials produced in the Philippines. Specifically, the assessment aimed to achieve the following objectives:
 1. Determine how WHO-DOH-UNICEF communication materials contributed to the achievement of RESBAKUNA: Kasangga ng BIDA's campaign objectives.
 2. Determine the association between the ‘Sa Boosters: PinasLakas’ campaign and booster uptake.
 3. Generate insights and provide specific recommendations that will inform the development of the DOH's communication, social mobilization, and advocacy activities to strengthen vaccine trust and confidence.
 4. Establish a protocol for evaluating advocacy tools as part of periodic reassessment by the DOH team.
- Looking back, looking forward: lessons learned from COVID-19 communication measurement, evaluation, and learning (MEL) (under review). WPSAR: <https://ojs.wpro.who.int/ojs/index.php>
- CAI Annual Report 2021. <https://www.unicef.org/drcongo/en/documents/cai-annual-report-2021>
- RD Congo : Cellule d'Analyse Intégrée (CAI) - Rapport annuel 2022. <https://reliefweb.int/report/democratic-republic-congo/rd-congo-cellule-danalyse-integree-cai-rapport-annuel-2022>
- DR Congo: The Integrated Analytics Cell (CAI) - 2022 Annual Report. <https://reliefweb.int/report/democratic-republic-congo/dr-congo-integrated-analytics-cell-cai-2022-annual-report>
- The case for collecting, analysing and utilising sex-disaggregated data and gendered data to inform outbreak responses, a systematic review of the literature from 2012-2022. <https://doi.org/10.1016/j.ijid.2023.07.022>
- What is Integrated Outbreak Analytics? online training. <https://youtu.be/f8W5JE3Lpjl>
- What is Integrated Outbreak Analytics (IOA)? <https://youtu.be/orXddIFoX4k>
- Qu'est-ce que L'Analyse intégrée des épidémies (ou AIE)? <https://youtu.be/OBXsPmjbVic>
- IOA is a Multi-Actor and Multi-Discipline Approach. <https://youtu.be/NOSHYA4Klu0>
- l'AIE c'est une approche multi-acteurs et multidisciplinaire. <https://youtu.be/xwtIDHmz3-U>
- IOA approach for decision-making in public health emergencies. <https://youtu.be/RyU9fsGYBcE>
- L'Approche de l'AIE Pour La Prise de Décision dans Les Urgences de Santé Publique. <https://youtu.be/s7FRv6UENqU>
- ¿Qué es el Análisis Integrado de Epidemias? <https://youtu.be/O78S3Fb263A>
- Análisis Integrado de Epidemias (AIE): un enfoque multipartido y multidisciplinar. <https://youtu.be/UOUT8sf0Les>
- Análisis Integrado de Epidemias (AIE) para la toma de decisiones en emergencias de salud publico. <https://youtu.be/c2zgATwvjrE>
- IOA Field Exchange volume 1: Applying an Integrated Outbreak Analytics Lens to COVID-19 vaccination. <https://reliefweb.int/report/world/iaa-field-exchange-issue-1-december-2021>
- IOA Field Exchange volume 2: Integrated Outbreak Analytics and Community-Sourced Data. <https://reliefweb.int/report/world/iaa-field-exchange-issue-2-april-2022>
- IOA Field Exchange volume 3: Prediction and Risk Mapping of Outbreaks. <https://reliefweb.int/report/world/iaa-field-exchange-volume-3-june-2022>
- IOA Field Exchange volume 4: Early Warning, Alert and Response to Outbreaks. <https://reliefweb.int/report/world/iaa-field-exchange-volume-4-september-2022>
- IOA Field Exchange volume 5: Integrated Outbreak Analytics and Health Information Systems. <https://reliefweb.int/report/world/iaa-field-exchange-volume-5-december-2022>

Tackling infodemics

Peer-reviewed publications

- T Sonia Boender; Paula Schneider Claudia Houareau; Tina D Purnat, Atsuyoshi Ishizumi; Elisabeth Wilhelm; Christopher

Voegeli, PhD, MPH Lothar Wieler; Christina Leuker. Establishing infodemic management in Germany: a framework for social listening and integrated analysis to report insights at the national public health institute. JMIR infodemiology. 2023. Accepted. <https://preprints.jmir.org/preprint/43646>

- Dunn AG, Purnat TD, Ishizumi A, Nguyen T, Briand S. Measuring the burden of infodemics with a research toolkit for connecting information exposure, trust, and health behaviours. Archives of Public Health. 2023. Accepted. <https://doi.org/10.21203/rs.3.rs-2507748/v1>
- Wilhelm E, Ballalai I, Belanger ME, Benjamin P, Bertrand-Ferrandis C, Bezbaruah S, Briand S, Brooks I, Bruns R, Bucci LM, Calleja N, et al. Towards measuring the burden of infodemics: Methods and results of the 5th WHO Infodemic Management Conference. 2023. JMIR Infodemiology. <https://doi.org/10.2196/44207>
- Elkin JA, McDowell M, Yau B, Machiri SV, Pal SN, Briand S, Muneene D, Nguyen T, Purnat T. The Good Talk! A serious game to boost people's competence to have open conversations about COVID-19: Protocol for a Randomized Controlled Trial. 2023. JMIR Research Protocols. <https://doi.org/10.2196/40753>
- Weekly epidemiological record, 8 July 2022, No 27, 2022, 97, 313-324. Delivering actionable infodemic insights and recommendations for the COVID-19 pandemic response. Weekly Epidemiological Record= Relevé épidémiologique hebdomadaire. 2022 Jul 8;97(27):313-24. <https://apps.who.int/iris/handle/10665/359145>
- Uttakar, Shraddha, et al. “Empowering Health Workers to Build Public Trust in Vaccination: Experience from the International Pediatric Association's Online Vaccine Trust Course, 2020–2021.” Vaccine (2022). <https://doi.org/10.3390/vaccines9020081>
- Rubinelli S*; Purnat T*; Wilhelm E; Traicoff D; Namageyo-Funa A; Thomson A; Wardle C; Lamichhane J; Briand S; Nguyen T. 2022. WHO competency framework for health authorities and institutions to manage infodemics: its development and features. Human Resources for Health. 20,35 <https://doi.org/10.1186/s12960-022-00733-0>

WHO publications

- WHO policy brief: COVID-19 infodemic management, 14 September 2022 https://www.who.int/publications/i/item/WHO-2019-nCoV-Policy_Brief-Infodemic-2022.1
- WHO fifth infodemic management conference: steps toward measuring burden of infodemics <https://apps.who.int/iris/handle/10665/353410>
- Digital solutions to health risks raised by the COVID-19 infodemic: policy brief. <https://apps.who.int/iris/handle/10665/356315>
- OpenWHO: Infodemic Management 101. <https://openwho.org/courses/infodemic-management-101>

WHO Initiative on Trust and Pandemic Preparedness

References

- 1 [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(22\)00172-6/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00172-6/fulltext)
- 2 <https://www.youtube.com/watch?v=WOI91oYbwHk>
- 3 <https://www.youtube.com/watch?v=zQgdOaUgqsU>
- 4 https://www.youtube.com/watch?v=GLW_pxsDY_4

Good participatory practice for clinical trials of new or re-emerging pathogens (GPP-EP)

References

- 1 Good Participatory Practice (who.int)
- 2 A rapid review of community engagement and informed consent processes for adaptive platform trials and alternate design trials for public health emergencies (2023) | Wellcome Open Research

WHO publications/wider research activity

- Clinical Trials for new or re-emerging pathogens: GPP a handbook for practitioners
- Clinical Trials for new or re-emerging pathogens: Crisis Communication Handbook
- Trial specific: STV Suite of engagement and learning materials for standardized best practice
- Trial specific: Tokomeza Ebola Suite of engagement and learning materials for standardized best practice
- Trial specific: STV Suite of engagement and learning materials for standardized best practice

WHO Headquarters in Geneva

Avenue Appia 20

1202 Geneva

Telephone: +41-22-7912111



**World Health
Organization**



R&D Blueprint

Powering research
to prevent epidemics

